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Professor James J. Havranek, Chairperson	  	  	  	   One	  of	  the	  key	  properties	  of	  proteins	  is	  that	  they	  exhibit	  remarkable	  affinities	  and	  specificities	  for	  small-­‐molecule	  and	  peptide	  binding	  partners.	  	  To	  improve	  the	  success	  rate	  of	  rational,	  computational	  protein	  design	  and	  widen	  the	  scope	  of	  potential	  applications,	  it	  is	  useful	  to	  define	  generalized	  strategies	  and	  automated	  methodology	  to	  improve	  and/or	  alter	  the	  affinity	  and	  specificity	  of	  interactions.	  I	  have	  implemented	  several	  strategies	  for	  engineering	  protein-­‐small	  molecule	  interactions	  including:	  improvement	  of	  substrate	  accessibility,	  stabilization	  of	  the	  bound	  state,	  truncation	  and	  surface	  engineering,	  and	  transplantation	  of	  residue	  level,	  native	  (or	  native-­‐like)	  interactions.	  Each	  strategy	  was	  applied	  to	  one	  or	  more	  model	  protein,	  and	  the	  resulting	  changes	  in	  affinity,	  specificity,	  and	  activity	  were	  characterized	  experimentally.	  Finally,	  we	  designed	  a	  biomolecular	  tool-­‐kit,	  consisting	  of	  17	  engineered	  proteins	  for	  amino	  acid	  side-­‐chain	  recognition	  and	  a	  single	  enzyme	  to	  catalyze	  the	  Edman	  degradation.	  We	  profiled	  the	  affinity	  and	  
 xiii	  
specificity	  of	  each	  protein,	  and	  implemented	  a	  computational	  framework	  that	  demonstrates	  its	  utility	  for	  amino	  acid	  calling	  in	  a	  single	  molecule	  protein	  sequencing	  assay.	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CHAPTER 1: 
INTRODUCTION 
 
 DNA sequencing has rapidly advanced the study of genomics while 
advancements in proteomics have lagged behind (Figure 1). This is primarily due to a 
lack of technological tools that allow us to sequence proteins with a high-throughput 
assay. A major hurdle to protein sequencing is the absence of natural enzymes and 
biomolecules that enable the probing of peptides in an amino acid specific way. For 
nucleic acids, the canonical base pairs coupled with an abundance of enzymes that 
incorporate these base pairs reduces the problem to a question of measurement. That is, 
how do we measure incorporation of different bases into DNA? A vast number of 
extraordinarily innovative approaches have been developed and we are now able to 
sequence DNA in an incredibly fast and cost effective way. For protein sequencing there 
is no replication process analogous to PCR for DNA, so the approach to sequencing must 
be a single-molecule one. Our collaborators in Rob Mitra’s lab have developed an 
approach that, at a single molecule resolution, images successive amino acids in a peptide 
by degrading the peptide chain from the N-terminus. The missing piece of a functional 
sequencing technology is amino acid identification. The question then becomes: how can 
we identify individual amino acids in a side-chain specific way? 
 
 Our contribution consists of the engineering and analysis of a protein-based tool-
kit for single molecule sequencing. In developing this tool-kit, a number of strategies for 
improving and/or altering proteins to achieve the realization of target activities and 
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specificities were explored. These strategies constitute an important component of the 
rapidly developing computational protein design field in and of themselves, while the 
tool-kit represents an enabling component of a revolutionary way to achieve a high-
throughput scale in proteomics. 
 
 In Chapter 2, I will describe our initial selection of scaffolds and a minimalist 
approach to engineering a set of N-terminal amino acid binding proteins (NAABs) and 
describe their characterization. These NAABs form the basis for a tool-kit which is a 
critical component of a novel protein sequencing technology (Figure 2), digital analysis 
of proteins by end sequencing (DAPES). In Chapter 3 I will describe a computational 
framework for identification of amino acids using the tool-kit that we have developed and 
show how it can be coupled with DAPES to achieve high-throughput identification of 
protein sequences with high confidence. In Chapter 4, I will describe a general strategy 
for improving the stability of engineered proteins. Protein stability is a major limitation in 
the use of engineered proteins for applications that require robust, insensitive 
components. Chapter 5 will focus on a computational technique, motif-based design, 
which we have extended to design protein-small molecule interactions. This approach is 
generalizable to a wide range of enzyme redesign problems. Chapter 6 will focus on our 
efforts at the computational design and biophysical characterization of a novel enzyme to 
catalyze the Edman degradation. This component of the DAPES tool-kit will alleviate the 
need for harsh chemical treatments during the assay. Chapter 7 will summarize the 
important conclusions from my work and discuss a few potential future directions. 	  
Protein Design 
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 Over the past decade, advances in computational and experimental analysis of 
protein structure have led to the design of proteins with novel structures and activities. 
From thermo-stabilization to enhance structural stability	  (1-11) to the transplantation of 
tailored active sites into protein scaffolds to create new enzymes	  (12-17), a number of 
groups have provided evidence that rational protein design is feasible and rapidly 
becoming a useful field of research. Protein engineering has shown extraordinary 
potential for generating new designs for therapeutic drugs and biomolecules to treat 
and/or prevent cancers (18-22), genetic diseases (23-25), and other types of metabolic 
diseases (26-29). There is also excitement at the possibility that engineered industrial and 
pharmaceutical enzymes will enable us to produce valuable and desirable chemicals at 
lower costs while simultaneously being more efficient and a reduced these industries 
impact on the environment (30-35).  
 
 Protein design can be roughly broken into two categories: rational design (36, 37) 
and directed evolution	  (38-42). The latter relies on the strategic choice of selection 
schemes to harness cellular processes to generate proteins that satisfy a specific 
functional requirement. Directed evolution has become the predominant method of 
protein engineering primarily because, given a suitable experimental design, success is all 
but guaranteed. The ability to target mutations to specific locations on a protein or 
mechanisms of action or to insert completely novel activities is, however, reduced in 
directed evolution. Additionally, the ability to identify and/or control the mode by which 
a mutation alters activity is often diminished (43, 44).  
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 By contrast, rational, knowledge-based protein design relies on the engineer’s 
knowledge of protein structure and macromolecular interactions to choose mutations 
based on suspected or projected consequences. The advantage being that if generalizable 
principles can be identified, the development of novel, designer macromolecules for 
biotechnology and therapeutics would become more rapid and cost effective. The 
drawback is that success-rate of rational engineering endeavors is relatively low (45), a 
direct reflection of the state of knowledge regarding determinants of macromolecular 
specificity, affinity and protein structure and function.  
 
Protein Structure  
 Proteins are biologically synthesized linear polypeptide chains composed of 
combinations of amino acids that fold into a specific conformation or ensemble of 
conformations.  The primary structure of a protein is defined by its linear sequence of 
amino acids, which uniquely determines the protein’s identity. The 20 canonical, alpha-
amino acids that make up the polypeptide chain are shown in Figure 3. Amino acid side 
chains exhibit a wide range of sizes, from 10 heavy atoms for tryptophan to none for 
glycine, and a similarly wide range of chemical properties. It is the diverse physio-
chemical structure of these amino acids that govern the formation of higher order protein 
structures, and the activities that they impart.  
 
 Secondary structure refers to the localized formation of alpha-helices, beta-sheets 
and other turn/helix structures (Figure 4), while tertiary structure refers to the 3-
dimensional structure of a protein monomer (see examples in Figure 5), often referred to 
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as ‘folds.’ Folds are largely driven to form by non-specific, hydrophobic interactions but 
are stabilized by specific tertiary interactions like salt bridges and disulfide bonds. It is 
the folded structure of proteins that imparts such characteristics as enzymatic activity and 
molecular recognition. 
 
Molecular Recognition 
 Molecular recognition plays a critical role in many biological functions including 
antigen-antibody recognition (protein-protein), gene expression (protein-DNA), and 
cellular signaling (protein-ligand). Recognition of small-molecule and peptide substrates 
is primarily achieved by complementarity at the level of tertiary structure.  To achieve the 
exquisite affinities and specificities seen with biological molecules, these complementary 
regions rely heavily on steric fit, electrostatic complementation, and hydrogen bond 
patterning (46-48).  
 
 An example is the biotin-streptavidin interaction (Figure 5), in which a small 
molecule (biotin) binds to a surface cleft in a small protein (streptavidin) with the 
remarkably strong affinity of 10-14 M (49-51). The binding pocket for biotin shows very 
high shape complementarity, and there are 8 direct hydrogen bonds (involving 7 distinct 
residues on streptavidin) made to the substrate. The biotin-binding pocket is highly 
hydrophobic and there are extensive van der Waals contacts made between biotin and 
streptavidin, which are thought to account for much of the high affinity (52). Finally, 
binding of biotin is accompanied by the stabilization of a flexible loop that closes, with a 
mechanism that resembles the lid of a container, over the binding pocket and enhances 
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the extremely slow dissociation rate	  (52). Protein engineering seeks to understand and 
harness interactions such as these to meet the various demands for specific applications. 
 
Structure-based, Computational Protein Design 
 Rational protein design utilizes the detailed knowledge of protein structure, 
function and physical characteristics to select amino acid mutations that will result in 
targeted functional changes  (53, 54). While this has the advantage of being inexpensive, 
relatively fast and technically simple, there are several major pitfalls. Detailed structural 
knowledge (i.e. a X-ray crystal or NMR structure) of a protein scaffold is required to 
begin the design process, and it can be very difficult to accurately predict the effect of 
various mutations, especially in the case of combinatorial or supporting mutations.  
 
 Computational protein design programs seek to aid in the identification of 
favorable amino acid substitutions that improve the energetics of protein-protein, protein-
ligand and protein-DNA interactions. Several computational frameworks are being 
productively used to engineer novel molecules (55-60).  While the algorithms differ in 
some of the details, there are several common components to computational design 
techniques. In particular: 
1. Force-field – Specifically enumerates energetic contributions to the stability 
of a structure or complex.  Force-fields can be either general (globally applied 
to an entire structure) or local (specific to an interface or region). The former 
are usually physics based (61-66), that is, they rely on a formulation of van 
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der Waals energies, a solvation model and electrostatic interactions, while the 
latter are often knowledge based, statistical potentials generated by sampling 
from the PDB (67-72). 
2. Amino acid alphabet – An alphabet of amino acids that can be used to target 
the desired functional state. This can range from a subset of canonical amino 
acids that are appropriate for a specific region (e.g. hydrophobic residues in 
the core of a protein) to an enhanced alphabet which includes modified and 
unnatural amino acids (e.g. phospho-amino acids or acetyl-alanine) (73-75).  
3. Rotamer libraries – A library of conformations for each member of the amino 
acid alphabet that allows exploration of the conformational space for 
candidate mutations. Rotational isomers, or rotamers (76-79) from these 
libraries are made up of physically accessible conformations, and are often 
‘weighted’ according to their observed occurrence in the protein data bank 
(80, 81). 
4. Search algorithm – A computational technique for identifying the optimal 
rotamer conformation and amino acid identity at a target position. This and 
the force-field are the main components that differ between available software 
suites. For example, RosettaDesign (59, 60) uses a Monte Carlo search to 
identify low energy conformations, while alternative programs use 
deterministic algorithms such as dead-end elimination. 
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 Ultimately, the goal of any computational design algorithm is to identify novel 
amino acid sequences that are low in energy when folded into a target structure or a 
multimeric complex. The two primary challenges of computational design are: the sheer 
size of the amino acid-rotamer conformational space and the selection of a suitably 
detailed energy function that is accurate enough to distinguish between many low-energy 
structures, yet simple enough to remain computationally efficient. This latter requirement 
has largely limited the terms used in design energy functions to pair-wise factorable 
formulations of molecular interactions.  
 
 Using the described computational methods, a number of significant milestones in 
protein design have been achieved. A common application of computational design, for 
example in protein-protein or protein-substrate pairs, is to increase the affinity of 
interactions	  (82-85). Engineered protein variants that bind with a stronger affinity than 
native interactions are helpful for studying existing examples of protein interactions, and 
they may additionally have other applications such as protein therapeutics or other 
biotechnological applications	  (86, 87). A powerful example of a proof-of-concept design 
success in this context is the improvement of the affinity of antibody-antigen interactions 
beyond in vivo levels	  (88, 89). 
 
 The specificities of protein-DNA interactions have been altered to generate DNA 
cleaving enzymes with novel cut sites (90-92), as well as synthetic transcription factors	  
(93, 94). Engineering of protein-substrate interactions often take the form of enzyme 
design. Recently, there have been several successes in the design of enzymes with novel 
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activities	  (16, 17). The design of novel structures is also a goal of protein design. An 
entirely novel fold has been designed, de novo, from it’s primary sequence. The resulting 
protein, dubbed Top7, folded stably into a tertiary conformation not yet observed in 
known proteins	  (95). Computational design has also recently been used to engineer 
complex molecular structures assembled from multiple protein domains (96). 
 
 Despite the impressive array of results demonstrated by the protein design 
community, the majority of notable projects have thus far been limited in scope, and been 
more focused on proving the feasibility of specific approaches than on novel, 
biotechnological or industrial applications. For example, while there is widespread 
sentiment that protein-based therapeutics represents a vast and relatively underexplored 
potential for pharmaceutical use (97-100), that field of study is heavily focused on 
discovery rather than on design. In all likelihood, this is because no significantly 
designed (or redesigned) protein-based drug has, to date, been definitively shown to be 
more effective than naturally produced products (98). The temporal investment and 
restrictions associated with the necessity of choosing an efficient selection scheme are 
often seen as a deterrent from pursing therapeutic protein engineering, at least for 
exploratory designs. Additionally, the relatively low success rate of computational design 
in creating novel, bio-active molecules has thus far proved unattractive enough to prevent 
regular use. 
 
 In order to increase the practicality and improve the success rates of 
computational approaches to protein engineering, the enumeration of specific, 
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generalized design principles is critical. These generalized design principles, some of 
which I will demonstrate in my thesis work, are applicable to a variety of design 
problems and have the potential to improve computational protein design results. 
 
Methods in computational protein design 
 The force-fields used in computational protein design can be classified in two 
primary categories: knowledge-based and physics-based. Knowledge-based energy terms 
rely on statistical information about amino acid preferences, conformations, and 
interactions derived from the PDB (67-72). A typical example of a knowledge-based 
energy term is the quantification of the well-described phenomenon that hydrophobic 
residues prefer to remain in contact with each other, and prefer to minimize their solvent 
accessibility. This statement is quantified into an energy by extracting statistics regarding 
the placement of a hydrophobic residue in all known protein structures.  The Boltzmann 
function (based on, for example, the distribution of distances between a hydrophobic 
residue and all of its hydrophilic neighbors) can then be used to generate a derived energy 
function (71, 72, 101). This type of force-field essentially allows the engineer to vary 
amino acids (i.e. simulate mutations) while maintaining near native contacts and 
conformations, but strongly favors interactions which have been previously observed. 
While this has generally shown to be helpful in realized designed interaction, there is 
potential to miss favorable conformations.  
 
 Physics based force-fields attempt to reconstruct the interactions of amino acids in 
a protein from first principles (61-66). Arguably, the most well-known physics-based 
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energy term is the Lennard-Jones potential, which is an approximation describing the 
steric attractive and repulsive interactions between atoms. Energy terms such as the 
Generalized Born formulation of electrostatic interactions (102), and the LK solvation 
model (103) are further examples of physics based functions. 
 
 This work will focus on the use and extension of the RosettaDesign algorithms. 
RosettaDesign is a computational framework originally introduced in (59, 60), which has 
been extensively and successfully used by the protein engineering community.  
RosettaDesign uses a hybrid energy function to model mutations in a fixed backbone 
structure. Various combinations of knowledge-based and physics-based terms are 
utilized, depending on the application and system being modeled. 
 
Applications in computational protein design 
 The monumental proof-of-principle successes mentioned above, along with 
increasingly standardized and codified approaches to computational protein engineering 
have led to the emergence of applied protein design. This thesis is largely devoted to 
strategies for applied protein design along with an important application to technology 
development, hence I have outlined a few of the most significant advances in applied 
design fields below.  
  
Therapeutics 
 Protein therapeutics have been repeatedly shown to demonstrate very high levels 
of potency and safety. They have also been able to address a number of previously unmet 
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needs in the pharmaceutical industry. PROLOR Biotech Inc. was the first company to 
supply a definition of therapeutic proteins as “those that are either extracted from human 
cells or engineered in the lab for pharmaceutical use” (PROLOR Biotech Inc., 2006). 
This categorization includes natural, recombinant proteins that are expressed in 
microorganisms and used as replacement therapies (e.g. insulin) as well as novel, 
designed proteins. We typically think of small molecules when we define what a drug is; 
however, therapeutic proteins have a number of definable advantages over small 
molecules. These advantages include a higher specificity than small molecules, which 
helps to reduce the possible side effects, less likelihood to be attacked by the immune 
system since many proteins are already present on the body, and efficient enzyme 
replacement treatments for certain genetic disorders which does not require more 
technically difficult gene therapies (104).	  
 
Biosensors 
 Protein engineered biosensors provide the next best step in the advancement of 
protein-based sensors that can specifically identify chemical substrates. For example, a 
group engineered a FRET-based calcium biosensor employing troponin C as calcium-
binding moiety (105, 106). The resulting biosensor exhibited fast kinetics, was stable in 
imaging experiments, and showed a significantly enhanced change in fluorescence.  
Biosensor design is a very active field of research with several centers focused on the 
task emerging in recent years. 
 
Biocatalysts 
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 Over the past ten years, scientific and technological advances have established 
biocatalysis as an economical and environmentally friendly alternative to more 
traditionally used processes such as metallo- and organocatalysis in chemical production 
both in the laboratory and on an industrial scale. Engineering enzymes to improve the 
methods by which we produce biofuels has also been an active area of interest (107-109). 
In this area, rational design offers opportunities to enhance biocatalysts instead of 
accepting sub-optimal kinetic or interaction properties as limitations in natural cellular 
biofuel ‘factories’. For example, the molecular stability of the enzymes themselves 
frequently determine the useful lifetime of biofuel cells (110-112). Successful 
engineering strategies for increasing protein stability, including core redesign and surface 
‘supercharging’, can be readily applied to the protein components of a biofuel cell to 
improve its efficiency or expand its applicability. For example, a group recently 
stabilized human carbonic anhydrase II (HCA II), which functions near diffusion-limited 
efficiency at room temperature. As temperature increases, however, its activity is rapidly 
attenuated (113). Improved thermal stability allows this enzyme to be used in very high-
temperature applications such as carbon sequestration from CO2 produced by coal power 
plants (114). 
 
 Additionally, biocatalytic enzymes have been extensively improved for a variety 
of pharmaceutical applications and form a vital component in the production of a number 
of active pharmaceutical ingredients (APIs). There are many examples, including an 
engineered transaminase for the synthesis of Januvia® (improved up to 28,000-fold using 
well-established protein design techniques), and haloalkane dehalogenases with over 
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4000-times the activity of native enzymes for synthesizing two widely used drugs, 
Lipitor® and Singulair® (Codexis). 
 
Nanotechnology 
 Engineered protein-polymer composites present a large number of physical 
properties and chemical compositions that can potentially be utilized as components in 
prosthetics, medical devices, and tissue-engineered applications	  (115-118). Biomaterials 
combine the advantages of many common industrial materials, such as reproducibility 
and easy customization, with the advantages of natural materials, such as cell 
compatibility and biodegradability	  (119). As one example, Heilshorn et al. have designed 
protein materials that blend the elastic-like mechanical properties of synthetics with cell-
adhesive biochemical properties (120, 121). Recently, de Grado et al. designed a self-
assembling nano-fibre, which consisted of a helical bundle that cooperatively self-
assembled onto the surface of a carbon nanotube demonstrating that synthetic-biological 
materials can be effectively designed (122). 
 
 My thesis work will apply the novel approaches to protein design that I’ve 
developed to create a biomolecular tool-kit for protein sequencing. To the best of my 
knowledge, this tool-kit represents the largest system of designed proteins for a 
biotechnological application thus far attempted. 
 
Protein Sequencing 
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 Automated protein sequencing has evolved considerably with greater sensitivity, 
speed and ease of operation. The vast majority of protein sequencing is currently done 
using two primary experimental methods—mass spectrometry (MS) and a process called 
Edman degradation. Mass spectrometry is the most heavily developed methods and is 
becoming wide spread due to technological advances and improved computational 
techniques for analyzing outputs (123, 124). MS has a number of significant weaknesses 
which limit it’s ability to fully resolve the proteome in a high-throughput way	  (125). 
 
Mass spectrometry 
 While mass spectrometry techniques for sequencing a proteome have advanced 
considerably, the quantitation of a complete set of proteins from a biological system 
remains an unresolved problem (125). Application of current mass spectrometry 
techniques have led to a coverage of over 50% in single celled organisms. However, 
coverage beyond around 10% has proven elusive in more complex organisms. If we 
consider only proteins that can be quantified, the numbers are significantly lower 
primarily because the range of physiochemical characteristics of amino acids renders it 
difficult to quantify mass spectrometry data(126-128). 
 
 For example, de novo sequencing is based on mass. Several amino acids have the 
same masses (e.g. leucine and isoleucine), which makes distinguishing between these two 
relatively common amino acids difficult (129, 130). This makes the very frequently 
occurring hydrophobic peptides from protein cores difficult to map. Peptides fragmented 
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by mass spectrometry can also lose neutral chemical groups (e.g. NH3) which obscures 
the source of the peptide by affecting the mass measurement (131, 132). Protein 
identification using mass spectrometry is also heavily dependent on existing databases of 
genomic sequences (133, 134). Additionally, splice variants and alternative isoforms are 
particularly difficult to recognize using mass spectrometry. Because approximately 74% 
of human genes are alternatively spliced, this presents a problem that makes it difficult to 
account for the full molecular diversity of proteins (135-137). While mass spectrometry-
based proteomics remains an invaluable tool and is (arguably) the most actively 
developed high-throughput approach to proteomics, these points illustrate several 
potential pitfalls at different levels of the process. A reasonable assessment of the field of 
proteomics would be that we remain relatively far from being able to generate 
quantitative proteomic sequence data at a large enough scale to allow comprehensive 
interrogation of most biological phenomenon.  
 
Edman Degradation 
 The other method commonly used for protein sequencing is the Edman 
degradation reaction. This involves either a whole or digested protein with an exposed N-
terminus. The N-terminus is then chemically modified allowing removal amino acids one 
at a time, then identifying each using chromatography (Figure 2) (138, 139). Efficiencies 
of all steps within the Edman sequencing process are generally around 98%, which 
allows proteins or peptides of up to 50 amino acids in length to be determined with a high 
level of accuracy (140). Sequencing by Edman degradation is a well-developed 
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technique, with automated sequencers being currently utilized in proteomic centers (141).  
The primary drawback to Edman degradation is that it is inherently low throughput, 
requiring a sample of a single, highly purified protein. Because of this, Edman 
degradation has been largely abandoned in the current drive for high-throughput, 
systems-wide biology. 
 
Recent developments in proteomics 
 While protein sequencing by mass spectrometry and Edman degradation are both 
developed fields, there are a number of newer technologies that are being actively 
developed for systems level proteomics research. Perhaps the most well-developed and 
promising technology is being developed by Somalogic, which utilizes a series of slow 
off-rate modified aptamers (SOMAmers) to target each protein in the human proteome. 
Currently, SOMAlogic can accurately quantify 1,129 proteins across around eight logs of 
concentration, with a goal of 6,000 proteins by the end of 2014 (142-144). The inherent 
limitation of this technique is that it does not determine the primary sequence of the 
targeted proteins, thus limiting it’s applicability to the discovery of novel biomarkers for 
disease states, and the ability to distinguish alternative isoforms including post-
translational modifications. 
 
 DNA sequencing using nanopores is considered a third generation DNA 
sequencing technology that is just coming into commercial use (145). Nanopore 
sequencing relies on differential current drops as different bases pass through a small 
biological pore (146). Recently, there have been several papers that have laid the 
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groundwork for sequencing peptide chains using the same technology (147-150). In 
contrast to SOMAlogic’s approach, this would yield protein primary sequence 
information on par with mass spectrometry. This technology is in a very early stage with 
a number of proof-of-principle experiments that still need to be completed. To the best of 
my knowledge, however, this is the only novel protein sequencing technology currently 
being developed which would provide the same level of information as the assay 
described in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19	  
REFERENCES 
1. Ahern TJ, Casal JI, Petsko GA, Klibanov AM (1987) Control of oligomeric enzyme 
thermostability by protein engineering. Proceedings of the National Academy of 
Sciences 84:675–679. 
 
2. Chen J, Lu Z, Sakon J, Stites WE (2000) Increasing the thermostability of 
staphylococcal nuclease: implications for the origin of protein thermostability. 
Journal of Molecular Biology 303:125–130. 
 
3. Eijsink VGH, Bjørk A, Gåseidnes S, Sirevåg R, Synstad B, Burg Bvd, Vriend G 
(2004) Rational engineering of enzyme stability. Journal of biotechnology 
113:105–120. 
 
4. Fersht AR, Serrano L (1993) Principles of protein stability derived from protein 
engineering experiments. Current Opinion in Structural Biology 3:75–83. 
 
5. Gribenko AV, Patel MM, Liu J, McCallum SA, Wang C, Makhatadze GI (2009) 
Rational stabilization of enzymes by computational redesign of surface charge–
charge interactions. Proceedings of the National Academy of Sciences 106:2601–
2606. 
 
6. Hoseki J, Yano T, Koyama Y, Kuramitsu S, Kagamiyama H (1999) Directed 
evolution of thermostable kanamycin-resistance gene: a convenient selection 
marker for Thermus thermophilus. Journal of biochemistry 126:951–956. 
 
7. Korkegian A, Black ME, Baker D, Stoddard BL (2005) Computational 
thermostabilization of an enzyme. Science 308:857–860. 
 
8. Lehmann M, Wyss M (2001) Engineering proteins for thermostability: the use of 
sequence alignments versus rational design and directed evolution. Current Opinion 
in Biotechnology 12:371–375. 
 
9. Matthews BW, Nicholson H, Becktel WJ (1987) Enhanced protein thermostability 
from site-directed mutations that decrease the entropy of unfolding. Proceedings of 
the National Academy of Sciences 84:6663–6667. 
 
10. Perl D, Mueller U, Heinemann U, Schmid FX (2000) Two exposed amino acid 
residues confer thermostability on a cold shock protein. Nature Structural & 
Molecular Biology 7:380–383. 
 
11. Perl D, Schmid FX (2001) Electrostatic stabilization of a thermophilic cold shock 
protein. Journal of molecular biology 313:343–357. 
 
 
 20	  
12. Baker D (2010) An exciting but challenging road ahead for computational enzyme 
design. Protein science 19:1817–1819. 
 
13. Frushicheva MP, Cao J, Chu ZT, Warshel A (2010) Exploring challenges in rational 
enzyme design by simulating the catalysis in artificial kemp eliminase. Proceedings 
of the National Academy of Sciences 107:16869–16874. 
 
14. Nanda V, Koder RL (2010) Designing artificial enzymes by intuition and 
computation. Nature chemistry 2:15–24. 
 
15. Privett HK, Kiss G, Lee TM, Blomberg R, Chica RA, Thomas LM, Hilvert D, Houk 
KN, Mayo SL (2012) Iterative approach to computational enzyme design. 
Proceedings of the National Academy of Sciences 109:3790–3795. 
 
16. Röthlisberger D, Khersonsky O, Wollacott AM, Jiang L, DeChancie J, Betker J, 
Gallaher JL, Althoff EA, Zanghellini A, Dym O (2008) Kemp elimination catalysts 
by computational enzyme design. Nature 453:190–195. 
 
17. Siegel JB, Zanghellini A, Lovick HM, Kiss G, Lambert AR, Clair JLS, Gallaher JL, 
Hilvert D, Gelb MH, Stoddard BL (2010) Computational design of an enzyme 
catalyst for a stereoselective bimolecular Diels-Alder reaction. Science 329:309–
313. 
 
18. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nature 
Reviews Cancer 1:118–129. 
 
19. Carter PJ (2006) Potent antibody therapeutics by design. Nature Reviews 
Immunology 6:343–357. 
 
20. Binz HK, Amstutz P, Plückthun A (2005) Engineering novel binding proteins from 
nonimmunoglobulin domains. Nature biotechnology 23:1257–1268. 
 
21. Presta LG (2008) Molecular engineering and design of therapeutic antibodies. 
Current opinion in immunology 20:460–470. 
 
22. Stayton PS, Hoffman AS, Murthy N, Lackey C, Cheung C, Tan P, Klumb LA, 
Chilkoti A, Wilbur FS, Press OW (2000) Molecular engineering of proteins and 
polymers for targeting and intracellular delivery of therapeutics. Journal of 
controlled release 65:203–220. 
 
23. Ulge UY, Baker DA, Monnat RJ (2011) Comprehensive computational design of 
mCreI homing endonuclease cleavage specificity for genome engineering. Nucleic 
acids research 39:4330–4339. 
 
24. Arı́s A, Villaverde A (2004) Modular protein engineering for non-viral gene 
therapy. Trends in biotechnology 22:371–377. 
 21	  
 
25. De Laporte L, Cruz Rea J, Shea LD (2006) Design of modular non-viral gene 
therapy vectors. Biomaterials 27:947–954. 
 
26. Hecht R, Li Y-S, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, 
Smith S (2012) Rationale-based engineering of a potent long-acting FGF21 analog 
for the treatment of Type 2 diabetes. PloS one 7:e49345. 
 
27. Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA (2010) Structure-based 
design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Current 
opinion in structural biology 20:54–62. 
 
28. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW 
(2005) Native state kinetic stabilization as a strategy to ameliorate protein 
misfolding diseases: a focus on the transthyretin amyloidoses. Accounts of chemical 
research 38:911–921. 
 
29. Lachmann RH (2011) Enzyme replacement therapy for lysosomal storage diseases. 
Current opinion in pediatrics 23:588–593. 
 
30. Alcalde M, Ferrer M, Plou FJ, Ballesteros A (2006) Environmental biocatalysis: 
from remediation with enzymes to novel green processes. TRENDS in 
Biotechnology 24:281–287. 
 
31. Gavrilescu M, Chisti Y (2005) Biotechnology—a sustainable alternative for 
chemical industry. Biotechnology advances 23:471–499. 
 
32. Hatti-Kaul R, Törnvall U, Gustafsson L, Börjesson P (2007) Industrial 
biotechnology for the production of bio-based chemicals–a cradle-to-grave 
perspective. Trends in biotechnology 25:119–124. 
 
 
33. Pollard DJ, Woodley JM (2007) Biocatalysis for pharmaceutical intermediates: the 
future is now. Trends in biotechnology 25:66–73. 
 
34. Tao J, Xu J-H (2009) Biocatalysis in development of green pharmaceutical 
processes. Current opinion in chemical biology 13:43–50. 
 
35. Woodley JM (2008) New opportunities for biocatalysis: making pharmaceutical 
processes greener. Trends in biotechnology 26:321–327. 
 
36. Lanio T, Jeltsch A, Pingoud A (2000) On the possibilities and limitations of rational 
protein design to expand the specificity of restriction enzymes: a case study 
employing EcoRV as the target. Protein engineering 13:275–281. 
 
 
 22	  
37. Pokala N, Handel TM (2001) Review: protein design—where we were, where we 
are, where we're going. Journal of structural biology 134:269–281. 
 
38. Arnold FH (1998) Design by directed evolution. Accounts of chemical research 
31:125–131. 
 
39. Eijsink VGH, Gåseidnes S, Borchert TV, van den Burg B (2005) Directed evolution 
of enzyme stability. Biomolecular engineering 22:21–30. 
 
40. Jäckel C, Kast P, Hilvert D (2008) Protein design by directed evolution. Annu Rev 
Biophys 37:153–173. 
 
41. Kuchner O, Arnold FH (1997) Directed evolution of enzyme catalysts. Trends in 
biotechnology 15:523–530. 
 
42. Powell KA, Ramer SW, del Cardayré SB, Stemmer WPC, Tobin MB, Longchamp 
PF, Huisman GW (2001) Directed evolution and biocatalysis. Angewandte Chemie 
International Edition 40:3948–3959. 
 
43. Chica RA, Doucet N, Pelletier JN (2005) Semi-rational approaches to engineering 
enzyme activity: combining the benefits of directed evolution and rational design. 
Current Opinion in Biotechnology 16:378–384. 
 
44. Lutz S (2010) Beyond directed evolution—semi-rational protein engineering and 
design. Current opinion in biotechnology 21:734–743. 
 
45. Lippow SM, Tidor B (2007) Progress in computational protein design. Current 
opinion in biotechnology 18:305–311. 
 
46. Mannhold R, Kubinyi H, Folkers G, Böhm H-J, Schneider G (2006) Protein-ligand 
interactions: from molecular recognition to drug design (John Wiley & Sons). 
 
47. Baron R, McCammon JA (2013) Molecular recognition and ligand association. 
Annual review of physical chemistry 64:151–175. 
 
48. Katchalski-Katzir E, Shariv I, Eisenstein M, Friesem AA, Aflalo C, Vakser IA 
(1992) Molecular surface recognition: determination of geometric fit between 
proteins and their ligands by correlation techniques. Proceedings of the National 
Academy of Sciences 89:2195–2199. 
 
49. DeChancie J, Houk KN (2007) The origins of femtomolar protein-ligand binding: 
hydrogen-bond cooperativity and desolvation energetics in the biotin-(strept) avidin 
binding site. Journal of the American Chemical Society 129:5419–5429. 
 
50. Diamandis EP, Christopoulos TK (1991) The biotin-(strept) avidin system: 
principles and applications in biotechnology. Clinical chemistry 37:625–636. 
 23	  
 
51. Wilchek M, Bayer EA, Livnah O (2006) Essentials of biorecognition: the (strept) 
avidin–biotin system as a model for protein–protein and protein–ligand interaction. 
Immunology letters 103:27–32. 
 
52. Weber PC, Ohlendorf DH, Wendoloski JJ, Salemme FR (1989) Structural origins of 
high-affinity biotin binding to streptavidin. Science 243:85–88. 
 
53. Saven JG (2008) Computational protein design. Protein Engineering Handbook, 
Volume 1 & Volume 2 325–342. 
 
54. Street AG, Mayo SL (1999) Computational protein design. Structure 7:R105–R109. 
 
55. Donald BR (2011) Algorithms in structural molecular biology (The MIT Press) 
 
56. Butterfoss GL, Kuhlman B (2006) Computer-based design of novel protein 
structures. Annu Rev Biophys Biomol Struct 35:49–65. 
 
57. Das R, Baker D (2008) Macromolecular modeling with rosetta. Annu Rev Biochem 
77:363–382. 
 
58. Kaufmann KW, Lemmon GH, DeLuca SL, Sheehan JH, Meiler J (2010) Practically 
useful: what the Rosetta protein modeling suite can do for you. Biochemistry 
49:2987–2998. 
 
59. Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, Kaufman K, 
Renfrew PD, Smith CA, Sheffler W (2011) ROSETTA3: an object-oriented 
software suite for the simulation and design of macromolecules. Methods Enzymol 
487:545–574. 
 
60. Liu Y, Kuhlman B (2006) RosettaDesign server for protein design. Nucleic acids 
research 34:W235–W238. 
 
61. Boas FE, Harbury PB (2007) Potential energy functions for protein design. Current 
opinion in structural biology 17:199–204. 
 
62. Gordon DB, Marshall SA, Mayot SL (1999) Energy functions for protein design. 
Current opinion in structural biology 9:509–513. 
 
63. Hao M-H, Scheragat HA (1999) Designing potential energy functions for protein 
folding. Current opinion in structural biology 9:184–188. 
 
64. Lazaridis T, Karplus M (2000) Effective energy functions for protein structure 
prediction. Current opinion in structural biology 10:139–145. 
 
 
 24	  
65. Pokala N, Handel TM (2004) Energy functions for protein design I: efficient and 
accurate continuum electrostatics and solvation. Protein science 13:925–936. 
 
66. Pokala N, Handel TM (2005) Energy functions for protein design: adjustment with 
protein–protein complex affinities, models for the unfolded state, and negative 
design of solubility and specificity. Journal of molecular biology 347:203–227. 
 
67. Gohlke H, Hendlich M, Klebe G (2000) Knowledge-based scoring function to 
predict protein-ligand interactions. Journal of molecular biology 295:337–356. 
 
68. Lu H, Skolnick J (2001) A distance‐dependent atomic knowledge‐based potential 
for improved protein structure selection. Proteins: Structure, Function, and 
Bioinformatics 44:223–232. 
 
69. Poole AM, Ranganathan R (2006) Knowledge-based potentials in protein design. 
Current opinion in structural biology 16:508–513. 
 
70. Rojnuckarin A, Subramaniam S (1999) Knowledge‐based interaction potentials for 
proteins. Proteins: Structure, Function, and Bioinformatics 36:54–67. 
 
71. Sippl MJ (1990) Calculation of conformational ensembles from potentials of mena 
force: an approach to the knowledge-based prediction of local structures in globular 
proteins. Journal of molecular biology 213:859–883. 
 
72. Sippl MJ (1995) Knowledge-based potentials for proteins. Current opinion in 
structural biology 5:229–235. 
 
73. Link AJ, Mock ML, Tirrell DA (2003) Non-canonical amino acids in protein 
engineering. Current opinion in biotechnology 14:603–609. 
 
74. Lu Y (2005) Design and engineering of metalloproteins containing unnatural amino 
acids or non-native metal-containing cofactors. Current opinion in chemical biology 
9:118–126. 
 
75. Yoder NC, Kumar K (2002) Fluorinated amino acids in protein design and 
engineering. Chemical Society Reviews 31:335–341. 
 
76. Dunbrack Jr RL, Karplus M (1993) Backbone-dependent rotamer library for 
proteins application to side-chain prediction. Journal of molecular biology 
230:543–574. 
 
77. Dunbrack RL, Cohen FE (1997) Bayesian statistical analysis of protein side‐chain 
rotamer preferences. Protein Science 6:1661–1681. 
 
 
 25	  
78. Dunbrack RL, Karplus M (1994) Conformational analysis of the backbone-
dependent rotamer preferences of protein sidechains. Nature Structural & 
Molecular Biology 1:334–340. 
 
79. Dunbrack Jr RL (2002) Rotamer Libraries in the 21st Century. Current opinion in 
structural biology 12:431–440. 
 
80. Berman H, Henrick K, Nakamura H, Markley JL (2007) The worldwide Protein 
Data Bank (wwPDB): ensuring a single, uniform archive of PDB data. Nucleic 
acids research 35:D301–D303. 
 
81. Sussman JL, Lin D, Jiang J, Manning NO, Prilusky J, Ritter O, Abola EE (1998) 
Protein Data Bank (PDB): database of three-dimensional structural information of 
biological macromolecules. Acta Crystallographica Section D: Biological 
Crystallography 54:1078–1084. 
 
82. Joachimiak LA, Kortemme T, Stoddard BL, Baker D (2006) Computational design 
of a new hydrogen bond network and at least a 300-fold specificity switch at a 
protein− protein interface. Journal of molecular biology 361:195–208. 
 
83. Kortemme T, Baker D (2004) Computational design of protein–protein interactions. 
Current opinion in chemical biology 8:91–97. 
 
84. Looger LL, Dwyer MA, Smith JJ, Hellinga HW (2003) Computational design of 
receptor and sensor proteins with novel functions. Nature 423:185–190. 
 
85. Kortemme T, Joachimiak LA, Bullock AN, Schuler AD, Stoddard BL, Baker D 
(2004) Computational redesign of protein-protein interaction specificity. Nature 
structural & molecular biology 11:371–379. 
 
86. Karanicolas J, Kuhlman B (2009) Computational design of affinity and specificity 
at protein–protein interfaces. Current opinion in structural biology 19:458–463. 
 
87. Grigoryan G, Reinke AW, Keating AE (2009) Design of protein-interaction 
specificity gives selective bZIP-binding peptides. Nature 458:859–864. 
 
88. Lippow SM, Wittrup KD, Tidor B (2007) Computational design of antibody-
affinity improvement beyond in vivo maturation. Nature biotechnology 25:1171–
1176. 
 
89. Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, Gnanapragasam 
PNP, Abadir A, Seaman MS, Nussenzweig MC (2011) Increasing the potency and 
breadth of an HIV antibody by using structure-based rational design. Science 
334:1289–1293. 
 
 26	  
90. Chevalier BS, Kortemme T, Chadsey MS, Baker D, Monnat Jr RJ, Stoddard BL 
(2002) Design, activity, and structure of a highly specific artificial endonuclease. 
Molecular cell 10:895–905. 
 
91. Ashworth J, Taylor GK, Havranek JJ, Quadri SA, Stoddard BL, Baker D (2010) 
Computational reprogramming of homing endonuclease specificity at multiple 
adjacent base pairs. Nucleic acids research 38:5601–5608. 
 
92. Thyme SB, Jarjour J, Takeuchi R, Havranek JJ, Ashworth J, Scharenberg AM, 
Stoddard BL, Baker D (2009) Exploitation of binding energy for catalysis and 
design. Nature 461:1300–1304. 
 
93. Falke D, Fisher M, Ye D, Juliano RL (2003) Design of artificial transcription 
factors to selectively regulate the pro‐apoptotic bax gene. Nucleic acids research 
31:e10–e10. 
 
94. Sera T (2009) Zinc-finger-based artificial transcription factors and their 
applications. Advanced drug delivery reviews 61:513–526. 
 
95. Kuhlman B, Dantas G, Ireton GC, Varani G, Stoddard BL, Baker D (2003) Design 
of a novel globular protein fold with atomic-level accuracy. Science 302:1364–
1368. 
 
96. King NP, Sheffler W, Sawaya MR, Vollmar BS, Sumida JP, André I, Gonen T, 
Yeates TO, Baker D (2012) Computational design of self-assembling protein 
nanomaterials with atomic level accuracy. Science 336:1171–1174. 
 
97. Caravella J, Lugovskoy A (2010) Design of next-generation protein therapeutics. 
Current opinion in chemical biology 14:520–528. 
 
98. Carter PJ (2011) Introduction to current and future protein therapeutics: a protein 
engineering perspective. Experimental cell research 317:1261–1269. 
 
99. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR (2003) Rational design and 
engineering of therapeutic proteins. Drug discovery today 8:212–221. 
 
100. Stayton PS, Hoffman AS, Murthy N, Lackey C, Cheung C, Tan P, Klumb LA, 
Chilkoti A, Wilbur FS, Press OW (2000) Molecular engineering of proteins and 
polymers for targeting and intracellular delivery of therapeutics. Journal of 
controlled release 65:203–220. 
 
101. Sippl MJ (1993) Boltzmann's principle, knowledge-based mean fields and protein 
folding. An approach to the computational determination of protein structures. 
Journal of computer-aided molecular design 7:473–501. 
 
 27	  
102. Archontis G, Simonson T (2005) A residue-pairwise Generalized Born scheme 
suitable for protein design calculations. The Journal of Physical Chemistry B 
109:22667–22673. 
 
103. Lazaridis T, Karplus M (1999) Effective energy function for proteins in solution. 
Proteins: Structure, Function, and Bioinformatics 35:133–152. 
 
104. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and 
pharmacological classification. Nature Reviews Drug Discovery 7:21–39. 
 
105. Mank M, Reiff DF, Heim N, Friedrich MW, Borst A, Griesbeck O (2006) A FRET-
based calcium biosensor with fast signal kinetics and high fluorescence change. 
Biophysical journal 90:1790–1796. 
 
106. Mank M, Santos AF, Direnberger S, Mrsic-Flogel TD, Hofer SB, Stein V, Hendel 
T, Reiff DF, Levelt C, Borst A (2008) A genetically encoded calcium indicator for 
chronic in vivo two-photon imaging. Nature Methods 5:805–811. 
 
107. Peralta‐Yahya PP, Keasling JD (2010) Advanced biofuel production in microbes. 
Biotechnology Journal 5:147–162. 
 
108. Bornscheuer UT, Huisman GW, Kazlauskas RJ, Lutz S, Moore JC, Robins K 
(2012) Engineering the third wave of biocatalysis. Nature 485:185–194. 
 
109. Wen F, Nair NU, Zhao H (2009) Protein engineering in designing tailored enzymes 
and microorganisms for biofuels production. Current opinion in biotechnology 
20:412–419. 
 
110. Kim J, Jia H, Wang P (2006) Challenges in biocatalysis for enzyme-based biofuel 
cells. Biotechnology advances 24:296–308. 
 
111. Minteer SD, Liaw BY, Cooney MJ (2007) Enzyme-based biofuel cells. Current 
opinion in biotechnology 18:228–234. 
 
112. Moehlenbrock MJ, Minteer SD (2008) Extended lifetime biofuel cells. Chemical 
Society Reviews 37:1188–1196. 
 
113. Mårtensson L-G, Karlsson M, Carlsson U (2002) Dramatic stabilization of the 
native state of human carbonic anhydrase II by an engineered disulfide bond. 
Biochemistry 41:15867–15875. 
 
114. Savile CK, Lalonde JJ (2011) Biotechnology for the acceleration of carbon dioxide 
capture and sequestration. Current opinion in biotechnology 22:818–823. 
 
 
 28	  
115. Arias FJ, Santos M, Fernandez-Colino A, Pinedo G, Girotti A (2014) Recent 
Contributions Of Elastin-Like Recombinamers To Biomedicine And 
Nanotechnology. Curr Top Med Chem.  
 
116. Main ER, Phillips JJ, Millership C (2013) Repeat protein engineering: creating 
functional nanostructures/biomaterials from modular building blocks. Biochem Soc 
Trans 41:1152–1158. 
 
117. Walters BD, Stegemann JP (2013) Strategies for directing the structure and function 
of three-dimensional collagen biomaterials across length scales. Acta Biomater  
 
118. Wong JY, McDonald J, Taylor-Pinney M, Spivak DI, Kaplan DL, Buehler MJ 
(2012) Materials by Design: Merging Proteins and Music. Nano Today 7:488–495. 
 
119. DiMarco RL, Heilshorn SC (2012) Multifunctional materials through modular 
protein engineering. Adv Mater 24:3923–3940. 
 
120. Straley K, Heilshorn SC (2009) Designer protein-based scaffolds for neural tissue 
engineering. Conf Proc IEEE Eng Med Biol Soc 2009:2101–2102. 
 
121. Sengupta D, Heilshorn SC (2010) Protein-engineered biomaterials: highly tunable 
tissue engineering scaffolds. Tissue Eng Part B Rev 16:285–293. 
 
122. Grigoryan G, Kim YH, Acharya R, Axelrod K, Jain RM, Willis L, Drndic M, 
Kikkawa JM, DeGrado WF (2011) Computational design of virus-like protein 
assemblies on carbon nanotube surfaces. Science 332:1071–1076. 
 
123. Zhang Y, Fonslow BR, Shan B, Baek MC, Yates JRr (2013) Protein analysis by 
shotgun/bottom-up proteomics. Chem Rev 113:2343–2394. 
 
124. Van Riper SK, de Jong EP, Carlis JV, Griffin TJ (2013) Mass spectrometry-based 
proteomics: basic principles and emerging technologies and directions. Adv Exp 
Med Biol 990:1–35. 
 
125. Vaudel M, Sickmann A, Martens L (2014) Introduction to opportunities and pitfalls 
in functional mass spectrometry based proteomics. Biochim Biophys Acta 1844:12–
20. 
 
126. Chen T, Kao M-Y, Tepel M, Rush J, Church GM (2001) A dynamic programming 
approach to de novo peptide sequencing via tandem mass spectrometry. Journal of 
Computational Biology 8:325–337. 
 
127. Ma B, Zhang K, Hendrie C, Liang C, Li M, Doherty‐Kirby A, Lajoie G (2003) 
PEAKS: powerful software for peptide de novo sequencing by tandem mass 
spectrometry. Rapid communications in mass spectrometry 17:2337–2342. 
 
 29	  
128. Taylor JA, Johnson RS (2001) Implementation and uses of automated de novo 
peptide sequencing by tandem mass spectrometry. Analytical chemistry 73:2594–
2604. 
 
129. Frank AM, Savitski MM, Nielsen ML, Zubarev RA, Pevzner PA (2007) De novo 
peptide sequencing and identification with precision mass spectrometry. Journal of 
proteome research 6:114–123. 
 
130. Münchbach M, Quadroni M, Miotto G, James P (2000) Quantitation and facilitated 
de novo sequencing of proteins by isotopic N-terminal labeling of peptides with a 
fragmentation-directing moiety. Analytical chemistry 72:4047–4057. 
 
131. Cagney G, Emili A (2002) De novo peptide sequencing and quantitative profiling of 
complex protein mixtures using mass-coded abundance tagging. Nature 
biotechnology 20:163–170. 
 
132. Dancik V, Addona TA, Clauser KR, Vath JE, Pevzner PA (1999) De novo peptide 
sequencing via tandem mass spectrometry. Journal of computational biology 
6:327–342. 
 
133. Shevchenko A, Chernushevich I, Ens W, Standing KG, Thomson B, Wilm M, 
Mann M (1997) Rapid'de novo'peptide sequencing by a combination of 
nanoelectrospray, isotopic labeling and a quadrupole/time-of-flight mass 
spectrometer. Rapid Communications in Mass Spectrometry 11:1015–1024. 
 
134. Taylor JA, Johnson RS (1997) Sequence database searches via de novo peptide 
sequencing by tandem mass spectrometry. Rapid Communications in Mass 
Spectrometry 11:1067–1075. 
 
135. Graveley BR (2001) Alternative splicing: increasing diversity in the proteomic 
world. TRENDS in Genetics 17:100–107. 
 
136. Home BCM, Centers BCM Alternative Splicing and its Significance.  
 
137. Lareau LF, Green RE, Bhatnagar RS, Brenner SE (2004) The evolving roles of 
alternative splicing. Current opinion in structural biology 14:273–282. 
 
138. Edman P (1950) Method for determination of the amino acid sequence in peptides. 
Acta chem scand 4:7. 
 
139. Edman P (1956) On the mechanism of the phenyl isothiocyanate degradation of 
peptides. Acta chem scand 10:761–768. 
 
140. Han KK, Tetaert D, Debuire B, Dautrevaux M, Biserte G (1976) [Sequential Edman 
degredation]. Biochimie 59:557–576. 
 
 30	  
141. Niall HD (1973) Automated Edman degradation: the protein sequenator. Methods in 
enzymology 27:942. 
 
142. Mehan MR, Ostroff R, Wilcox SK, Steele F, Schneider D, Jarvis TC, Baird GS, 
Gold L, Janjic N (2013) in Complement Therapeutics, (Springer, pp 283–300. 
 
143. Ostroff R, Foreman T, Keeney TR, Stratford S, Walker JJ, Zichi D (2010) The 
stability of the circulating human proteome to variations in sample collection and 
handling procedures measured with an aptamer-based proteomics array. Journal of 
proteomics 73:649–666. 
 
144. Wilson R (2011) High-content aptamer-based proteomics. Journal of proteomics 
74:1852–1854. 
 
145. Shendure J, Ji H (2008) Next-generation DNA sequencing. Nature biotechnology 
26:1135–1145. 
 
146. Clarke J, Wu H-C, Jayasinghe L, Patel A, Reid S, Bayley H (2009) Continuous base 
identification for single-molecule nanopore DNA sequencing. Nature 
nanotechnology 4:265–270. 
 
147. Sutherland TC, Long Y-T, Stefureac R-I, Bediako-Amoa I, Kraatz H-B, Lee JS 
(2004) Structure of peptides investigated by nanopore analysis. Nano letters 
4:1273–1277. 
 
148. Talaga DS, Li J (2009) Single-molecule protein unfolding in solid state nanopores. 
Journal of the American Chemical Society 131:9287–9297. 
 
149. Nivala J, Marks DB, Akeson M (2013) Unfoldase-mediated protein translocation 
through an [alpha]-hemolysin nanopore. Nature biotechnology.  
 
150. Larkin J, Henley RY, Muthukumar M, Rosenstein… JK (2014) High-Bandwidth 
Protein Analysis Using Solid-State Nanopores. Biophysical journal . 
 
151. Eich RF, Li T, Lemon DD, Doherty DH, Curry SR, Aitken JF, Mathews AJ, 
Johnson KA, Smith RD, Phillips GN (1996) Mechanism of NO-induced oxidation 
of myoglobin and hemoglobin. Biochemistry 35:6976–6983. 
 
152. Eren E, Parkin J, Adelanwa A, Cheneke B, Movileanu L, Khalid S, Van den Berg B 
(2013) Toward Understanding the Outer Membrane Uptake of Small Molecules by 
Pseudomonas aeruginosa. Journal of Biological Chemistry 288:12042–12053. 
 
153. Wu H-Y, Liu M-S, Lin T-P, Cheng Y-S (2011) Structural and functional assays of 
AtTLP18. 3 identify its novel acid phosphatase activity in thylakoid lumen. Plant 
physiology 157:1015–1025. 
 
 31	  
FIGURE 1: Number of papers in proteomics and genomics from 2000-2013. A 
keyword search on PubMed illustrates that papers using genomics techniques, 
specifically DNA sequencing and analysis, are far more prevalent than proteomics 
research. 
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FIGURE 2: DAPES and the Edman reaction. A schematic of the proposed protein 
sequencing method, DAPES, is shown in (A). N-terminal amino acids are bound with a 
flouresent probe and imaged. The bind-image cycle is repeated for a probe specific to 
each amino acid. All N-terminal amino acids on the array are then removed using the 
Edman degredation (B), and the process is repeated to identify the primary sequence of 
each peptide on the array. 
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FIGURE 3: The 20 canonical amino acids. Molecular structures and selected properties 
are shown below. These serve both as the building blocks for protein design and illustrate 
the difficulty of engineering a set of probes which binds each side chain with specificity. 
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FIGURE 4: Protein secondary structure types. Shown in blue are examples of alpha-
helices (A), beta-sheet regions (B), short beta-turn (C), extended beta turn (C, red), and 
disordered loop region (D). 
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FIGURE 5: Examples of protein folds. (A) The number of classified protein folds from 
the SCOP database from 1997 to 2013. No new folds have been identified since 2008. 
(B) One of the first structures determined was that of myoglobin, which exhibits an 
alpha-helical fold and binds a heme cofactor (PDB 1TES(151)). (C) A beta-barrel protein 
from pseudomonas (PDB 4FOZ(152)). (D) The Rossman fold, a member of the alpha-
beta superfamily (PDB 3PTJ(153)). (E) The first novel fold achieved by computational 
design, Top7 (PDB 1QYS(95)). 
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FIGURE 6: Biotin-streptavidin interaction, one of the strongest non-covalent 
interactions known. The high specificity and affinity are achieved using many of the 
physical interactions that protein design seeks to harness including steric 
complementarity, extensive hydrogen bonding networks, and surface electrostatics. The 
various force-fields used in computational design allow us to create and modify these 
interactions to achieve novel affinities and activities. 
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FIGURE 7: Computational protein design methods. (A) Several examples of 
fundamental physics-based energy functions used in computational protein design. (B) 
An example of a knowledge based energy, the amino acid dependence of backbone 
torsion angles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38	  
CHAPTER 2:  
MINIMAL ENGINEERING OF A SET OF N-
TERMINAL AMINO ACID BINDING 
PROTEINS FROM tRNA SYNTHETASES  
 
This chapter consists of work that will be combined with chapter 3 in a manuscript that is 
currently being prepared for publication. I carried out all of the experiments, which were 
conceived by Jim Havranek and myself.  
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ABSTRACT 
 
 The studious choice of scaffolds is a critical component of successfully designing 
functional proteins. As our database of protein structures rapidly grows, the chance of 
finding a design scaffold with a function or specificity similar to the design target also 
increases. It is therefore desirable to test and catalogue general strategies for altering or 
improving native interactions in a way that is minimally disruptive to the rest of the 
protein. These approaches are also useful when naturally occurring proteins provide 
inherent specificity that would otherwise be extremely difficult to design. In this chapter, 
I enumerate several of these strategies and implement them to improve the affinity of 
amino-acid tRNA synthetases, the basis of our molecular tool-kit of NAABs. I also 
characterize a series of native and truncated synthetases that are utilized in the formation 
of a biomolecular tool-kit for single molecule protein sequencing. 
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INTRODUCTION 
 
 Rational protein design can refer either to the de novo, “bottom-up” design of a 
folded, functional molecule, designed directly from primary sequence or to the redesign 
of existing protein scaffolds (1). The former provides a stringent and comprehensive test 
of our knowledge of protein structure, folding, stability and function and represents the 
ultimate goal of protein engineers. The combinatorial complexity of predicting a folded 
protein conformation from primary sequence renders such engineering efforts 
extraordinary difficult. Despite this difficulty, several groups have made strides in this 
type of protein design (2-9). Nearly all practical design problems, however, have relied 
on protein redesign, or “top-down” design	  (10-15). In this approach, a known, stable 
scaffold is repurposed to produce a new protein with altered enzymatic or interaction 
activity. Top-down design makes use of the hypothesis that nature has already supplied 
the ambitious protein engineer with a wide variety of building blocks to generate a vast 
number of proteins with practical applications in biotechnology. 
 
 While the top-down design concept is the cornerstone of protein engineering by 
directed-evolution techniques, it has also been heavily utilized by the rational design 
community. Several groups have implemented variations on this strategy both as proof-
of-principle and in practical applications. Novel protein-protein interfaces have been 
designed which have native-like or better affinities (11). The DNA specificity of both 
transcription factors and restriction enzymes has been successfully altered (10, 16-18). 
Enzymes have been re-designed to catalyze new reactions or alter the balance of 
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intermediate products in metabolic pathways (19-22). One group has rationally re-
designed a cellular entry protein to change the organism specificity of an invasive 
microbe (23). Here we extend the minimalist design principles associated top-down 
redesign to generate a novel tool-kit for a biotechnological application: single-molecule 
protein sequencing. 
 
 Recently, a technique has been proposed for sequencing individual peptide chains 
using single-molecule imaging via Total-internal Reflectance microscopy (TIRFm). The 
assay, dubbed Digital Analysis of Proteins by End Sequencing (DAPES), revolves 
around sequential sequencing of short peptide reads using parallelized Edman 
degradation. Briefly, a complex mixture of proteins is digested into short fragments and 
immobilized onto a slide. Fluorescently labeled probes specific to each individual, N-
terminal amino-acid side chain are then flowed over the surface, and the bound probe is 
imaged using TIRFm to determine the identity of each N-terminal amino acid on the 
slide. Next, the N-terminal amino acid is removed from each peptide chain by Edman 
degradation, and the process is repeated sequentially. This process is summarized in 
Figure 8.  
  
 To help make DAPES feasible, we have implemented minimalist protein design 
on a series of strategically chosen scaffolds to generate a set of N-terminal Amino Acid 
Binding probes (NAABs) that recognize each side chain with varying specificity.  
Furthermore, we have experimentally characterized a complete set of NAABs using 
native and designed probes for identifying each of the canonical amino acids. Our results 
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demonstrate that the each NAAB exhibits an affinity for its cognate amino acid with a KD 
no worse than the µM range, and that the set of NAABs contains a minimum of four 
distinct groups of specificity profiles. 
 
RESULTS 
Modeling and selection of truncations 
 The physio-chemical similarity of many groups of amino acids makes engineering 
NAABs exceptionally challenging, hence an appropriate starting point is critical. We 
choose to use the amino acid tRNA syntheses (aaRSs). aaRSs are a critical component of 
protein biosynthesis in all known organisms. Each aaRS is an enzyme that binds it's 
cognate amino acid and it's cognate tRNA, then catalyzes the amino-acylation reaction to 
charge tRNAs which then have their newly attached amino acid incorporated into a 
growing peptide chain by the ribosome (24). The advantage of the aaRSs for our 
application is that they have natural affinity and specificity for each amino acid side-
chain. A disadvantage is that many aaRSs are known to bind their tRNA and amino acid 
cooperatively (25-27), hence the absence of one binding partner (the tRNA in our case) 
may decrease the affinity or specificity for it's cognate amino acid. 
 
 Several structural models for each aaRS are available in the PDB (Table 1). Using 
this structural data, we observed that most aaRSs have a distinct domain for binding the 
amino-acid and a distinct domain for binding the tRNA. We reasoned that removal of the 
tRNA binding domains would reduce the need for tRNAs to simultaneously bind in 
concert with the cognate amino acid. Using the available structures as templates, we first 
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generated homology models for each aaRS from E. coli. We then rationally identified 
truncation mutants that led to only minor decreases in predicted Rosetta energies (28, 29) 
(Figure 9). This rational, computationally aided design strategy led us to identify soluble 
truncation mutants for most of the aaRSs. A few were either already monomers or had 
suitable truncations identified from previous works (Table 2).  
 
Increasing pocket accessibility by loop redesign improves affinity of hisRS. 
 During the homology modeling and substrate docking, we noticed that several of 
the placed peptide substrates showed significant steric clash with the surrounding NAAB 
domain. While this is not surprising, considering that the aaRSs natively bind an isolated 
amino acid, rather than an N-terminal amino acid, we reasoned that this could be a 
potential affinity-robbing property for our NAABs. For each NAAB, we modeled the 
peptide substrate with the N-terminal amino acid superimposed on the empirically 
determined, bound position of the cognate amino acid. In examining the modeled 
structures, we found several instances where a large loop occluded the ability of the 
peptide substrate to position its N-terminus in the required location. We reasoned that 
removing this obstacle could improve the binding affinity of our NAABs.  
 
 We identified a candidate loop in hisRS, which had a truncation mutant with a 
high µM affinity. This loop (Figure 11) linked a pair of anti-parallel beta sheets and could 
potential obstruct substrate binding, especially with the modeled peptide. In the crystal 
structure, this loop has direct overlap with the third and fourth amino acid of the peptide 
substrate. Furthermore, these clashes cannot be resolved by loop remodeling, energy 
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minimization, or a combination of the two. One approach might be to mutate several of 
the loop residues to glycine, which might allow the loop to pivot out of the pocket. 
However, this could also have undesirable effects on binding depending on the dynamics, 
which are difficult to model. 
 
 Instead, we chose to remove this loop at each of its termini and replace it with a 
canonical, four amino acid beta-turn. This type of motif grafting has been used by 
previous groups to design proteins or for structural modeling (30, 31), and is a natural 
extension to fragment insertion (30, 31). The grafted loop removes all direct contact with 
the modeled peptide substrate. Additionally, the Rosetta energy for the apo-design is not 
significantly worse than the apo-truncation, indicating that the binding pocket should 
remain unaltered.  
 
 The engineered mutant was expressed and purified as described in the methods 
section, then assayed for binding affinity using BLI (see methods). The mutant exhibited 
almost a full order of magnitude improvement in binding affinity, from 294.0 µM to 68.2 
µM. Additionally, the improvement is almost exclusively in the association rate, while 
the dissociation rate remains unchanged (Figure 11). This supports the hypothesis that 
pocket occlusion was a barrier to binding the unnatural substrate. 
 
Switching binding mechanism from induced fit to lock-and-key increases the 
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affinity of metRS. 
 The observation that the in vitro function of the aaRSs utilizes cooperative 
binding of tRNAs and amino acids motivated us to generate truncation mutants to 
alleviate this codependency. We reasoned that the necessity of a cognate tRNA to 
cooperatively improve binding affinity for a cognate amino acid was only partially 
alleviated by the removal of the tRNA binding domain. Additional improvement to our 
NAABs could potentially be gained by further decreasing the dependence of affinity on 
the tRNA cofactor. A previous study generated a metRS that was demonstrated to show a 
binding mechanism swap from induced fit to lock-and-key (32). This study had classified 
the mutated tRNA synthetase as an active, acylating enzyme. They additionally solved 
the mutant crystal structure in both apo and holo forms to determine that the binding 
mechanism had been changed by their mutations. The choice of appropriate mutations 
relies heavily on knowledge of both the apo and holo crystal structures, which places a 
significant restriction on the generality of this approach.  
 
 We modeled a peptide substrate into the binding pocket of the mutated holo 
structure. Evaluation of the Rosetta energy revealed one amino acid, an aspartate 
immediately adjacent to the active site, which had poorly matched interactions with the 
substrate (Figure 12). We reasoned that removing this interaction would be essential to 
promoting substrate binding and thus mutated this amino acid to a glycine, which 
alleviated the energetic penalty. 
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 The resulting mutated protein was expressed and purified as described in the 
methods, and assayed for binding affinity using BLI. We found that the dissociation 
constant was improved by nearly 5-fold, from 305.1 µM to 60.7 µM (Table 3). Further 
characterization revealed that the affinity for several other amino acids also increased, so 
the change was not specific to methionine. Both leucine and isoleucine are also bound 
more tightly by the lock-and-key metRS, however, the affinity for the remaining amino 
acids was unaffected. 
 
Reengineering the surface of pheRS to improve solubility also increases its 
affinity towards phenylalanine. 
 A third approach we used to increase the NAAB binding affinity was to stabilize 
the truncation mutant. In the case of pheRS, implementing the domain truncation 
drastically decreased the stability of the NAAB and led to the formation of aggregates on 
the DAPES surface. Examination of the structural model showed that the truncation was 
significantly different from the other aaRSs in that ~60% of the truncation’s surface area 
was previously buried. A previous study demonstrated that placing large amounts of like 
charge on the surface of designed proteins increased thermo-tolerance of these proteins 
(33). We reasoned that we could alleviate the aggregation problem by following this 
strategy.  
 
 We implemented 12 mutations on the surface of the pheRS mutant (Figure 13) 
and observed a drastic decrease in surface adsorption using the single molecule detection 
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surface described in (34). We then characterized the binding using BLI (described in the 
methods). Surprisingly, the affinity of the pheRS for its cognate peptide substrate was 
increased by approximately 16-fold (62.9 µM for the native compared to 3.91 µM for the 
design). We hypothesize that this increase is due to a stabilization of phenylalanine 
binding pocket, and is similar to swapping the binding mechanism as described above. 
 
Full experimental characterization of binding affinities and cross 
specificities. 
 The complete set of NAABs, which includes the three designed NAABs along 
with 14 truncation and native tRNA synthetases, is described in Table 1. We 
characterized the affinity of each NAAB for it’s cognate amino acid as well as all the 
other canonical amino acids relevant to the DAPES assay (Table 3). Cysteine is omitted 
since, as in DAPES, we use thiol-chemistry to couple the peptides to our surface and 
have gone through considerable optimization to assure the absence of exposed thiols. We 
expressed each of the truncation mutants or the engineered mutants as described in the 
methods section of this chapter and characterized their binding to each N-terminal amino 
acid with BLI using short, pentapeptide substrates. Many of the probes behave as 
expected. Both the argRS and trpRS truncations bind their cognate amino acids with nM 
affinity, and nearly all the NAABs bind their cognate substrates with at least low µM 
affinity (Figure 10). This demonstrates that our computationally guided truncation 
strategy produced a set of stable proteins that maintain a substantial portion of their 
native recognition properties. There is, however, abundant cross specificity that we see as 
strong affinities off the diagonal of the matrix.  
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NAAB cross-specificities cluster according to physio-chemical 
characteristics. 
 Having quantified all the possible binding events we wanted to determine whether 
or not some NAABs were redundant. To accomplish this, we first examined how the 
binding characteristics clustered between NAABs. Each NAAB possesses a vector of 
binding affinities that describes its specificity profile. A hierarchical clustering algorithm 
was applied to the set of vectors using the cluster package in R. Several distinct groups 
emerge (Figure 14) which cluster according to their physio-chemical characteristics, for 
example, the largest cluster contains the NAABs corresponding to tRNA synthetases for 
hydrophobic amino acids. Similarly, the second cluster contains aaRSs for the aromatic 
amino acids, the third contains aaRSs for the small polar amino acids (cysRS, serRS and 
thrRS), and the fourth contains most of the larger polar aaRSs. We next performed a 
factor analysis to determine if individual NAABs contained redundant information. 
Figure 15 shows a scree plot of the original binding matrix and the correlation matrix. 
There is little apparent structure in the original matrix, but the correlation matrix shows a 
significant bend in the scree plot at four clusters. The clustered correlation matrix is 
shown in Figure 16, where the four similar groups, again according to amino acid 
characteristics, emerge.  
 
DISCUSSION 
 We have demonstrated the utility and desirability of strategically selecting protein 
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scaffolds for minimalist computational design, as well as demonstrating the ability of the 
RosettaDesign framework to choose stable, active truncation mutants using current 
computational design energy functions as a guide. Additionally, we have shown that our 
set of truncation mutants exhibit a range of appreciable affinities for our target 
application and demonstrated that we can improve these affinities using several 
potentially generalizable, rational-design strategies.  The set of engineered molecules 
provide a potential tool-kit for protein end-sequencing using a single molecule detection 
technique. 
 
 Not all of the applied strategies will lead to the same level of success with all 
proteins. For example, improving pocket accessibility would do little to improve a highly 
dynamic binding site. The fact that this approach was so successful with hisRS is likely 
because of the change from a native substrate (histidine) to a substrate at the N-terminus 
of a peptide. Similarly, it can be difficult to accomplish some of these design strategies 
without a significant amount of structural knowledge. Swapping the binding mechanism 
from an induced fit to a lock and key would, in general, require knowledge of both the 
apo and holo crystal structures so that critical residues could be identified.  
 
 While the set of protein probes is complete in the sense that each amino acid has 
an associated NAAB which binds with at least a µM affinity, these affinities vary widely 
from low nM to high µM. Additionally, some NAABs have a large amount of cross 
specificity.  These two facts indicate that the tool-kit has plenty of room to be further 
improved using protein engineering techniques should the end application necessitate it. 
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Given the abundance of filtering using editing domains and tRNA specificity used by 
tRNA synthetases	  (35-42), it is unlikely that perfect specificity for each amino acid can 
be achieved. 
  
 We have demonstrated several approaches that can be applied to this tool-kit to 
improve NAABs including: binding pocket accessibility, surface reengineering, and 
binding mechanism swapping. Ultimately, however, both the affinity and specificity of 
the NAABs is limited by the physiochemical characteristics, particularly the size and 
similarity, of the target substrates. This however, is not necessarily a limitation in terms 
of using the toolkit in a functional proteomic assay. 
 
MATERIALS AND METHODS 
Homology modeling 
 Homology models were generated for each of the aaRSs by aligning the sequence 
of the available crystal structure to the sequence of the E. coli homologue. This resulted 
in sequence homology of between 30 % and 70%. Each experimentally determined 
crystal structure was computationally mutated to match the E. coli sequence at any 
aligned position using Rosetta (28). Initially, the repulsive portion of the energy function 
was reduced to zero, in order to accommodate positions that might have significant steric 
clash. The Lennard-Jones repulsive energy was then gradually ramped up while 
performing gradient minimization, and holding the backbone in place with gradually 
relaxed harmonic constraints. Following these steps, stretches of the E. coli sequence that 
were insertions were rebuilt using either the fragment insertion (if it was in a region of 
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defined secondary structure) or the loop rebuilding modules in Rosetta. The constrained 
backbone minimization was then repeated. Finally, deleted regions were accommodated 
by adding harmonic constraints to the N- and C-termini of the deletion and re-
implementing the constrained backbone minimization to drag the two termini together.  
 
 Truncations were chosen by visual inspection of the domain boundaries. The 
selected region (red in Table 2) was then manually removed and the resulting truncation 
was scored using the Rosetta “score12” energy function (28). If the energy of the 
resulting truncation was less stable by more than ten Rosetta energy units, amino acids 
were added back to the truncated terminus until the energy deficit failed to decrease.  
 
Cloning, expression and purification 
 Primers specific for each NAAB were ordered from Integrated DNA 
Technologies (IDT). Each NAAB was then amplified from isolated, E. coli genomic 
DNA and transferred to a pET42a expression vector at various positions, depending on 
the gene sequence. These constructs were transformed into either E. coli BL21(DE3) or 
“Arctic Express” competent cells for expression. 
  
 Protein was over-expressed following Studier’s auto-induction protocol (43). 
Bacterial cells were harvested by centrifugation of the cell culture at 5000 rpm and 4 
degrees for 10 minutes. Cells were then re-suspended in 1x PBS with 10% glycerol, pH 
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7.4. Cells were then lysed by sonication on ice. The cell lysate was centrifuged at 18,000 
rpm, 4 degrees for 20 minutes. The supernatant was then filtered through a 0.2 um 
cellulose acetate filter. The filtered lysate was loaded onto a 1 mL GSTrap column and 
washed with 5 column volumes of binding buffer (1x PBS). Bound protein was then 
eluted in 50 mM Tris-HCl, 10 mM reduced glutathione. Purified fractions were prepared 
for SDS-PAGE analysis by mixing 2 parts sample with 1 part 4x loading dye. Samples 
were analyzed on 16% SDS-PAGE precast gels, and visualized by Coomassie staining.  
 
 Protein concentration was determined using the calculated molar extinction 
coefficient and measuring the A280 on an ND-8000 spectrophotometer (Thermo Fisher 
Scientific). Site-directed mutagenesis was accomplished using the QuikChange protocol 
(Agilent Technologies) and verified by sequencing. 
 
Binding assays 
 Real time binding assays between peptides and purified NAABs were performed 
using biolayer interferometry on the Blitz and Octet systems (Fortebio, Menlo Park, CA). 
These systems monitors interference of light reflected from the surface of a fiber optic 
sensor to measure the thickness of molecules bound to the sensor surface. The 
dissociation constant Kd can be determined from Kd = koff/kon, where kon is the rate of 
protein binding to the material on the sensor surface (the association-rate) and koff is the 
rate at which the analyte can be removed from the sensor with a buffer solution (the 
dissociation-rate).  
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 Peptide substrates were ordered from Celtek Peptides, with a specific N-terminal 
residue, and a C-terminal Cysteine. Peptides were immobilized by first activating the 
surface with 1M 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 0.2M N-
hydroxysuccinimide (NHS) then incubating with a bifunctional 3-Maleimidopropionic 
acid hydrazide	  (BMPH) cross-linker to introduce a sulfhydral reactive maleimide group. 
Unreacted surface groups were quenched with 1M ethanolamine. Peptide was then 
immobilized by reacting the C-terminal cysteine with the maleimide. Unreacted 
maleimide was quenched with 50 mM cysteine.  
 
 Sensors coated with peptides were allowed to bind to the NAABs in 1x PBS at 
several different protein concentrations. Sensors without peptide attached were used as 
negative controls for each NAAB. Binding kinetics were calculated using the Blitz 
software package, which fit the observed binding curves to a 1:1 binding model to 
calculate the association rate constants. NAABs were allowed to dissociate by incubation 
of the sensors in 1x PBS. Dissociation curves were fit to a 1:1 model to calculate the 
dissociation rate constants. Binding affinities were calculated as the kinetic dissociation 
rate constant divided by the kinetic association rate constant. 
 
Clustering 
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 Hierarchical clustering was performed in the R software package. The algorithm 
(44) uses a complete linkage method which starts by assigning each vector of NAAB 
affinities to its own cluster, then joins the two clusters with the highest similarity and 
continues until there only a single cluster remains. It utilizes a dissimilarity matrix based 
on the square Euclidean distances between cluster means. 
 
 Clustering of the NAAB correlations was performed using k-means clustering in 
R. The correlation of each NAABs affinity vector with all other NAABs created a 17 x 
17 matrix. The within cluster sum of square errors was plotted against the number of 
clusters for one to seventeen clusters and plotted as a function of cluster size to determine 
the optimal number of groups.  
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FIGURE 8: A schematic of DAPES (Digital Analysis of Proteins by End 
Sequencing). In step 1, a digested protein sample consisting of one or more proteins is 
immobilized onto a surface with its N-terminus projecting out into solution. In step 2, a 
NAAB targeting a specific amino acid (or group of amino acids) is added to the slide and 
positions where it binds are imaged or recorded. Following imaging, the NAAB is 
removed and the process repeated for all NAABs in the tool-kit. After a single position 
has been fully characterized, the Edman Degradation (either chemically or, in this case, 
enzymatically) is carried out on the surface (step 4-5).  The result is a regenerated surface 
of N-termini with peptides 1 amino acid shorter than before. The entire process is 
iteratively repeated for every amino acid on the peptide chain. 
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FIGURE 9: Examples of truncation mutants from the tRNA synthetase families. (A) 
Valyl-tRNA synthetase with the retained domain in blue and the two removed domains in 
green. (B) A Histidyl-tRNA synthetase showing the removed multimerization domain in 
green and the retained domain in blue. 
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FIGURE 10: Affinity and specificity matrix for the set of 17 NAABs. Each row is a 
NAAB and each column is an N-terminal amino acid, thus each spot corresponds to the 
binding affinity of a NAAB for a particular amino acid. On this scale, black represents 
the tightest binding NAABs (high nM affinity), and white is no binding observed. 
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FIGURE 11: Binding accessibility mutations in Histidyl-tRNA synthetase. The 
native conformation is shown in blue, with the inserted beta-turn motif shown in red. The 
peptide substrate with an N-terminal histidine is shown in a stick representation. 
Normalized sensograms for the two variants are shown below. 
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FIGURE 12: Mutations in methionyl-tRNA synthetase. The mutated positions of the 
metRS which resulted in a change from an induced fit to a lock-and-key binding 
mechanism are shown in a stick representation. The modeled peptide is shown in a space-
filling representation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64	  
FIGURE 13: Surface redesign of phenylalanyl-tRNA synthetase. Swapping twelve 
apolar or positively charged, solvent exposed residues on the surface pheRS removed the 
aggregation problems observed on the DAPES surface. Additionally, the structural 
stabilization of the scaffold improved the binding affinity of the NAAB for it’s cognate 
amino acid. 
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FIGURE 14: Hierarchal clustering of the NAABs. Non-iterative clustering of the 
NAAB affinities leads to five distinct groups.  
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FIGURE 15: Scree plot showing cluster sum of square errors compared to number 
of clusters for the original matrix (left) and the correlation matrix (right). The 
within-cluster sum of square error is plotted against the number of k-means clusters to 
determine the appropriate number of clusters in the data set. The SSE will fall off rapidly 
until the optimal number is reached. The original matrix does not show significant 
grouping compared to randomized data, while the correlation matrix allows a clearer 
extraction of features, and points to four distinct clusters. 
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FIGURE 16: Clustered correlation matrix. Correlation of each NAAB with the rest of 
the set was computed by comparing their binding affinity vectors. A factor analysis 
indicates that the optimum number of factors is four, which are shown grouped within the 
blue boxes.  
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TABLE 1: Structural data for aaRSs. tRNA	  Synthetase	   Number	  of	  Structures	   E.	  coli	  structure?	  Glutamine	   22	   Y	  Arginine	   6	   Y	  Alanine	   20	   Y	  Phenylalanine	   15	   Y	  Tyrosine	   42	   Y	  Histidine	   12	   Y	  Cysteine	   5	   Y	  Threonine	   15	   Y	  Serine	   9	   N	  Glutamate	   18	   N	  Asparagine	   3	   N	  Aspartate	   13	   Y	  Glycine	   12	   N	  Isoleucine	   11	   N	  Leucine	   22	   Y	  Valine	   5	   N	  Lysine	   12	   Y	  Methionine	   28	   Y	  Proline	   15	   N	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TABLE 2: Sequences of NAABs used in this study. Arginine	  (1BS2)	   mniqallsekvrqamiaagapadcepqvrqsakvqfgdyqangmmavakklgmaprqlaeqvlthldlngiaskveiagpgfinifldpaflaehvqqalasdrlgvstpEKQTIVVDYSAPNVAKEMHVGHLRSTIIGDAAVRTLEFLGHKVIRANHVGDWGTQFGMLIAWLEKQQQENAGEMELADLEGFYRDAKKHYDEDEEFAERARNYVVKLQSGDEYFREMWRKLVDITMTQNQITYDRLNVTLTRDDVMGESLYNPMLPGIVADLKAKGLAVESEGATVVFLDEFKNKEGEPMGVIIQKKDGGYLYTTTDIACAKYRYESLHADRVLYYIDSRQHQHLMQAWAIVRKAGYVPESVPLEHHMFGMMLGKDGKPFKTRAGGTVKLADLLDETLERARRLVAEKNPDMPADELEKLANAVGIGAVKYADLSKNRTTDYIFDWDNMLAFEGNTAPYMQYAYTRVLSVFRKAEINEEQLAAAPVIIREDREAQLAARLLQFEETLTVVAREGTPHVMCAYLYDLAGLFSGFYEHCPILSAENEEVRNSRLKLAQLTAKTLKLGLDTLGIETVERM Asparagine	  	   msvvpvadvlqgrvavdsevtvrgwvrtrrdskagisflavydgscfdpvqavinnsllnynedvlrlttgcsvivtgkvvaspgqgqqfeiqaskvevagwvedpdtypmaakrhSIEYLREVAHLRPRTNLIGAVARVRHTLAQALHRFFNEQGFFWVSTPLITASDTEGAGEMFRVSTLDLENLPRNDQGKVDFDKDFFGKESFLTVSGQLNGETYACALSKIYTFGPTFRAENSNTSRHLAEFWMLEPEVAFANLNDIAGLAEAMLKYVFKAVLEERADDMKFFAERVDKDAVSRLERFIEADFAQVDYTDAVTILENCGRKFENPVYWGVDLSSEHERYLAEEHFKAPVVVKNYPKDIKAFYMRLNEDGKTVAAMDVLAPGIGEIIGGSQREERLDVLDERMLEMGLNKEDYWWYRDLRRYGTVPHSGFGLGFERLIAYVTGVQNVRDVIPFPRTP Aspartate	   mrteycgqlrlshvgqqvtlcgwvnrrrdlgslifidmrdregivqvffdpdradalklaselrnefciqvtgtvrardek
ninrdmatgeievlassltiinradvLPLDSNHVNTEEARLKYRYLDLRRPEMAQRLKTRAKITSLVRRFMDDHGFLDIETPMLTKATPEGARDYLVPSRVHKGKFYALPQSPQLFKQLLMMSGFDRYYQIVKCFRDEDLRADRQPEFTQIDVETSFMTAPQVREVMEALVRHLWLEVKGVDLGDFPVMTFAEAERRYGSDKPDLRNPMELTDVADLLRSVEFAVFAGPANDPKGRVAALRVPGGASLTRKQIDEYDNFVKIYGAKGLAYIKVNERAKGLEGINSPVAKFLNAEIIEAILDRTAAQDGDMIFFGADNKKIVADAMGALRLKVGKDLGLTDESKWAPLWVIDFPMFEDDGEGGLTAMHHPFTSPKDMTAAELKAAPENAVANAYDMVINGYEVGGGSVRIHNGDMQQTVFGILGINEEEQREKFGFLLDALKYGTPPHAGLAFGLDRLTMLLTGTDNIRDVIAFPKttaa aclmteapsfanpaalaelsiqvvkkaenn 	  Cysteine	   MLKIFNTLTRQKEEFKPIHAGEVGMYVCGITVYDLCHIGHGRTFVAFDVVAR
YLRFLGYKLKYVRNITDIDDKIIKRANENGESFVAMVDRMIAEMHKDFDALN
ILRPDMEPRATHHIAEIIELTEQLIAKGHAYVADNGDVMFDVPTDPTYGVLSR
QDLDQLQAGARVDVVDDKRNPMDFVLWKMSKEGEPSWPSPWGAGRPGWH
IECSAMNCKQLGNHFDIHGGGSDLMFPHHENEIAQSTCAHDGQYVNYWMHS
GMVMVDREKMSKSLGNFFTVRDVLKYYDAETVRYFLMSGHYRSQLNYseenl
kqaraaverlytalrgtdktvapaggeafearfieamdddfntpeaysvlfdmarevnrlkaedmaaanamashlrkl
savlglleqepeaflqsgaqaddsevaeiealiqqrldarkakdwaaadaardrlnemgivledgpqgttwrrk 	  Glutamine	   mseaearpTNFIRQIIDEDLASGKHTTVHTRFPPEPNGYLHIGHAKSICLNFGIAQD
YKGQCNLRFDDTNPVKEDIEYVESIKNDVEWLGFHWSGNVRYSSDYFDQLH
AYAIELINKGLAYVDELTPEQIREYRGTLTQPGKNSPYRDRSVEENLALFEKM
RTGGFEEGKACLRAKIDMASPFIVMRDPVLYRIKFAEHHQTGNKWCIYPMYD
FTHCISDALEGITHSLCTLEFQDNRRLYDWVLDNITIPVHPRQYEFSRlnleytvms
krklnqlvtdkhvegwddprmptisglrrrgytaaairefckrigvtkqdntiemaslesciredlnenapramavidp
vklviknyqgegemvtmpnhpnkpemgsrqvpfsgeiwidradfreeankqykrlvlgkevrlrnayvikaerve
kdaegnittifctydadtlskdpadgrkvkgvihwvsaahalpveirlydrlfsvpnpgaaddflsvinpeslvikqgfa
epslkdavagkafqferegyfcldsrhstaekpvfnrtvglrdtwakvge 	  Glutamate	   IKTRFAPSPTGYLHVGGARTALYSWLFARNHGGEFVLRIEDTDLERSTPEAIE
AIMDGMNWLSLEWDEGPYYQTKRFDRYNAVIDQMLEEGTAYKCYCSKERL
EALREEQMAKGEKPRYDGRCRHSHEHHADDEPCVVRFANPQEGSVVFDDQI
RGPIEFSNQELDDLIIRRTDGSPTYNFCVVVDDWDMEITHVIRGEDHINNTPRQ
INILKALNAPVPVYAHVSMINGDDGKKLSKRHGAVSVMQYRDDGYLPEALL
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NYLVRLGWSHGDQEIFTREEMIKYFTLNAVSKSASAFNTDKLLWLNHHYInal
ppeyvathlqwhieqenidtrngpqladlvkllgercktlkemaqscryfyedfaefdadaakkhlrpvarqplevvrd
klaaitdwtaenvhhaiatadelevgmgkvgmplrvavtgagqspaldvtvhaigktrsierinkaldfiaerenqq 	  Histidine	  (1KMM)	   KNIQAIRGMNDYLPGETAIWQRIEGTLKNVLGSYGYSEIRLPIVEQTPLFKRAIGEVTDVVEKEMYTFEDRNGDSLTLRPEGTAGCVRAGIEHGLLYNQEQRLWY
IGPMFRHERPQKGRYRQFHQLGCEVFGLQGPDIDAELIMLTARWWRALGISE
HVTLELNSIGSLEARANYRDAlvafleqykdkldedckrrmytnplrvldsknpevqallndapalgd
yldeesrehfaglckllesagiaytvnqrlvrgldyynrtvfewvtnslgsqgtvcaggrydglveqlggratpavgfam
glerlvllvqavnpefkadpvvdislvasgadtqsaamalaerlrdelpgvklmtnhgggnfkkqfaradkwgarvav
vlgesevangtavvkdlrsgeqtavaqdsvaahlrtllg 	  Isoleucine	   msdykstlnlpetgFPMRGDLAKREPGMLARWTDDDLYGIIRAAKKGKKTFILHDG
PPYANGSIHIGHSVNKILKDIIIKSKGLSGYDSPYVPGWDCHGLPIELKVEQEY
GKPGEKFTAAEFRAKCREYAATQVDGQRKDFIRLGVLGDWSHPYLTMDFKT
EANIIRALGKIIGNGHLHKGAKPVHWCVDCRSALAEAEVEYYDKTSPSIVAFQ
AVDQDALKTKFGVSNVNGPISLVIWTTTPWTLPANRAISIAPDFDYALVQIDG
QAVILAKDLVESMQRIGVSDYTILGTVKGAELELLRFTHPFMDFDVPAILGDH
VTLDAGTGAVHTAPGHGPDDYVIGQKYGLETANPVGPDGTYLPGTYPTLDG
VNVFKANDIVVALLQEKGALLHVEKMQHSYPCCWRHKTPIIFRATPQWFVS
MDQKGLRAQSLKEIKGVQWIPDWGQARIESMVANRPDWCISRQRTWGVPM
SLFVHKDTEELHPRTLELMEEVAKRVEVDGIQAWWDLDAKEILGDEADQYV
KVPDTLDVWFDSGSTHSSVVDVRPEFAGHAADMYLEGSDQHRGWFMSSLMI
STAMKGKAPYRQVLTHGFTVDGQGRKMSKSIGNTVSPQDVMNKLGADILRL
WVASTDYTGEMAVSDEILKRAADSYRRIRNTARFLLANLNGFDPAKDMVKP
EEMVVLDRWAVGCAKAAQEDILKAYEAYDFHEVVQRLMRFCSVEMGSFYL
DIIKDRQYTAKADSVARRSCQTALYHIAEALVRWMAPILSFTADEVWGYLPG
EREkyvftgewyeglfgladseamndafwdellkvrgevnkvieqaradkkvggsleaavtlyaepelaakltalgd
elrfvlltsgatvadyndapadaqqsevlkglkvalskaegekcprcwhytqdvgkvaeyaeicgrcvsnvagdgekr
kfa 
 Leucine	   IESKVQLHWDEKRTFEVTEDESKEKYYCLSMLPYPSGRLHMGHVRNYTIGDV
IARYQRMLGKNVLQPIGWDAFGLPAEGAAVKNNTAPAPWTYDNIAYMKNQ
LKMLGFGYDWSRELATCTPEYYRWEQKCFTELYKKGLVYKKTSAVNWCPN
DQTVLANEQVIDGCCWRCDTKVERKEIPQWFIKITAYADELLNDLDKLDHWP
DTVKTMQRNWIGRSEGVEITFNVKDYDNTLTVYTTRPDTFMGCTYLAVAAG
HPLAQKAAENNPELAAFIDECRNTKVAEAEMATMEKKGVDTGFKAVHPLTG
EEIPVWAANFVLMEYGTGAVMAVPGHDQRDYEFASKYGLNIKPVILAADGS
EPDLSQQALTEKGVLFNSGEFNGLDHEAAFNAIADKLTEMGVGERKVNYRL
RDWGVSRQRYWGAPIPMVTLEDGTVMPTPDDQLPVILPEDVVMDGITSPIKA
DPEWAKTTVNGMPALRETDTFDTFMESSWYYARYTCPEYKEGMLDSKAAN
YWLPVDIYIGGIEHAIMHLLYFRFFHKLMRDAGMVNSDEPAKQLLCQGMVL
ADAFYYVGENGERNWVSPVDAIVERDEKGRIVKAKDAAGHELVYTGMSKM
SKSKNNGIDPQVMVERYGADTVRLFMMFASPADMTLEWQESGVEGANRFL
KRVWKLVYEHTAKGDVAALNVDALTEDQKALRRDVHKTIAKVTDDIGRRQ
TFNTAIAAIMELMNKLAKAPTDGEQDRALMQEALLAVVRMLNPFTPHICFTL
WQELKGEGDIDNAPWPvadekamvedstlvvvqvngkvrakitvpvdateeqvreragqehlvakyld
gvtvrkviyvpgkllnlvvg 	  Lysine	   mseqetrganeaidfndelrnrreklaalrqqgvafpndfrrdhtsdqlheefnakdnqeleslnievsvagrmmtrri
mgkasfvtlqdvggriqlyvardslpegvyndqfkkwdlgdiigargtlfktqtgelsihctelrlltkalrplpdkfhglq
dqevryrqryldliANDKSRQTFVVRSKILAAIRQFMVARGFMEVETPMMQVIPGGA
SARPFITHHNALDLDMYLRIAPELYLKRLVVGGFERVFEINRNFRNEGISVRH
NPEFTMMELYMAYADYHDLIELTESLFRTLAQEVLGTTKVTYGEHVFDFGKP
FEKLTMREAIKKYRPETDMADLDNFDAAKALAESIGITVEKSWGLGRIVTEIF
DEVAEAHLIQPTFITEYPAEVSPLARRNDVNPEITDRFEFFIGGREIGNGFSELN
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DAEDQAERFQEQVNAKAAGDDEAMFYDEDYVTALEYGLPPTAGLGIGIDRM
IMLFTNSHTIRDVILFPAMRP Methionine	  	   AKKILVTCASPYANGSIHLGHMLEHIQADVWVRYQRMRGHEVNFICADDAH
GTPIMLKAQQLGITPEQMIGEMSQEHQTDFAGFNISYDNYHSTHSEENRQLSE
LIYSRLKENGFIKNRTISQLYDPEKGMFLPDRFVKGTCPKCKSPDQYGDNCEV
CGATYSPTELIEPKSVVSGATPVMRDSEHFFFDLPSFSEMLQAWTRSGALQEQ
VANKMQEWFESGLQQWDISRDAPYFGFEIPNAPGKYFYVWLDAPIGLMGSF
KNLCDKRGDSVSFDEYWKKDSTAELYHFIGKGIVYFLSLFWPAMLEGSNFRK
PSNLFVHGYVTVNGAKMSKSRGTFIKASTWLNHFDADSLRYYYTAKLSSRID
DIDLNLEDFVQRVNADIVNKVVNLASRNAGFINKRFDGVLASELADPQLYKT
FTDAAEVIGEAWESREFGKAVREIMALADLANRYVDEQAPWVVAKQEGRD
ADLQAICSMGINLFRVLMTYLKPVLPKLTERAEAFLNTELTWDGIQQPLLGH
KVNPFKALYNRIDMRQVEALVEASKeevkaaaapvtgpladdpiqetitfddfakvdlrvalienae
fvegsdkllrltldlggekrnvfsgirsaypdpqaligrhtimvanlaprkmrfgisegmvmaagpggkdifllspdag
akpghqvk 	  Phenylalanine	   VDVSLPGASLFSGGDHPITLMERELVEIFRALGYQAVEGPEVESEFFNFDALNI
PENGPARDMWDTVGKTGEGFRLEGPDGEEVEGRLLLRTHTSPMQVRYMVA
HTPPFRIVVPGRVFRAEQTDATAEAVFHQLEGLVVGEGVNEGDLYGAIYELA
QALFGPDSKVRFQPVTFPFVEPGAQFAVWWPEGGKWLELGGAGMVGPNVF
QAVDAYRERLGDPPAYRGVTGFAFGLGVERLAMLRYGIPDIRYFAGTRGKFL
EQFKGVL Serine	   MLDPNLLRNEPDAVAEKLARRGFKLDVDKLGALEERRKVLQVKTENLQAER
NSRSKSIGQAKARGEDIEPLRLEVNKLGEELDAAKAELDALQAEIRDIALTIPN
LPADEVPVGKDENDNVEVSRWGTPREFDFEVRDHVTLGEMYSGLDFAAAVK
LTGSRFVVMKGQIARMHRALSQFMLDLHTEQHGYSENYVPYLVNQDTLYGT
GQLPKFAGDLFHTRPLEEEADTSNYALIPTAEVPLTNLVRGEIIDEDDLPIKMT
AHTPCFRSEAGSYGRDTRGLIRMHQFDKVEMVQIVRPEDSMAALEEMTGHA
EKVLQLLGLPYRKIILCTGDMGFGACKTYDLEVWIPAQNTYREISSCSNVWDF
QARRMQARCRSKSDKKTRLVHTLNGSGLAVGRTLVAVMENYQQADGRIEV
PEVLR PYMNGLEYI Threonine	   matattkccnvftvrrgqtkkalnaylqrleeaakRDHRKIGKQLDLYHMQEEAPGMVFWHND
GWTIFRELEVFVRSKLKEYQYQEVKGPFMMDRVLWEKTGHWDNYKDAMFT
TSSENREYCIKPMNCPGHVQIFNQGLKSYRDLPLRMAEFGSCHRNEPSGSLHG
LGRVRGFTQDDAHIFCTEEQIRDEVNGCIRLVYDMYSTFGFEKIVVKLSTRPE
KRIGSDEMWDRAEADLAVALEENNIPFEYQLGEGAFYGPKIEFTLYDCLDRA
AQCGTVQLDFSLPSRLSASYVGEDNERKVPVMIHRAILGSMEVFIGILTEEFAG
FFPTWLAPVQVVIMNITDSQSEYVNELTQKLSNAGIRVKADLRNEKIGFKIRE
HTLRRVPYMLVCGDKEVESGKVAVRTRRGKDLGSMDVNEVIEKLQQEIRSR
SLKQLEE Tryptophan	   MTKPIVFSGAQPSGELTIGNYMGALRQWINMQDDYHCIYCIVDQHAITVRQD
AQKLRKATLDTLALYLACGIDPEKSTIFVQSHVPEHAQLGWALNCYTYFGEL
SRMTQFKDKSARYAENINAGLFDYPVLMAADILLYQTNLVPVGEDQKQHLE
LSRDIAQRFNALYGDIFKVPEPFIPKSGARVMSLLEPTKKMSKSDDNRNNVIG
LLEDPKSVVKKIKRAVTDSDEPPVVRYDVQNKAGVSNLLDILSAVTGQSIPEL
EKQfegkmyghlkgevadavsgmltelqeryhrfrndeaflqqvmkdgaekasahasrtlkavyeaigfvakp 	  Tyrosine	   MASSNLIKQLQERGLVAQVTDEEALVERLAQGPIALYCGFDPTADSLHLGHL
VPLLCLKRFQQAGHKPVALVGGATGLIGDPSFKAAERKLNTEETVQEWVDKI
RKQVAPFLDFDCGENSAIAANNYDWFGNMNVLTFLRDIGKHFSVNQMINKE
AVKQRLNREDQGISFTEFSYNLLQGYDFACLNKQYGVVLQIGGSDQWGNITS
GIDLTRRLHQNQVFGLTVPLITKADGTKFGKTEGGAVWLDPKKTSPYKFYQF
WINTADADVYRFLKFFTFMSIEEINALEEEDKNSGKAPRAQYVLAEQVTRLV
HGEEGLQAAKRITECLFSGSLSALSEADFEQLAQDGVPMVKMEKGADLMQA
LVDSELQPSRGQARKTIASNAITINGEKQSDPEYFFKEEDRLFGRFTLLRRGKK
NYCLICWK 
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Valine	  (1GAX)	   mknatfylldndttvdglsaveqlvceiaaerwrsgkrvliacedekqayrldealwarpaesfvphnlagegprggapveiawpqkrsssprdilislrtsfadfataftevvdfvpyedslkqlarerykslprgwfqpeygnleimektynpqdieq
plyehwekqgyfkpngdesqesfcimipppnvtgslhmghafqqtimdtmiryqrmqgkntlwqvgtdhagiat
qmvverkiaaeegktrhdygreafidkiwewkaesggtitrqmrrlgnsvdwererftmdeglsndvkevfvrlyke
dliyrgkrlvnwdpklrtaisdlevenreskgsmwhirypladgaktadgkdylvvattpetllgdtgvavnpedpryk
dligkyvilplvnrripivgdehadMEKTYNPQDIEQPLYEHWEKQGYFKPNGDESQESFC
IMIPPPNVTGSLHMGHAFQQTIMDTMIRYQRMQGKNTLWQVGTDHAGIATQ
MVVERKIAAEEGKTRHDYGREAFIDKIWEWKAESGGTITRQMRRLGNSVDW
ERERFTMDEGLSNAVKEVFVRLYKEDLIYRGKRLVNWDPKLRTAISDLEVEN
RESKGSMWHIRYPLADGAKTADGKDYLVVATTRPETLLGDTGVAVNPEDPR
YKDLIGKYVILPLVNRRIPIVGDEHADMEKGTGCVKITPAHDFNDYEVGKRH
ALPMINILTFDGDIRESAQVFDTKGNESDVYSSEIPAEFQKLERFAARKAVVA
AIDALGLLEEIKPHDLTVPYGDRGGVVIEPMLTDQWYVRADVLAKPAVEAVE
NGDIQFVPKQYENMYFSWMRDIQDWCISRQLWWGHRIPAWYDEAGNVYVG
RNEEEVRKENNLGADVALRQDEDVLDTWFSSALWTFSTLGWPENTDALRQF
HPTSVMVSGFDIIFFWIARMIMMTMHFIKDENGKPQVPFHTVYMTGLIRDDE
GQKMSKSKGNVIDPLDMVDGISLPELLEKRTGNMMQPQLADKIRKRTEKQFP
NGIEPHGTDALRFTLAALASTGRDINWDMKRLEGYRNFCNKLWNASRFVLM
NTEGQDCGFNGGEMTLSLADRWILAEFNQTIKAYREALDSFRFDIAAGILYEF
TWNQFCDWYLELTKPVMNGGTEAELRGTRHTLVTVLEGLLRLAHPIIPFITET
IWQrvkvlcgitadtimlqpfpqydasqvdeaaladtewlkqaivavrniraemniapgkplelllrgcsadaerrvn
enrgflqtlarlesitvlpaddkgpvsvtkiidgaellipmaglinkedelarlakevakiegeisrienklanegfvarape
aviakereklegyaeakaklieqqaviaal 	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TABLE 3: Measured affinity constants used to create the binding matrix (in M). 	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TABLE 4: Mutant vs. Native affinities for hisRS, metRS, pheRS. NAAB	   Native	  Affinity	   Engineered	  Affinity	  Phenylalanine	   62.9	  µM	   3.4	  µM	  Histidine	   294.0	  µM	   68.2	  µM	  Methionine	   305.1	  µM	   60.7	  µM	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CHAPTER 3:  
A PROBABILISTIC FRAMEWORK FOR 
PEPTIDE-SEQUENCING USING A SINGLE 
MOLECULE ASSAY. 
 
This chapter, along with chapter 2, will be compiled into a manuscript for submission to a 
peer-review journal. Rob Mitra conceived the idea for parallel, single-molecule end 
sequencing, while Jim Havranek originated the idea of using protein design to generate a 
tool-kit. I carried out all experiments, simulations, and computational analysis in this 
chapter as well as developing the Bayesian framework. 
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ABSTRACT 
 
 As critical as design strategies are to the development of functional proteins for 
practical applications, an iterative process between application and design can be an 
important part of achieving the desired goals. In the previous chapter, I demonstrated 
several techniques for improving protein-peptide affinities. Here, I demonstrate how 
application-specific modeling of the assay, which takes advantage of information that 
emerged in the engineering phase, can drastically improve results in the final application. 
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INTRODUCTION 
 Protein engineering tools provide a wide range of benefits that can often be 
effectively harnessed to generate new activities of affinities in biomolecules (1-9). 
Despite these tools, there are situations in which it is impossible to generate the levels of 
specificity required for a particular application. An effective combination of 
computational modeling and application refinement may provide a way forward when 
protein design reaches its limits. 
 
 A technique recently proposed by our collaborators attempts to implement a 
parallelized variation of the Edman technique. This was briefly described in Chapter 2 
(Figure 10), but will be explored in more depth here. Following a trypsin digest of a set 
of proteins of interest, the resulting peptides are immobilized onto a glass slide coated in 
a low-adsorption nanogel material with their N-termini projecting outwards from the 
slide. The slide is then interrogated with a set of probes that bind at each N-terminal 
amino acid according the affinity and specificity of each probe.  
 
 During each binding cycle (step 2-3 in Figure 10), a probe either does or does not 
bind at a specific x-y coordinate on the chip. The spatial separation imposed by 
immobilization of peptides on the slide allows each end-sequencing reaction to be carried 
out in parallel.  As envisioned, DAPES will return a set of Boolean vectors, one for each 
cycle of binding and imaging at each spatial location on the array. Using probes for each 
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amino acid except cysteine (thiol chemistry is utilized to couple the peptide to the 
surface), we will have a 3-dimension matrix of dimensions 
€ 
n × m × p, where 
€ 
n  is the 
number of horizontal bins, 
€ 
m  is the number of vertical bins, and 
€ 
p is the number of 
probes, here 19. The matrix will consist of binary data as a result of any one complete 
cycle of binding and cutting.  
 
 Utilizing the molecular tool-kit characterized in Chapter 2 to call individual 
amino acids in a DAPES assay presents a number of problems. Chief among them is the 
cross-specificity and redundancy of information made apparent by the cluster analysis in 
Chapter 2. As previously mentioned, however, this is not an absolute barrier to utilizing 
the tool-kit for its intended purpose. In fact, the cross-specificity may provide significant 
advantages. 
 
 To see how cross-specificity could be beneficial consider an ideal set of NAABs 
which would bind 10 of the 20 canonical amino acids with strong affinity and bind with 
no appreciable affinity to the other 10. A single DAPES bind-image cycle will then 
divide each amino acid into two groups. The second member of the ideal set of NAABs 
would further divide each of the two groups into two more groups in a bind-image cycle, 
and so on. If such NAABs were available, the cross-specificity would allow complete 
identification of all amino acids with only five NAABs. While there is almost no 
possibility that such NAABs could be engineered, it does demonstrate the utility of 
binding subsets of amino acids rather than specifically binding only one. 
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 Here I demonstrate the suitability of the characterized set of NAABs for a single 
molecule, protein-sequencing assay that utilizes N-terminal degradation and a novel 
computational framework. While this assay is still in development, the computational 
framework is applicable to any similar digital, single molecule assay on which such 
binding events can be reliably imaged and recorded. 
 
RESULTS 
A Bayesian framework for de novo peptide identification. 
 A high-throughput, single molecule protein-sequencing assay, such as DAPES 
(described above), will require the spatial segregation of individual peptides on a surface.  
Sequential probing with NAABs will then return a vector of binary binding events 
(Figure 18). For example, 
€ 
vαβ = 1,0,1{ }  implies that at coordinates of 
€ 
x = α,y = β  the first 
NAAB binds, the second does not and the 3rd also binds. We define this general vector of 
position specific binding events as 
€ 
Vαβ . Given that we have appreciable cross-specificity 
between NAABs (Chapter 2), we can utilize this to quantify and improve our 
identification of individual amino acids on the peptide chain.  
 
 The quantity of interest is the probability that a specific amino acid is present 
given an observed binding sequence 
€ 
Vαβi ∈ Vαβ1 ,...,Vαβn{ } (where n is the number of 
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NAABs used) is, 
€ 
P aaVαβ( )  where 
€ 
aa∈ ala,cys,...,tyr{ }. Using Bayes theorem (10), we 
have: 
 
€ 
P aaVαβ( ) =
P Vαβ aa( )P aa( )
P Vαβ( )
 
We can then define the probability 
€ 
P Vαβ aa( )  directly from the binding matrix in Chapter 
2 as: 
 
€ 
P Vαβ aai( ) = Vαβj( )bij + 1− Vαβj( )( ) 1− bij( )
j
∑
j
∑  
where we define the binding matrix 
€ 
B ≡ bij( ) , as having components equal to the 
probability of binding each NAAB 
€ 
j( ) for its target and off-target substrates at a 
specified concentration. The concentration at which the NAABs are added to the slide 
play a critical role in our ability to visualize bound molecules on the surface (Figure 17) 
and is used to convert the binding affinities into probabilities (see methods). 
 
 We then define the prior probability of observing any individual amino acid, 
€ 
P aa( ) where 
€ 
aa{ } = ala,cys,...,tyr{ }, as being identical to the theoretical background of 
the organism from which the sample came. For example in the human proteome, the least 
common amino acid in E. coli is tryptophan at 1.0% so 
€ 
P aa = trp( ) = 0.01, and the most 
common is alanine at 13%, so 
€ 
P aa = ala( ) = 0.13  (11).  
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 The probability of observing a specific combination of binding/not binding 
events,
€ 
P Vαβ( ) , is calculated by summing over all of the expected values for each 
sequence according to Bayes theorem. Equation 1 thus allows us to compute the 
probability of a specific N-terminal amino acid being present at a coordinate on the array 
at the position
€ 
α,β( ) , given that a specific binary vector is observed.  
 
The full binding matrix demonstrates that there is sufficient information to 
determine identities for all 19 assayable amino acids 
 To determine the ability of the NAAB tool-kit to call amino acids in a DAPES 
assay, we ran simulations using all possible binary sequences with 17 entries (equivalent 
to the number of NAABs). The Bayesian model outputs a likelihood of identifying each 
amino acid given the observance of a particular combination of binding events, which I 
will refer to as a footprint. The distribution of likelihoods for all possible footprints for 
each amino acid is shown in Figure 19, and demonstrates that 82% of the time, footprints 
are unlikely to be called as an amino acid if we apply a high probability (>95%) threshold 
for calling. This is not necessarily detrimental, since it is more likely that each spot on the 
DAPES array will be called according to it’s highest probability amino acid. In this case, 
it will be important to have a single call for each sequence. If we relax the above criteria 
to requiring a greater than 50% probability, then 71% of the time a given footprint will be 
uniquely callable.   
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 One way to determine how good the tool-kit is, in absence of the ability to 
conduct an actual sequencing assay, is to consider the maximal ability to identify 
individual amino acids. This is formulated as a 19 amino acid vector of probabilities, 
which we call the maximum probability of identification or MPI vector. The MPI vector 
for the full tool-kit is shown in Figure 20. This demonstrates that using the designed tool-
kit, there is at least one observable sequence for each amino acid that can be called with a 
greater than 85% probability. In fact, only tryptophan is called with a probability below 
94%. This is due to the fact that tryptophan occurs less frequently than any other amino 
acid and thus has a very low prior probability rather than any inherent gap in the set of 
NAABs.  
 
Enumeration and correlation with the full matrix reveals optimal 
combinations of NAABs for any number of binders 
 We next wanted to determine if there were subsets of NAABs that would suffice 
for calling amino acids in the DAPES assay. The motivation being that minimizing the 
number of bind-image-wash-cut cycles may be important to the practicality of DAPES. 
To determine which subsets of NAABs were optimal, we conducted simulations with all 
possible subsets. The MPI vectors of amino acid calling were then compared to that of 
the full matrix by computing the correlation coefficient of each. There are some flaws to 
this approach; namely, we may find that calling more amino acids with a lower 
probability may be desirable in the final version of DAPES. Or we may find that calling 
groups of amino acids is more effective to provide high-confidence mapping back to the 
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genome. In these cases, the MPI correlation would be a poor choice of metric to measure 
the optimal set. However, the goal here is to demonstrate the general usefulness of the 
tool-kit in determining amino acid identity, since we do not yet know what the final 
application will require. To meet this goal, the correlation metric between MPI vectors is 
sufficient. 
 
 The resulting optimal matrix correlations for between five and 16 NAABs is 
shown in Figure 21. We observe that the correlation rapidly increases from five to ten 
NAABs then slows considerably. Looking at the effects on each individual amino acid 
(Figure 22), we see that many are above an 80% probability of identification with as low 
as only eight or nine NAABs. Tryptophan lags behind considerably, again because of it’s 
extremely low prior probability. The identity of NAABs chosen in each optimized subset 
is shown in Figure 23. 
 
Relaxing the identification requirements allows 95% of amino acids to be 
identified with only 6 NAABs 
 As previously mentioned, we may benefit from calling an amino acid at every 
point in the array rather than discarding low probability spots. This approach may be 
more representative of what would be performed in an actual DAPES assay. The 
probability of each amino acid call can then be compiled at the completion of bind-wash 
cycles, and positions on the array with very low total probability distributions can be 
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discarded. This precise threshold will be determined once it is feasible to run control 
experiments on the DAPES single molecule platform. For now, if we choose to remove 
the probability threshold, then the majority of amino acids can be called with only six 
NAABs (Figure 24). The sole outlier at this point is tryptophan due to its low prior 
probability. Again, once it is possible to run the DAPES assay, we may find it prudent to 
either omit identification of tryptophan, or increase the number of NAABs to 11. 
 
A fitness function for the optimal set of NAABs 
 In it’s finished form, DAPES will require us to make trade-offs between our 
ability to discriminate amino acid identities and the speed or reliability of the assay. 
Several important factors will play a role in determining the combination of NAABs to be 
used in the assay. The number of cycles needed to identify amino acids is expected to be 
a driving factor in the number of NAABs that it will be possible to use. Higher affinity 
NAABs will require lower concentrations during the assay (or less incubation time), 
which will reduce the amount of non-specific surface adsorption and perhaps allow less 
harsh reagents during washing. The cost of using a set of NAABs should be proportional 
to the number used, while the benefit realized should be proportional to the MPI vector 
and the number of amino acids uniquely identified. A simple fitness function for 
evaluating the correct number of NAABs to use in DAPES would then be: 
   
€ 
φ = α
 
M •
 
I t f t( ) − β
 
N  
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where the vector   
€ 
 
M  is the MPI, the vector   
€ 
 
I  is a Boolean vector determining whether or 
not an amino acid is called with a probability above some threshold 
€ 
(t) , 
€ 
f  is the number 
of footprints that map to at least one amino acid with a probability greater than the 
threshold, and 
€ 
N  is the number of NAABs used. 
€ 
α  and 
€ 
β are parameters that will 
depend on the relative importance of high identification probabilities vs. number of 
cycles. 
 
DISCUSSION 
 We have computationally demonstrated that our designed biomolecular tool-kit 
can be used in a single molecule protein-sequencing assay to call amino acid identities 
with a high probability. Furthermore, this analysis can be computed in real time, as 
binding cycles occur, or a posteriori, once all relevant data has been gathered. While the 
practical effectiveness of the tool-kit will be determined only once we’ve solved several 
limitations of our imaging and surface chemistries, this framework provides a strong 
starting point for amino acid calling in the DAPES assay. 
 
 Bayes theorem has been informatively applied to study a wide-range of biological 
phenomenon (12-17), especially studies of DNA sequence characteristics. The extension 
here to calling and identifying amino acids is novel, especially as it is applied to the 
single molecule sequencing technology being developed by our collaborators. The 
framework provides additional information gained from an experimental procedure 
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(DAPES) to improve the resolving power of the biomolecular tool-kit. A point to note is 
the probe concentration dependence of binding probabilities. This presents a large hurdle 
for single molecule application, since the protein concentrations required to observe 
binding (generally µM) are much higher than are feasible (high pM). Our collaborators 
are currently working on a modification to DAPES which will allow imaging of transient 
binding events, which should attenuate this issue. 
 
 The main concern about this framework, and the identification of optimal sets of 
binders is that all characterization of the NAABs was performed using a non-optical 
technique and distinctly different surface than the DAPES assay uses. We may find that 
the DAPES surface significantly alters bind affinities or (more likely) that higher than 
µM affinities are required for single molecule imaging. If this proves to be the case, the 
framework will remain applicable but the set of NAABs may have to be significantly 
altered. At the very least, the full specificity matrix will have to be re-determined on any 
alternate surface. We expect that it will be proportional to the matrix determined on the 
BLI surface since any change in affinity due to surface characteristics should be 
relatively uniform. 
 
 Within the demonstrated framework, we have limited ourselves to identifying 
only the canonical amino acids. While this provides an important proof-of-principle for 
the tool-kit the library of amino acids found in a protein sample is much larger when 
post-translational modifications are taken into account. However, this is a limitation of 
the NAABs within the tool-kit rather than the computational framework presented here. It 
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is possible that the existing tool-kit will exhibit distinct binding profiles (and hence 
unique footprints) for other post-translation modifications. Though we have recently 
developed NAABs for the phospho-amino acids, and will target other small molecule 
post-translation modifications moving forward. Instances where the modification is a 
macromolecule, such as ubiquitination or SUMOylation, are unlikely to fit cleanly into 
the framework, and alternative identification techniques will have to be explored to target 
these. 
 
 The final caveat is in the optimization of sets of NAABs for protein sequencing. 
We do not yet know whether minimizing the number of NAABs used or maximizing the 
identification probability will be more important in the final assay. The optimal subsets 
should therefore be viewed as a demonstration of how the computational framework 
coupled with the tool-kit allows us to optimize the assay, rather than a fully optimized 
version. 
 
MATERIALS AND METHODS 
Implementation of the framework 
 The above framework was implemented in C++ and simulations were run using 
experimentally derived binding data for each NAAB as determined by BLI in Chapter 2. 
Each affinity was converted into a binding probability.  This is likely to be a process that 
is particular to the actual surface composition utilized for the single molecule assay. 
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However, the general framework presented here should suffice, given adjustment of the 
relevant parameters. The energy of each binding interaction is determined by a ratio of 
the observed Kd to the concentration of the binder present in the assay (C), then converted 
to an energy using the function: 
 
€ 
P Binding( ) = 1
1+ exp −α log C( ) − log Kd( )( )( )
 
Here 
€ 
α  is a scaling factor that can be adjusted depending on surface properties and assay 
conditions.  
 
 The binding probabilities are then used to compute P(aa|S) and P(S) as described 
above. Prior probabilities used in the simulations and optimization are taken from an 
estimation of the amino acid composition of the human proteome (11).  
 
Simulations 
 All simulations were run using a stand-alone program developed for this purpose. 
First, all possible binary footprints that could result from DAPES data collection were 
generated for between 5 and 17 NAABs. Next, sets of binding submatrices were 
generated with 5 to 17 NAABs and all possible combinations were tabulated. The 
Bayesian framework was then applied to each submatrix for each corresponding set of 
footprints. The output (one file for each submatrix) from these simulations was a set of all 
footprint probabilities for each amino acid. The maximum likelihood probability vector 
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was then extracted and compared to that of the full (17 NAAB) matrix by computing the 
correlation coefficient. 
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FIGURE 17: Binding matrix concentration dependence. Binding matrix as a function 
of concentration of probe used in a single-molecule assay. In each matrix, the y-axis is 
the NAAB type and the x-axis is the amino acid that is being probed with that NAAB. 
Probabilities of binding at 500 uM (top left), 50 uM (top right), 5 uM (bottom left), and 
500 nM (bottom right).  
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FIGURE 18: Data collection for DAPES. The image on the left is from a single 
molecule data acquisition run using the TIRF set-up which DAPES utilizes. The green 
spots correspond to a targeted molecule (in our case, the N-terminus of a peptide) and the 
red spots correspond to the binding molecule (the NAABs). At each position where a 
NAAB is bound, we see overlap (in yellow). Yellow spots are thus recorded as a binding 
event, or a 1 in the Boolean footprint, while green spots are recorded as a 0. The red spots 
then indicate non-specific adsorption of the peptides onto the surface. 
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FIGURE 19: Sequence mapping data (number of sequences). The cumulative 
probability of identifying any of the 19 amino acids in our set is plotted against the cut-
off probability. For example, if we require a 95% probability to call an amino acid then 
the cumulative probability of calling an amino acid from all possible footprints is 18%.  
At greater than 50%, this increases to 71% of all possible footprints. 
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FIGURE 20: Maximum probability of identification for 19 amino acids. The 
maximum probability of calling an amino acid using the full-set of NAABs is shown 
below. An informed prior, based on human proteome amino acid frequencies, was 
utilized. Tryptophan is the only amino acid with a probability of identification at less than 
95%, and most amino acids are greater than 99%. 
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FIGURE 21: Increasing correlation of submatrices. The correlation of the MPI vector 
with the full set of NAABs is shown in the plot below. There is a rapid increase in the 
correlation from around 5 to 9 binders, and only incremental increases thereafter. 
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FIGURE 22: Increase in identification for each amino acid as a function of number 
of NAABs. The y-axis is the maximum probability of calling an amino acid for 
increasing number of NAABs (darkest bar is 6 NAABs, lightest is 17). As noted 
previously, tryptophan is the most problematic amino acid to identify using the Bayesian 
framework because of its low prior probability (1.3%). 
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FIGURE 23: Optimal subsets of NAABs. For a fixed number of NAABs (which 
corresponds to fixed number of bind-wash-image cycles in DAPES) the optimal subset, 
computed by MPI correlation with the full matrix, is shown below. 
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FIGURE 24: Amino acid calling with relaxed minimum probability requirements. 
Under a system where each sequence is called at whatever amino acid is most probable, 
the ability to identify more amino acids is possible with fewer binders. At just 6 NAABs, 
all but tryptophan is identified, while 11 NAABs are required for the full set of 19 amino 
acids. 
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CHAPTER 4: 
AUTOMATED SELECTION OF STABILIZING 
MUTATIONS IN DESIGNED AND NATIVE 
PROTEINS. 
 
This chapter contains a manuscript published in December of 2012 in the Proceedings of 
the National Academy of Sciences. PNAS allows the authors to reproduce published 
work for inclusion in a thesis or dissertation without copyright release required. All 
experiments and computational analysis were carried out by me. Jim Havranek and I 
conceived and designed the research.  
 
Citation: 
Borgo, Benjamin, and James J. Havranek. "Automated selection of stabilizing mutations 
in designed and natural proteins." Proceedings of the National Academy of Sciences 
109.5 (2012): 1494-1499. 
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ABSTRACT 
 
 This chapter demonstrates a general computational approach to the problem of 
stabilizing designed and native proteins. Stabilization is critical when designing proteins 
for biotechnological applications since the conditions in which they are to be utilized are 
often much more harsh than the intracellular environment.  
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INTRODUCTION 
 Well-packed hydrophobic cores are a hallmark of protein structure (1, 2).  
Consistent with the central role the hydrophobic effect plays in protein stability, defects 
in core packing are associated with decreased stability(3)and loss of conformational 
specificity(4, 5).  Analytical tools for the assessment of core packing are useful for 
identifying errors in experimentally determined structures and for rationalizing and 
predicting the effects of mutations on protein stability.  Not surprisingly, the assembly of 
well-packed cores has been a central goal for computational protein design since its 
inception(6). 
 
 Despite this central focus, models generated by computational protein design 
algorithms often exhibit poor hydrophobic packing.  This is due to both the simplified 
structural representation and the scoring methods used by standard design protocols.  
Structurally, the protein backbone is treated as rigid, and different side chain orientations 
are sampled at each position.  These side chains are limited to a discrete set of commonly 
observed conformations known as rotamers.  This combination implies a limited ability 
to fill arbitrary volumes compactly.  The coarseness of this representation is exacerbated 
by the scoring functions, which generally include some form of the Lennard-Jones atom-
atom interaction term taken from molecular mechanics.  There is a severe and well-
known mismatch between the distances over which this term can vary strongly and the 
resolution afforded by a rotameric representation of side chains.  Xiang and Honig 
addressed this problem by increasing the number of allowable rotamers until the scoring 
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function could be satisfactorily sampled(7).  More commonly, the scoring function is 
modified to accommodate the rotameric representation.  This can be accomplished by 
reducing the atomic radii to mitigate clashes or by modifying the potential at short 
distances (8, 9).  Many such approaches were evaluated by Keating and coworkers(10). 
 
 When computational design does yield a well-packed core, the redesigned protein 
often exhibits enhanced stability.  Complementary steric interactions and an increase in 
the amount of buried hydrophobic surface area have been shown to stabilize the folded 
state of native proteins(11). Furthermore, small globular proteins with computationally 
optimized hydrophobic cores have exhibited increases in TM up to 20° C(8, 12).  
Increased stability additionally confers upon proteins the potential benefits of resistance 
to proteolysis(13) and longer half-life in-vivo (14), two desirable properties for protein 
therapeutics.  Furthermore, enhanced thermostability can preserve enzymatic activity at 
elevated temperatures(15), aiding in the development of biocatalysts. Consequently, 
computational design for stability is likely to play a major role in future protein 
engineering efforts. 
 
 What current computational design methods lack is a way forward when design 
models are not well-packed.  The initial backbone template may be randomly perturbed 
in the hope that some new side chain arrangement will emerge, and the number of 
allowable rotamers may be increased, but the fundamental problems often remain.  In the 
following, we present an automated protocol, RosettaVIP (Void Identification and 
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Packing), for improving the packing of a structural model.  We use the RosettaHoles 
analysis tool(16, 17) and a simple geometric scoring function to identify a small set of 
mutations that may yield improved packing.  We are able to devote more effort towards 
evaluating this reduced set of possibilities, including consideration of computationally 
expensive refinement steps incorporating backbone flexibility and off-rotamer side chain 
freedom.  We demonstrate the utility of our approach by identifying 'rescue' mutations for 
two previously reported designed proteins and verifying experimentally that the selected 
mutations yield more stable proteins.  We demonstrate the broader relevance of our 
approach beyond designed proteins by identifying and verifying a set of mutations that 
significantly stabilize a wild-type protein. 
 
RESULTS 
Fully redesigned proteins exhibit poorly packed hydrophobic cores 
 We selected a set of proteins from the PDB that satisfy a number of constraints 
(see Methods) and subjected each to complete sequence redesign.  Following design and 
relaxation, two structural assessments (the RosettaHoles packing score(17) and a simple 
tally of the number of buried, unsatisfied hydrogen bonds) identify problems that may 
lead to destabilized conformations. The difference in the number of buried, unsatisfied 
hydrogen bonds is small, though a clear trend is observed (Figure 1A). Packing quality as 
assessed by RosettaHoles is strikingly better for the native proteins than for models of 
proteins fully redesigned with Rosetta using either a standard or softened atomic 
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representation (Figure 1B).  Thus, the most obvious deficiency of designed proteins is in 
their packing. 
 
RosettaVIP: A protocol for the identification and resolution of packing flaws 
in design models 
 To refine protein design models, we used a simplified energy function (ERosettaVIP, 
see methods) implemented in the RosettaVIP ‘assessment-refinement’ protocol (Figure 2).  
The protocol locates regions in the model which are not well-packed and attempts to 
identify mutations that improve packing. After parameterizing the simplified energy 
function on an independent training set (see Methods), we evaluated the energy function 
on a series of previously characterized mutant proteins, and the full protocol on several 
poorly packed proteins. 
 
RosettaVIP recovers native amino acids and rotamer conformations from 
destabilized mutant crystal structures 
 We first assessed the ability of our energy function to rescue mutant proteins with 
cavity-creating core mutations.  A collection of 24 mutations of large buried hydrophobic 
residues to alanine was assembled with the further requirement that crystal structures be 
available for both the native and mutant proteins.  We modeled the reversion of the native 
amino acid in the context of the mutant crystal structure. Comparison to the mutant 
crystal structure yielded ΔΔE (difference in the respective energy function upon 
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mutation). We determined the rate of true positive prediction for reversion to the native 
(known to be favorable) with both our protocol and the current RosettaDesign protocol(9) 
(Figure 1C). The former has an 83% true positive rate, compared to only 46% for the 
latter, indicating an almost 2-fold improvement. Because the native structures are 
available, we compared χ1, χ2 side chain dihedrals of the natives to the reversion models 
generated by our algorithm.  93% (VIP) and 94% (RosettaDesign) of the models showed 
accurate rotamer recovery.  
 
RosettaVIP accurately predicts stabilizing non-native mutations in protein 
cores 
 We selected a set of core hydrophobic mutations from the ProTherm database that 
confer at least a 3° C increase in TM, and for which structures of the wild-type protein 
have been determined. Each has a mutation that replaces a small, buried hydrophobic 
residue with a larger one.  Using the wild-type structure as a template, we determined if 
RosettaVIP correctly predicted the mutation to be favorable. The algorithm performs 
exceptionally well (Figure 1D), with a true positive rate of 93%. In contrast, 
RosettaDesign had a true positive rate of only 40%. 
 
RosettaVIP does not select unfavorable small-to-large and 
volume-conserving point mutations   
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 We next addressed the possibility that our protocol is simply choosing larger 
amino acids to fill voids without regard for local steric complementarity.  We identified a 
set of mutations in the ProTherm database that replaced buried hydrophobic residues with 
residues of equal or greater volume, but which resulted in a decrease of at least 2° C in 
TM.  Using the wild-type structure as a template, we asked if RosettaVIP incorrectly 
predicted the mutation to be favorable.  For these mutations, RosettaVIP exhibits a false 
positive rate of 23%, compared to 5% for RosettaDesign.  The increase in false positives 
relative to RosettaDesign is expected, given the softness of the modified potential. 
Statistical analysis using Cohen’s kappa (k)(18) indicates a two-fold improvement 
(k=.623 for RosettaVIP and k=.323 for RosettaDesign) of correctly classified mutations.  
 
The protocol predicts mutations that stabilize a redesigned λ repressor 
 Dantas et. al. tested the ability of RosettaDesign to redesign completely nine small 
globular proteins (19). Most of these redesigns shared less than 50% sequence identity 
with the starting scaffold.  Remarkably, many were significantly stabilized in comparison 
to their native counterparts. Among the less successful designs was the DNA-binding 
domain (residues 3-89) of  λ repressor.  The designed λ repressor (λ0) exhibited a clear 
loss of cooperative folding compared to the wild-type (20), and adopted a molten globule 
state(19). Examination of a predicted model for λ0 revealed several buried cavities not 
present in the native structure.  The RosettaHoles packing metric indicates a low 
probability (.54) of native-like core packing. 
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 We subjected λ0 to iterative redesign using RosettaVIP. The protocol converged 
after five design cycles to yield a four-fold mutant with a predicted ΔΔEmut of 8.5 energy 
units, a reduction in buried void volume of 242.9 Å3, and a significant increase in packing 
quality (Table 1, Figure3A-B). We expressed and purified this mutant (λ4) and 
characterized the stability experimentally. The circular dichroism signal as a function of 
temperature has a steep folded baseline with a cooperative unfolding event between 
65° C and 75° C (Figure 3C, inset). We fit a two-state unfolding curve to the data and 
obtained a TM of 72.01° C (Figure 3D).  We also observed increased stability to 
guanidine-induced denaturation, with a ΔG0H2O of 7.71 kcal mol-1 (5.01 kcal mol-1 more 
stable than  λ0). 
 
 Reversion of two mutations individually recovers native-like unfolding in a 
redesigned λ repressor 
 We were concerned that the steep folded baseline of λ4 was indicative of partial 
non-cooperative unfolding below 60° C.  Visual inspection of the model showed that two 
mutations (F64W and L75W) had a small but potentially significant amount of solvent 
exposed non-polar surface area. While the interactions of these residues were considered 
favorable by our protocol, the exposure of hydrophobic surface area is only minimally 
penalized. We therefore decided to eliminate each of these mutations and characterize the 
pair of triple mutants independently. We expressed and purified the three-fold mutants 
(λ643 and λ753) to assess their conformational stability.  
 109	  
 
 Each of the triple mutants exhibited folding behavior more closely resembling the 
native λ repressor, though the slope of the transition region is less steep in both instances. 
Notably, the thermal denaturation temperature of λ753 is 60.2° C, which is approximately 
4° C above that of the native protein. Chemical denaturation showed a steeper transition 
for both triple mutants as well as a shift towards higher [GuHCl] midpoint relative to λ0. 
The ΔG0H2O for λ643 and λ753 were determined to be 4.46 and 4.77 kcal mol-1, an increase 
in stability of 1.76 and 2.07 kcal mol-1 over λ0. 
 
A predicted point mutation in a Protein L redesign increases stability 
 Protein L was redesigned to 46% sequence identity in (19). Though the TM for the 
redesigned protein was near 100° C, the ΔG0H2O was below that of the wild-type.  
RosettaHoles analysis indicated a packing score of 0.58 for the original design PL0, 
suggesting room for improved packing.  We applied RosettaVIP to PL0 and identified a 
pair of mutations that improved the Rosetta score and increased the packing score to 0.71. 
The protein L mutant PLdouble was expressed and characterized by circular dichroism.  
PLdouble exhibited a folded-unfolded transition that was clearly not two-state (Figure 5B, 
triangles).  Based on our computational results, we reasoned that one of the predicted 
mutations might be a false positive, and therefore expressed and characterized the pair of 
point mutants. This speculation turned out to be accurate, as the mutant PLA6W had a TM 
similar to that of PL0 but a higher ΔG0H2O of 4.6 kcal mol-1 (Table 1, Figure 4). The 
second mutant (PLF10W) exhibited non-cooperative thermal denaturation and was not 
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assayed further. Inspection of a model of the F10W mutation shows that the mutant side 
chain makes solvent-exposed (rather than buried) hydrophobic contacts.  Automated 
identification of this pathology will be addressed in future work. 
 
RosettaVIP predicts five mutations that significantly improve the stability of a 
native enzyme   
 Finally, we wished to assess the ability of RosettaVIP to improve the packing of a 
native protein.  We selected as our test case methionine aminopeptidase from E. coli 
(eMAP), a 287 amino-acid protein with α/β topology and a molecular weight of 30 kDa 
which we are familiar with from unrelated work.  eMAP has a moderate denaturation 
temperature (51.4° C) indicating potential for improved thermal tolerance. Application of 
our protocol selected five mutations that conferred a predicted ΔΔE of -5.8 energy units 
(Table 1, Figure 5). 
 
 We expressed the designed and native proteins and assayed them for stability by 
monitoring denaturation via circular dichroism. The native protein unfolds cooperatively 
at 51.4° C (Figure 5E).  The five-fold mutant (eMAP5-fold) exhibits an increase in TM of 
17.6° C.  Chemical denaturation of eMAP5-fold shows a transition midpoint shifted to 
higher GuHCl concentrations than eMAPwt. Fitting a two-state model to the guanidine 
induced denaturation curve of eMAP5-fold yields a ΔG0H2O of 4.6 kcal mol-1 versus 
3.2 kcal mol-1 for eMAPwt.  To assess the success of RosettaVIP on a residue-by-residue 
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basis, we expressed and characterized each of the five predicted point mutants. Three of 
the five mutations (C45L, V207I, and V24I) made a positive contribution to stability with 
ΔΔG ranging from 0.29 to 0.89 kcal mol-1.  The two remaining mutants, A152I and 
F156L were approximately neutral (Table 1). 
 
DISCUSSION 
 We have introduced RosettaVIP, a fully automated protocol for selecting point 
mutations that improve the quality of core packing of structural models, and shown that 
enhancement of these interactions leads to increased thermodynamic stability. The 
effectiveness of RosettaVIP was demonstrated computationally on several sets of 
previously characterized mutants, and validated experimentally by stabilizing two 
completely redesigned but under-packed proteins (λ repressor and Protein L), as well as a 
native enzyme (eMAP). RosettaVIP has demonstrated a high success rate for identifying 
favorable mutations despite its relative simplicity.  The false positive rate for selected 
mutations, while modest, necessitates experimental verification of each prediction. 
 
 RosettaVIP is meant to eliminate packing defects by selecting point mutations 
rather than implementing complete redesign of the hydrophobic core, which generally has 
given the largest improvements in stability for small globular proteins (8, 12, 19). 
However, the automated protocol presented here selects a minimal set of mutable amino 
acids to optimize stability. In contrast to a complete core redesign, application of our 
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protocol is expected to minimize structural perturbation of the design scaffold. This is 
likely to prove beneficial in many applications where retention of binding or enzymatic 
activity is as important as increasing stability. 
 
 We expect that RosettaVIP will be particularly useful to the enzyme design 
community, as we were able to realize a dramatic increase in denaturation temperature 
while minimizing loss of activity. The stabilization of methionine aminopeptidase led to 
an approximate 3-fold decrease in activity compared to native at room temperature. 
Native activity is sharply decreased at 50° C, while the 5-fold mutant remains active 
(Figure S1).  That there is still room for improvement in both the design and refinement 
process is evident given that the homologous aminopeptidase from P. furiosus has a 
melting temperature in excess of 100° C and is fully active up to 90° C. 
 
 Although we have focused on core packing, a number of other structural traits can 
influence protein stability. Fully satisfied, buried hydrogen bond networks, secondary 
structure capping motifs, optimized surface electrostatics, and backbone rigidity imparted 
by supporting residues are all known to contribute to the stability of the folded state.  In 
particular, we observe that buried, unsatisfied hydrogen bonds are more common in 
design models than in experimental structures (Figure 1). We are currently working on 
extensions to our protocol that can identify and resolve a broader range of structural 
defects. 
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MATERIALS AND METHODS 
Computational assessment of a library of completely redesigned proteins 
 A set of 500 crystal structures was selected from the PDB database. Each protein 
in the set is monomeric, smaller than 30 kDa, free of disulphide bonds, with a structure 
solved to 1.8 Å resolution or higher. HETATM and water entries were removed prior to 
analysis, and hydrogens were built with the Rosetta program. Each structure was 
subjected to relaxation under the Rosetta fullatom potential(21, 22). Packing quality was 
analyzed using the RosettaHoles metric(16, 17). A count of all buried, unsatisfied 
hydrogen bonds was obtained using a SASA probe of 1.4 Å. Hydrogen bonds were 
defined with a strict geometric criteria(23). To generate a library of fully redesigned 
models, all structures were then subjected to sequence optimization and rotamer 
repacking on a fixed backbone using RosettaDesign with both a standard and dampened 
Lennard-Jones potential(9). The resulting structures were analyzed for packing quality 
and buried, unsatisfied hydrogen bonds. Distributions were generated for each metric and 
a normal curve was fit (p < 0.001 in all cases) to each. 
 
VIP scoring term 
 In the RosettaVIP representation, each heavy atom in the initial structure is 
represented as a 'cloud' with 3-dimensional Gaussian density: 
€ 
ρ(r,R) = exp − r − R( )2 /σ 2( )  
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where r is the distance from the center of an atom, R is its coordinate vector, and σ is the 
variance. The variance can be thought of as defining the 'softness' of the atoms, with a 
larger σ indicating softer atoms.  σ was allowed to vary from 0.9 to 1.1 times the van der 
Waals radius in increments of 0.05. It was empirically determined that a scaling factor of 
0.95 yielded the best agreement with the three test sets, which is in line with previous 
work (8, 10). The overlap integral for any single atom (ai) within a structure S is then: 
€ 
EVIP (ai) = ρi(r,R)ρ j (r,R)dr
−∞
∞
∫j≠ i
j:a j ∈S∑ . 
The standard full-atom RosettaDesign scoring function consists of a linear superposition 
of terms including a 6-12 Lennard-Jones potential, the Lazaridis-Karplus implicit 
solvation model, an empirical hydrogen-bond term, rotamer probabilities, and amino acid 
probabilities based on ϕ, ψ orientations (21). We implemented a simplified version of 
this scoring function, substituting the VIP score term for the Lennard-Jones repulsion, 
and retaining only the Lennard-Jones attractive term and a term to penalize the exposure 
of additional surface area. The surface area term was included to prevent the insertion of 
amino acid-rotamer conformations that were solvent exposed. The weighted energy 
function used for fixed backbone sampling was: 
€ 
ERosettaVIP = −w1ELJr + w2ESASA + w3EVIP  
Linear weights for each energy term were chosen to optimize the recovery of native 
amino acid sequence from a randomly mutated structure. The training set consisted of a 
library of 41 small, globular protein domains.  
Native, positive and negative test sets 
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 We assembled a test set (the native set) of structurally characterized, void-creating 
point mutations. For each mutation in the set, high resolution (1.8 Å) crystal structures 
are available for both the wild-type and mutant proteins.  All mutations introduced an 
alanine residue at a fully buried position that decreased protein stability, as reported in 
the ProTherm database (8-17-2010 release).  We identified a second test set (the positive 
set) consisting of fully-buried point mutations that increase side chain volume and confer 
at least a 3° C increase in thermal denaturation temperature.  High-resolution crystal 
structures are only available for the wild-type proteins in this set.  Mutations removing or 
introducing polar amino acids were excluded. A final test set (the negative set) was 
assembled from structurally characterized, fully-buried, volume increasing mutations that 
resulted in a decrease in TM of at least 2° C.  
 
Identification of mutable residues 
 Buried cavities were identified using RosettaHoles(16, 17), which fills voids in 
the protein with 'cavity balls', pruning away any which have a non-zero solvent accessible 
surface area. The remaining balls represent the empty space within the molecule. 
Residues were defined as mutable if there is at least one side-chain atom within 7 Å of a 
cavity ball and if the residue is apolar and not on the surface of the protein. The set of 
mutable residues was subjected to one-at-a-time design using the RosettaVIP score within 
the RosettaDesign framework. RosettaHoles also provides a stochastic metric for packing 
quality that is based on a support vector machine trained against high-resolution crystal 
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structures. The metric returns the probability that a model has a native-like packing 
arrangement, and has been extensively validated(16, 17). 
 
Computational design 
 RosettaDesign consists of a Monte Carlo engine for the rapid optimization of 
sequence space and an energy function for scoring the search through sequence space. 
The Rosetta framework is thoroughly described in a pair of recent reviews(21, 22). For 
our purposes, the Monte Carlo search for favorable mutations is carried out on a fixed 
backbone using either RosettaVIP or Rosettadamp_rep, a 'dampened repulsive' Rosetta full 
atom scoring function(9). After identifying mutable residues and selecting several 
optimal amino acid-rotamer combinations at these positions, the two top scoring 
mutations are retained and both the backbone and side-chains are allowed to relax. 
Relaxation is an existing Rosetta protocol that combines gradient minimization with 
Metropolis-Monte Carlo sampling of rotamers over all residues in the protein(21). 
Following relaxation the design is rescored with the standard Rosetta fullatom score and 
compared to the starting structure, which gives ΔΔE in Table 1. The resulting model with 
the best Rosetta all-atom energy is then passed back to RosettaHoles and the process 
iterated until there is no further improvement in the final scoring step. Final designs were 
assessed and selected by Rosetta energies, RosettaHoles packing score (16) and volume 
of buried voids. An application encompassing the selection workflow (figure 2 and 
supplementary text) will be made available as part of the Rosetta software suite, which is 
freely available to academic users. 
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Cloning, expression and purification 
 A gene encoding λ repressor was purchased from Integrated DNA Technologies 
(IDT) and cloned into the pET42(a) expression vector (Novagen) upstream of a 6x his-
tag. Methionine aminopeptidase was amplified from E. coli genomic DNA, cloned into 
pET42(a) upstream of the 6x his-tag, and verified by sequencing.  Proteins were 
expressed using an autoinduction protocol(24). Proteins were purified by immobilized 
metal affinity chromatography and concentrated by ultrafiltration. Identity and purity 
were verified by SDS-PAGE. Purified protein was dialyzed against 50 mM potassium 
phosphate, 100 mM sodium chloride (pH 7) for 24 hours.  Concentrations were 
determined by absorbance at 280 nm(25). Site-directed mutagenesis was accomplished 
using the QuikChange protocol (Agilent Technologies) and verified by sequencing. 
 
Circular dichroism 
 Far-UV circular dichroism spectra were collected on an Applied Photosystems 
Chirascan spectrophotometer at protein concentrations of 20-30 µM. Temperature 
induced denaturation (10-95° C) was determined by stepped ramping in 5° increments 
with a 30 second set time at 222 nm in a 2 mm path length cuvette. For GuHCl induced 
denaturation, temperature was maintained at 25° C with a Peltier temperature control 
device and denaturation was determined by monitoring change in ellipticity for 0-8 M 
GuHCl in 0.5 M increments at 222 nm in a 10 mm path length cuvette. 
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Data analysis 
 Thermal denaturation curves were fit to a two-state model by converting to 
fraction folded (26): 
€ 
Ff =
θ −θu
θ f −θu
 
and then by non-linear least squares to the equation: 
€ 
Ff =
exp ΔH 1− TTM
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ RT
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ 
1+ exp ΔH 1− TTM
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ RT
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ 
 
(a rearrangement of the Gibbs-Helmholtz equation with Δcp = 0) to determine TM and the 
van't Hoff enthalpy ΔH. Chemical denaturation curves were fit for all parameters by non-
linear least squares according to the formulas in ref. (27) to determine ΔG0H2O and m, and 
converted to  fraction folded according to ref. (26). 
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FIGURE 25: Redesigned proteins exhibit decreased optimality of native-like 
hydrogen bonding and packing interactions. A set of 500 fully redesigned scaffolds 
exhibited an increase in buried, unsatisfied hydrogen bonds (A) and a decrease in packing 
quality (B) both of which can confer decreased stability. ‘Experimental’ refers to the 
unmodified crystal structures from the PDB. ‘Hard spheres’ refers to same set of 
structures refined using the traditional Lennard-Jones potential (Rosetta ‘standard’ energy 
weights), while ‘soft spheres’ refers to the structures refined with a modified Lennard-
Jones potential with reduced steric clashes (Rosetta ‘damp_rep’ energy weights). The 
RosettaVIP protocol successfully predicts stabilizing point mutations in a variety of 
different proteins.  Graphic representations of the sensitivity and specificity of the 
algorithm are shown for the native (C), positive (D), and negative (E) test sets. 
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FIGURE 26: Overview of the RosettaVIP protocol.  RosettaVIP starts with a structural 
model and identifies voids within the protein interior. These voids are used to select 
'mutatable' residues that are potentially positioned to fill these gaps upon mutation to a 
judiciously chosen amino acid. Each mutable residue is computationally optimized on a 
fixed backbone with all other amino acids held fixed, and favorable mutations are 
subjected to a full relaxation in which the backbone is allowed to move. This restricts the 
application of backbone flexibility (which is computationally demanding) to mutations 
likely to be favorable. The highest scoring design is kept and used as the starting structure 
for an additional round of selection, optimization, and relaxation.  The protocol 
terminates when no further voids are identified. 
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FIGURE 27: λ  repressor redesign. Structural models (A-B) of predicted mutations and 
denaturation experiments (C-D) for the rescued λ repressor. The protein backbone is 
represented in blue 'cartoon' representation (All figures made in pymol(28)). Voids are 
identified by yellow 'cavity balls' and mutated residues are represented as orange spheres. 
The upper panels show the modeled effects of mutations chosen by our protocol from two 
angles. The drastic reduction in buried void volume from λ0 to λ4 is indicative of 
improved packing of the hydrophobic core. The lower panel (C-D) shows the 
experimental determination of the mutants’ stability. Recovery of cooperative folding is 
evident in both the temperature (C) and chemical (D) denaturation.  The inset in panel C 
shows the sloped, folded baseline for λ4 in the raw ellipticity data. 
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FIGURE 28: Protein L redesign.  RosettaHoles analysis identifies two small voids in a 
model for PL0 (A), one of which is filled by the A6W mutation (orange) in PLdesign (B). 
The other void is reduced by a secondary interaction, where the A6W mutation causes the 
rotation of F8 into the void region. In (C), the fraction folded as a function of GuHCl 
concentration is plotted for PL0(open circles), PLdouble(triangles), and PLA6W(closed 
circles). 
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FIGURE 29: Stabilizing mutations for eMAP.  Modeled mutations (A-D) and induced 
unfolding curves (E-F) for methionine aminopeptidase as monitored by circular 
dichroism. The global reduction in buried void volume (A) is apparent from the 
RosettaHoles annotated model of the structure. Local reductions in void volume (B-D) 
around each mutated region are also apparent. The chemical and thermal melts (E and F) 
for the 5-fold mutant and each point mutation is shown in the lower panels. The bold, 
black lines are the native and 5-fold mutants while the dashed colored lines are each 
individual point mutant as noted in the legend. 
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TABLE 5: Thermodynamic parameters from experiments and Rosetta modeling 
were calculated as described in the text. Details on the full atom Rosetta Energy function 
can be found in ref. (22), while details on the experimental parameters can be found in 
ref. (26).  
Original Designed 
Protein       
 E 
Volburied (Å3
) 
Packing 
Score TM ΔG
0
H2O m 
 λ0 -217.1 298.3 0.54 nc 2.7 0.8 
PL0 -101.17 149.7 0.58 100 3.7 1.4 
eMAPwt -614.01 891.37 0.61 51.4 3.2 1.8 
Mutants ΔΔE    ΔΔG  
 λ4 -8.5 55.4 0.70 72.0 5.0 1.7 
 λ643 -4.7 94.7 0.64 58.5 2.2 1.0 
 λ753 -5.0 88.6 0.69 60.2 2.2 1.1 
PLA6W -3.1 42.5 0.66 100 0.9 1.4 
eMAP5-fold -5.8 828.4 0.68 69.0 1.4 1.2 
eMAPV24I -3.1 867.4 0.61 56.1 0.4 1.3 
eMAPC45L -2.4 860.1 0.62 52.9 0.5 2.6 
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eMAPV207I -3.9 862.2 0.62 58.8 0.9 0.9 
eMAPA152I -1.4 879.2 0.61 51.2 0.3 0.9 
eMAPF156L -0.6 887.4 0.60 51.1 0.2 1.1 
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CHAPTER 5:  
MOTIF-BASED DESIGN OF ENZYME 
SPECIFICITY 
 
This chapter consists of a manuscript published in February of 2014 in the peer-reviewed 
journal Protein Science. Protein Science allows the reproduction of published work by 
authors for use in dissertations without formal approval required. Jim Havranek 
developed the computational approach and implemented the design algorithms. I 
completed all experiments and subsequent data analysis. 
 
Citation: 
Borgo, Benjamin, and James J. Havranek. "Motif‐directed redesign of enzyme 
specificity." Protein Science (2014). 
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ABSTRACT 
 
 This chapter utilizes a previously described computational method for designing 
functional interactions. It is a generalizable approach to redesigning enzyme and substrate 
binding specificity in proteins. The model system on which it was tested (methionine 
aminopeptidase) was a candidate for the NAAB design in chapter 2 which we abandoned 
in favor of the aaRS scaffolds. 
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INTRODUCTION 
 Computational protein design has advanced rapidly over the past decade. Despite 
many impressive successes 1-9, generating novel, functional proteins with activity levels 
similar to natural proteins remains challenging.  Limitations in scoring functions, 
structural representation, and search strategies provide ample opportunity for 
improvement.  A common strategy for circumventing these limitations is to incorporate 
structural building blocks from experimentally determined structures. For example, 
computational protein design typically involves the combinatorial selection of 
experimentally observed amino acid conformations (rotamers) that optimize some 
scoring function when arranged on the backbone of a native protein4,10-13. Similarly, 
structure prediction algorithms often rely upon libraries of backbone fragments culled 
from the protein databank to reduce the conformational space that must be sampled when 
assembling structural models of proteins 14-18.  This strategy involves a trade-off: native 
structural building blocks ensure that our models contain plausible interactions, but bias 
us towards what has already been observed.  This can be particularly limiting for protein 
design, which usually seeks to realize a novel function or specificity. 
 
 Two strategies for leveraging native protein structures present themselves in the 
context of the design of protein function. At the macromolecular level, we can identify 
proteins that carry out related functions as starting templates and attempt to preserve 
aspects of this function while redesigning other residues to accommodate desired 
changes. At the atomic level, we can identify specific interactions involving residues in 
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unrelated proteins that may prove useful in achieving the change in function or specificity 
that we require to move from a starting template to a novel molecule.  We can direct the 
choice of mutations required to repurpose the native template by focusing on recreating 
previously observed interactions from other structural contexts. Using previously 
observed functional interactions is likely to increase the odds of success for a given 
protein engineering goal.  
 
 The transplantation of atomistic interactions onto a design template is challenging 
because the backbone conformation of the template is unlikely to present an optimal 
geometry to reproduce the interactions found in the native context.  Introducing modest 
backbone flexibility is likely to accommodate a large number of functional interactions, 
but it is not possible to know a priori how the backbone should be deformed.  We 
previously described a computational algorithm for addressing this problem in the 
context of protein-DNA interactions 19.  We identify a set of previously observed 
functional interactions (called motifs) and attempt to transplant them onto our design 
template.  A motif can be successfully incorporated if modest movement of the design 
template backbone accommodates placement of the motif’s functional amino acid. A 
previous computational approach to enzyme redesign utilized flexible backbones 20, 
however, this did not rely on library of putative functional interactions and required 
explicit selection of mutatable positions. 
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 In this report, we extend the method introduced in ref. 19 for selecting motifs 
from a set of native interactions to confer a change in the specificity of an enzyme. 
Starting with a library of potentially functional motifs, we implement an algorithm that 
utilizes iterative cycles of backbone relaxation and motif placement followed by the 
redesign of additional supporting mutations.  The extended method is general in the sense 
that it can be used to design for any target for which a comprehensive motif-library can 
be gathered from databases or constructed from computations.  We describe this 
approach in detail, and demonstrate its effectiveness by altering the specificity and 
activity of methionine aminopeptidase. Our results show that in this system the transfer of 
residue-level functional interactions can alter substrate specificity while preserving 
existing catalytic activity. 
 
RESULTS 
Computational redesign of specificity with backbone flexibility 
 Methionine aminopeptidase from E. coli (eMAP) is an essential metallo-
aminopeptidase responsible for post-translational removal of N-terminal methionine from 
proteins. As shown in Figure 2, the N-terminal methionine is directly contacted by two 
loop regions surrounding the active site. A number of residues required for catalysis have 
been identified by mutagenesis 21-23, while those involved in substrate recognition are less 
well-studied but can be inferred from the crystal structures. Comparing the apo and holo 
forms of the protein (purple and white, respectively, in Figure 1) reveals a relatively rigid 
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binding pocket that shifts only slightly during substrate recognition. This ‘lock-and-key’ 
binding site is amenable to specificity redesign since no large structural rearrangements 
appear to be required to accommodate the substrate. We therefore sought to switch the 
specificity for N-terminal methionine to specificity for N-terminal leucine using motif-
based design. This is a relatively stringent test for specificity redesign since leucine and 
methionine both have similar hydrophobic properties and are comparable in size24.  
 
Flexible backbone design can be directed by interaction motifs 
 A loop region of the protein recognizes the sidechain of the methionine substrate.  
We anticipated that the loop region would need to rearrange to recognize a leucine 
sidechain.  Because optimal loop conformations for recognition cannot be determined in 
the absence of side chain-side chain interactions, we employed motif-directed design.  In 
this approach, a library of previously observed amino acid-amino acid contacts is 
collected from a set of experimentally determined structures.   
 
 Each motif in the library is used to place a free, interacting amino acid in the 
appropriate location to realize the interaction with the desired leucine substrate.  An 
inverse rotamer library 19 is used to sample the side chain degrees of freedom of the 
introduced amino acid.  This yields a set of virtual amino acids poised to reproduce 
previously observed interactions with leucine, each with an enumerated set of backbone 
locations that could give rise to the interaction.  A computational procedure is employed 
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to search for interactions with the substrate that can easily be incorporated into the 
preexisting backbone of eMAP with a limited amount of conformation rearrangement. 
 
 Using this approach, we identified residue-level interactions that could be 
accommodated by the eMAP backbone with conformational flexibility.  The first is an 
interaction between two leucine residues (Figure 2A-B) taken from GTP cyclohydrolase 
II (positions 47A and 18A, pdb code:  2BZ1 25).  The second is between residues 
Leu428A and Ile378A (Figure 2C-D) from estrogen receptor a (pdb code:  2IOK 26).  To 
maximize flexibility during the search for compatible backbone-motif matches, we 
changed residues within the loop to alanine, with the exception of glycine and proline 
amino acids, which were unchanged.  Following the iterative incorporation of the two 
interaction motifs, non-motif residues within the loop were redesigned using the 
RosettaDesign 27 program (Figure 3). This process was repeated ten times, with backbone 
relaxation performed between each sequence redesign calculation 28,29.  The resulting 
protein is denoted eLAP, and differs from eMAP at 19 positions (Figure 4). 
 
Inactive eMAP exhibits binding specificity for N-terminal methionine 
peptides 
 In the presence of a metal chelator, we found that eMAP binds N-terminal 
methionine non-catalytically.  We first conducted bio-layer interferometry (BLI) 
experiments to measure the affinity of native eMAP for an N-terminal methionine peptide 
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ligand. The results indicate that methionine recognition by eMAP in the absence of 
catalytic activity is a fairly weak interaction, with a dissociation constant of 2.65 mM.  
Next, we assayed the binding activity of eMAP against an N-terminal leucine peptide 
ligand.  The measured dissociation constant was 54.2 mM (Table I). Thus, eMAP 
exhibits a >20-fold specificity preference for N-terminal methionine over leucine (Figure 
5, Table I).   
 
Inactive eLAP exhibits altered specificity profiles for N-terminal methionine 
and leucine 
 We next tested whether our designed eLAP protein possessed altered specificity 
for the N-terminal methionine and leucine peptides.  Ideally, a specificity ‘swap’ would 
result not only in a change of relative binding preferences relative to eMAP (such a 
mutant may still prefer methionine, but by a smaller amount), but in an absolute 
preference for leucine over methionine. We first measured the affinity of eLAP for the N-
terminal leucine peptide and found detectable binding with a dissociation constant of 
0.83 µM. This is slightly better than the affinity of eMAP for the methioinine peptide. We 
then attempted to confirm the specificity swap by measuring the eLAP affinity for 
methionine. The resulting dissociation constant (Kd = 19.08 µM) is more than an order of 
magnitude higher than eLAP for leucine. Thus, eLAP exhibits a 20-fold preference for 
leucine over methionine (Figure 5), verifying that the mutant’s affinity profile is opposite 
that of eMAP.  
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Active eLAP exhibits altered activity for N-terminal methionine and leucine 
substrates 
 To determine whether the change in binding specificity translates into a change in 
substrate specificity, we characterized the enzymatic activity of both eMAP and eLAP 
using a fluorogenic assay.  When the substrate [Met/Leu]-AMC is cleaved, the liberated 
AMC group fluoresces, allowing direct measurement of substrate accumulation.  While 
optimal eMAP activity is known to require longer peptide substrates for maximal 
activity, we selected these substrates for ease of measurement, and because we are 
interested in relative, rather than absolute, rates.  The Met-AMC substrate is roughly 
equivalent to a two-amino acid substrate, which according to previous reports should be 
cleaved with an activity around 5% of that of a pentapeptide 30. We measured the 
activities of both enzymes against both substrates. Initial velocities for each substrate 
(RFU min−1) were converted to concentrations of released AMC, and initial velocities 
(µM min−1) were plotted as a function of substrate concentration. We determined the 
kinetic constants for both enzymes against Met-AMC and Leu-AMC; the results are 
summarized in Table 7.  The measured kcat/Km (catalytic efficiency) for eMAP against 
the Met-AMC and Leu-AMc substrates was 0.74 sec-1 M-1 and 0.02 sec-1 M-1, 
respectively (Figure 6). Thus, the catalytic efficiency of eMAP against Leu-AMC 
substrate is approximately 2.7% of that against Met-AMC, similar to the relative 
efficiencies found in a previous study utilizing pentapeptides (~3%) 30, indicating that 
despite the difference in absolute magnitudes, the AMC substrate provides an accurate 
measurement of relative catalytic efficiency. 
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 We next assayed the activity of eLAP against both substrates. The engineered 
enzyme has a kcat/Km of .0056 sec-1 M-1 against Leu-AMC, and a kcat/Km of .0024 sec-1 
M-1 against Met-AMC. While the lower activity activity indicates that our mutated 
enzyme is significantly less efficient than the native for both substrates, eLAP is more 
than twice as efficient at cleaving the Leu-AMC substrate than the Met-AMC. The Km of 
eLAP for the methionine substrate is actually lower than the Km for the leucine substrate.  
However, kcat is nearly two orders of magnitude worse. We speculate this is due to the 
significantly greater conformational heterogeneity of the methionine side-chain and the 
adoption of a greater variety of bound states, which though they are tightly associated, 
render catalysis impossible.  The notion of a less-ordered loop is consistent with an 
observed decrease in solubility of eLAP versus eMAP. 
 
DISCUSSION 
 The ability to engineer specific activities into proteins using computational 
techniques has advanced rapidly over the past several years and has enormous potential 
for generating novel therapeutics, industrial enzymes, and biotechnology tools. Current 
algorithms rely heavily on harnessing the native properties of existing proteins, either 
explicitly through the use of rotamers or implicitly through knowledge-based energy 
terms, to reconstruct enzymes or proteins with altered activity or specificity. In 
algorithms that explicitly target pre-defined interactions, stable modules that possess the 
 138	  
desired properties are either designed or identified from a database of empirical structures 
and computationally matched to a region in the target protein. This type of “building-
block” approach to synthetic biology has become popular in metabolic engineering 31-34 
and several reports have demonstrated its applicability to protein design 7,8,35,36.  
 
 Perhaps the most striking examples of module transplantation have been 
generated as a product of de novo enzyme engineering. The Rosetta software suite’s 
enzyme design protocol, for example, has successfully transplanted artificial active sites 
onto native backbone scaffolds 7,9,37. While this is an extraordinary feat of protein 
engineering, and a stringent test of our understanding of protein structure and function, de 
novo design is a much more difficult problem than need be solved to generate novel 
enzymatic activities for many practical applications. By contrast, redesign of native 
enzymes requires less effort and can draw upon a supply of over 4,000 chemical activities 
38 that could be amenable to redesign. 
 
 We note that although computational design with motif-directed backbone 
flexibility was successful in this case, the two motifs that were incorporated into the 
flexible region of the protein both involved hydrophobic residues.  It remains to be seen 
whether this approach will prove successful for the design of hydrogen-bonded or 
electrostatic interactions, which has proven more difficult than design involving only 
hydrophobic contacts 39,40. Hydrogen bonded interactions require more stringent 
geometric constraints, and the many-body, networked nature of these interactions may be 
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a poor fit for standard design schemes, which typically employ scoring functions that are 
truncated at two-body terms. 
 
 In eMAP, the catalytic, metal-chelating residues are readily distinguished from 
the side-chain specificity-determining residues.  Approaches such as motif-directed 
design are likely to work well in proteins where this is the case, or when the desired 
function is limited to binding or recognition.  In this study, eLAP exhibited binding 
kinetics for an N-terminal leucine that were similar to those of eMAP for an N-terminal 
methionine. In general, however, specificity, catalysis, and binding energy are intimately 
entangled in enzymes 41. Our results from the enzymatic assays indicate that in the case 
of eMAP this is minimal but still apparent, as the kcat of the designed eLAP is 
significantly less than that of the native enzyme for both substrates.  This may limit the 
applicability of the residue level, motif-based approach for the design of certain novel 
catalysts.  
 
 Despite this limitation, our results also suggest that this approach may work well 
in combination with directed evolution.  Directed evolution is very effective at 
optimizing a pre-existing activity, but is often incapable of generating large, coordinated 
changes to establish novel function.  Our results demonstrate the ability of motif-based 
computational design to change specificity, and to cope with a large number of mutations 
(19 for eLAP relative to eMAP).  While it is likely that not all mutations are essential for 
our desired goal, such a large number of simultaneous mutations cannot be encoded in a 
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genetic library.  In cases where a preexisting activity is lacking, motif-based design may 
thus allow protein engineers to generate a starting point that would not be discoverable by 
directed evolution alone. It is also possible that directed evolution would be able to 
identify additional mutations to improve upon the activity of eLAP. 
 
MATERIALS AND METHODS 
Construction of motif library  
 We extracted motifs from a subset of the PDB 42 obtained from the PISCES server 
43,44. We required that all structures be solved using x-ray crystallography to a resolution 
of 1.6 Å or better, with R-factors of 0.25 or better, and that no two domains shared more 
than 20% sequence identity.  This yielded 1682 structures.  For each structure, all 
residue-residue interactions that include a leucine were scored using the Rosetta full-atom 
scoring function.  We isolated hydrophobic interactions by considering individual scoring 
terms.  If the total Lennard-Jones potential score was greater than -1.0 Rosetta energy 
units (REU) (lower values are more favorable), the interaction was discarded.  Otherwise, 
the geometry between the sidechains was determined as previously described 19. Briefly, 
a coordinate system is defined for each of the amino acids by pre-defined terminal heavy 
atoms (e.g., Cg, Cd1, and Cd2 for leucine).  The translation vector and rotation matrix 
relating the coordinate systems between residues is obtained, and may be used to recreate 
one interacting partner given the other.  To eliminate redundant interactions, the 
geometric transformation is checked against previously calculated examples.  Any 
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interaction whose translation vector and rotation matrix differ from another by less than 
1.0 Å and 0.4 radians, respectively, are deemed to be redundant and are discarded.  Each 
such interaction (called a motif) is defined by the identities of the amino acids involved, 
the atoms used to define the coordinate systems, and the transformation relating the two 
systems.  We call the resulting set of non-redundant, previously observed interactions a 
motif library. 
 
Design template preparation 
 The starting point for redesign calculations was the experimentally determined 
structure for eMAP in complex with the transition state analog norleucine phosponate 
(pdb code:  2GTX 45).  We modeled a leucine amino acid superimposed upon the 
norleucine phosponate, and predicted the favored side chain conformation using the 
Rosetta program 46.  The conformation of the leucine amino acid was held fixed for all 
subsequent calculations.  Residues 56-70 were selected as a loop region.  In order to give 
the loop region flexibility in accommodating interactions with the leucine substrate, 
residues 56-70, as well as neighboring residues 42,46,81,101,177, and 221 were replaced 
with alanine, with the exception of glycine and proline residues, which were not changed. 
 
Motif incorporation 
 The procedure for motif-directed backbone movement and incorporation of 
interacting virtual amino acids is given in detail in ref. 19. Briefly, the leucine-specific 
motif library was used to generate possible interactions between the protein and the 
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leucine substrate in two steps.  First, the geometric information for each motif was used 
to place a virtual interacting amino acid in contact with the substrate.  The motif defines 
the relative orientation of the terminal heavy atoms in the interacting amino acid.  
Second, we made copies of each virtual amino acid that differed only in their side chain 
torsion angles, which were taken from a rotamer library.  Copies that clashed with the 
substrate or residues outside the loop region, or that had main chain atoms too far from 
any protein residue (rmsd > 2.0 Å over the Cβ, Cα, C, and N atoms) were discarded.  
Thus, each motif in the motif library gives rise to multiple virtual amino acids, each 
satisfying the geometric requirements of the motif interaction, but with different locations 
for their backbone atoms. 
 
 We next determined whether the protein backbone atoms could be made to 
superimpose with those of each virtual interacting amino acid.  We performed loop 
relaxation under the Rosetta scoring function augmented with harmonic constraints 
between the Cβ, Cα, C, and N atoms of the amino acid and the corresponding atoms of the 
closest backbone position in the flexible loop.  Backbone movement was considered 
successful if the final rmsd over the constrained atoms was below 1.o Å.  In this case, the 
virtual motif amino acid was modeled onto the backbone.  As aligning the backbone 
atoms causes the terminal atoms to shift, we performed a second round of loop relaxation 
in which constraints are applied to restore the motif-defining terminal atoms to their ideal 
locations.  We accepted as successful those cases with final rmsd values below 1.0 Å.  
These motif-incorporating models served as the starting point for further attempts to 
incorporate additional motifs.   
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Redesign of loop residues 
 Following the final motif placement, surrounding residues in the design region are 
mutated to support the altered backbone conformation using a combination of standard 
protocols for fixed backbone design and energy minimization from RosettaDesign 27.  
First, we redesigned any positions in the flexible loop or the neighboring residues that 
had been replaced with alanine prior to motif incorporation, excluding incorporated motif 
residues.  Then, the ‘backrub’ loop relaxation protocol was applied to the loop (residues 
56-70) 29. We performed ten iterations of this combined procedure. 
 
Cloning and mutagenesis 
 The gene for methionine aminopeptidase was amplified from E. coli genomic 
DNA, cloned into the pET42(a) expression vector (Novagen, MA, USA) upstream of a 
6× his-tag, and verified by sequencing. Site directed mutagenesis was done by the Kunkel 
method, with oligos ordered from IDT and mutants verified by sequencing. Proteins were 
expressed using an autoinduction protocol 47. Proteins were purified by immobilized 
metal affinity chromatography, eluted with an imidazole gradient, and concentrated by 
ultrafiltration. Identity and purity were verified by SDS-PAGE. Purified protein was 
dialyzed against 1x phosphate buffered saline (pH 7.4) for 24 h, and stored in 50% 
glycerol. Concentrations were determined by absorbance at 280 nm. 
 
Binding Assays 
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 Substrate peptides with a sequence of X-GMMSC were obtained (Cel-Tek, TN, 
USA), where X is either methionine or leucine. Biolayer interferometry using the BLItz 
platform (Forte Bio, CA, USA) requires the immobilization of the substrate onto a fiber 
optic tip coated with amine-reactive chemical groups. Each substrate was attached by: 
activating the tip with a 0.4 M 1-ethyl-3-3-dimethylaminopropyl)-carbodiimide (EDC) 
and 0.1 M N-hydroxysuccinimide (NHS) solution for 10 minutes, attaching a N-beta-
Maleimidopropionic acid hydrazide (BMPH) hetero-bifunctional crosslinker in 0.1 M 
sodium borate at pH 8.5 to introduce an exposed, reactive thiol, quenching unreacted 
amine-reactive groups with 1M ethanolamine, attaching the substrate by reacting the C-
terminal Cysteine with the BMPH thiol, and quenching unreacted thiols with a solution of 
50 mM cysteine and 1 M NaCl in 0.1 M sodium acetate at pH 4.3. The substrate derived 
tips where then washed with 100 µM BSA and stripped to remove any protein 
contaminants with 8 M Guanidine Chloride twice before starting the binding assay. To 
measure affinity constants, each tip was first blanked against a 1x PBS buffer containing 
no protein. 4 uL of 1x PBS containing 3.7 µM (eMAP) or 4.9 µM (eLAP) were loaded 
and the association of the protein to the substrate was measured for two minutes. The tip 
was transferred back into a 1x PBS blank and dissociation kinetics were measured for 
two minutes. The tip surface was then washed with 8 M guanidine chloride to strip off 
any remaining protein before the tip was reused. Negative controls with both BSA and 
the buffer blank showed no association/dissociation curves. Data was globally fit using 
the built-in BLItz software to a 1:1 binding model to determine kon, koff and KD. 
 
Aminopeptidase assays 
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 Fluorogenic amino-methylcoumarin substrate (x-AMC, where x is either 
methionine or leucine) were ordered from BaChem. Cleavage of AMC from the 
substrates was monitored on a 96-well plate fluorometer using a Synergy 2 Multi-Mode 
Microplate Reader (Bio-Tek, VT, USA) at an excitation wavelength 360 nm and an 
emission wavelength 485 nm for all substrates. Assays were conducted on 96-well round 
bottom black polystyrene microplates (Corning Life Sciences, MA, USA) in a reaction 
volume of 150 µl containing 3.7 µM eMAP or 4.9 µM eLAP, assay buffer (1x PBS, pH 
7.4) and substrate at concentrations ranging from 1 to 80 mM. Reaction mixtures were 
held at 4° C during combining, pre-incubated for 1 hour at 25°C and started by addition 
of 10 µM Cobalt Chloride to the mixture. Fluorescence accumulation was monitored 
every 1 minute over a period of 60 minutes and relative fluorescence units were 
converted to rates of substrate cleavage by calibration with a free AMC standard curve 
(Sigma Aldrich, MO, USA). Reaction rates at steady state were calculated from the slope 
of the fluorescence time courses by linear regression of initial velocities, and kinetic 
parameters were calculated assuming Michaelis-Menten kinetics, v = Vmax(S)/(S)+Km by 
non-linear regression in the R statistical software package. 
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FIGURE 30: Motif-based Design Workflow. The motif-based design workflow starts 
by building a culled library of native interactions and enumerating inverse rotamer 
conformations from a pre-defined set of PDB files. The designer then selects an 
appropriate backbone scaffold on which to attempt candidate mutations, and an 
integration region. The algorithm then attempts to integrate each motif into the 
predefined site, rejecting any placement that exceeds a user-defined cutoff score. The 
majority of motifs from the library are rejected at this step, which can be performed 
iteratively to incorporate more than one motif. Once the number of motifs requested by 
the user are inserted, mutations in the integration region are made to accommodate the 
motif placement using fixed-backbone design, and then minimized. This final step is 
iterative, and the final output is the lowest scoring design. 
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FIGURE 31: Holo-eMAP (PDB ID 2MAT{Lowther et al., 1999, Biochemistry, 38, 
7678-7688}, white) shows minimal conformational changes (0.114 RMSD) when bound 
with methionine (PDB ID 1C21{Lowther et al., 1999, Biochemistry, 38, 14810-14819}). 
The residues which contact the substrate are shown in a stick representation.  
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FIGURE 32: The placed motifs are shown here in their native background (A-B) 
and in their final position in eLAP (C-D). The native contact orientation is maintained 
through-out the design process by constraining the three atoms which define the motif 
coordinate system. Backbone atoms are allowed to move in discrete ‘inverse-rotameric’ 
conformations to graft the motif into its acceptor position. 
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FIGURE 33: eLAP design. (A) Initial placement of the LL motif (cyan, sphere 
representation) pulls the remodeled loop (cyan, cartoon) inwards towards the substrate 
(orange). This step repositions the loop from its native conformation (green).  (B) A 
second motif, the LI motif (purple, right) is placed adjacent to the substrate, and the loop 
is again remodeled (purple, cartoon) to accommodate the new motif. The LL motif is 
constrained in this step. (C) Residues surrounding both motifs in the loop region (black) 
are mutated to support the dual-motif placement, and relaxed in 10 iterations. Resulting 
loop movement is minimal, and the native interactions are maintained during remodeling.  
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FIGURE 34: Alignment of methionine aminopeptidase with the final design for a 
leucine aminopeptidase. The flexible loop region encompasses residues 56-70 with the 
two motif placements shown in bright red. Additional mutations made to accommodate a 
greater range of loop conformations are shown in bold letters. 
 
 
        eMAP 1 SIKTPEDIEKMRVAGRLAAEVLEMIEPYVKPGVSTGELDRICNDYIVNEQ 
        eLAP 1 SIKTPEDIEKMRVAGRLAAEVLEMIEPYVKPGVSTGELERICWDYIVNEQ 
 
            54 HAVSACLGYHGYPKSVCISINEVVCHGIPDDAKLLKDGDIVNIDVTVIKD 
            54 HATDSLTGHNGIDGHGSISINEVVCHGVPDDAKLLKDGDIVNIDVTVRKD 
 
           104 GFHGDTSKMFIVGKPTIMGERLCRITQESLYLALRMVKPGINLREIGAAI 
           104 GFHGDTSKMFIVGKPTIMGERLCRITQESLYLALRMVKPGINLREIGAAI 
 
           154 QKFVEAEGFSVVREYCGHGIGRGFHEEPQVLHYDSRETNVVLKPGMTFTI 
           154 QKFVEAEGFSVVREYCGHGIGRGHHEEPQVLHYDSRETNVVLKPGMTFTI 
 
           204 EPMVNAGKKEIRTMKDGWTVKTKDRSLSAQYEHTIVVTDNGCEILTLRKD 
           204 EPMVNAGKKEIRTMKDGSTVKTKDRSLSAQYEHTIVVTDNGCEILTLRKD 
 
           254 DTIPAIISHD 
           254 DTIPAIISHD 
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FIGURE 35: Changes in specificity in designed eLAP. On, off and dissociation rates 
for eMAP and eLAP show similar specificities (~20-fold affinity preference) for their 
target substrates (A), indicating that motif-based design successfully changes the 
specificity of eMAP. A comparison of binding to each substrate (B), shows that the 
primary increase in affinity is for the positive design state (ie eLAP for leucine) rather 
than against methionine. A raw sensogram used to derive the specificity comparisons is 
shown in (C). 
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FIGURE 36: Enzyme kinetics data for (A) eMAP cleaving methionine (eMAP-met), 
(B) eMAP-leu, (C) eLAP-met, and (D) eLAP-leu. Best-fit curves using the Michaelis-
Menten model are overlaid along with error bars for reaction velocities measured in 
triplicate. Parameters are listed in Table 7. 
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TABLE 6: Binding parameters. 
Protein/Peptide Kon Koff Kd (µM) 
Emap/Met 1.85x103 4.89x10-3 2.65 
Emap/Leu 2.71x102 1.47x10-2 54.2 
Elap/Met 2.14x102 4.08x10-3 19.1 
Elap/Leu 1.72x103 1.42x10-3 0.826 
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TABLE 7: Kinetic parameters. 
Protein/Substrate Kcat Km Kcat/Km 
Emap/Met-AMC 0.0033 0.0044 0.7397 
Emap/Leu-AMC 0.0031 0.157 0.0201 
Elap/Met-AMC 8.22 x 10-5 0.0336 0.0024 
Elap/Leu-AMC 3.48 x 10-4 0.0619 0.00562 
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CHAPTER 6: 
RATIONAL DESIGN OF A NOVEL ENZYME 
TO CATALYZE THE EDMAN DEGREDATION 
USING SUBSTRATE ASSISTED CATALYSIS. 
 
The chapter contains a manuscript that is currently in preparation for submission to a 
peer-reviewed journal. Jim Havranek developed the conceptual background and carried 
out initial modeling steps. I completed the computational design along with all 
experiments and data analysis. 
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ABSTRACT 
 
 The protein sequencing framework introduced in Chapter 2 requires sequential 
degradation of peptides immobilized to a surface. The surface integrity, measured by low 
background adsorption of NAABs, must survive multiple rounds of bind-wash-image 
cycles. Because the Edman degradation requires a harsh acid-based catalysis step, which 
may affect surface integrity, it is detrimental to our ability to image at a single molecule 
level in multiple DAPES rounds. This chapter describes our efforts to engineer an 
enzyme to catalyze the Edman degradation. 
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INTRODUCTION 
 The remarkable efficiency and specificity of biological catalysts make enzyme 
design a critical target for the protein design field. Aside from being ‘readily’ modifiable 
as opposed to chemical catalysts, biocatalysts are generally more efficient, more specific 
to their respective substrates, require milder reaction conditions, and are more 
environmentally friendly. Hundreds of different enzymatic processes are routinely carried 
out in pharmaceutical, chemical, agricultural, and food industries (1-7). Products that 
utilize these processes range from simple research reagents (e.g. restriction enzymes) to 
commodity chemicals (e.g. fabric cleaners) and the number of applications continue to 
expand rapidly (8-11). Despite these many successful applications, the potential of 
biocatalysis is only beginning to be fully realized. 
 
 The computational design of novel biocatalysts to elaborate this potential is seen 
as one of the most promising fields of protein design and has exploded in recent years. 
Most computational protein design efforts focus on de novo enzyme design, which 
requires the matching of a designed, chemically functional active site into a protein 
scaffold (12). This approach has been notably been applied to generate enzymes for the 
Diers-Alderase (13, 14) and Kemp elimination reactions (15). Another approach, known 
as enzyme redesign, focuses on modifying an existing enzyme that possesses either an 
active site or substrate specificity helpful for the target application (16-18). This latter 
approach relies on many of the proven algorithms used in computational design, and 
leads to a higher probability of producing an active enzyme. It is also commonly used as 
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a rational starting point for experimentally-based protein design techniques, particularly 
directed evolution (19). 
 
 Several strategies have been used to redesign native enzymes for novel substrates. 
Most often, these designs center around active site chemistry and arranging the novel 
substrate into a conformation similar to the native substrate then selecting supporting 
mutations which reinforce the new specificity. A highly active designed enzyme can be 
difficult to express and purify especially if, as in proteases, the target substrate is present 
within the expression cells. An alternative mechanism for catalysis which side-steps this 
problem is called substrate assisted catalysis. 
 
 In substrate-assisted catalysis, the substrate provides one or more functional group 
required for the reaction to take place (20). Substrate assisted catalysis was first described 
for native enzymes inactivated by mutation. These mutations remove amino acid side 
chains critical to catalysis and result in the loss of activity. Several groups have 
demonstrated that modified substrates with chemical moieties similar to those that had 
been removed could rescue enzymatic activity. For example, when the serine component 
of a catalytic triad (21) is removed from a serine protease, then reintroduced in a peptide 
substrate a highly specific site for proteolytic cleavage is introduced (22). Substrate 
assisted catalysis was used by several groups (23, 24) to redesign more specific variants 
of proteases. 
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 We selected a cysteine protease scaffold and reengineered its specificity to 
catalyze the Edman degradation reaction. We removed the nucleophilic cysteine and 
adopted a substrate-assisted catalysis strategy analogous to the approach used with serine 
proteases. The resulting enzyme exhibits specificity for the presence of the Edman 
reagent, phenylisothiocyanate (PITC), at the N-terminus and catalyzes the removal of the 
N-terminal derivatized amino acid with catalytic efficiencies (kcat/Km) of up to 104 sec-1 
M-1. Additionally, we observed activity for all tested amino acid side chains in the 
penultimate position, suggesting that the enzyme can substitute for the standard acid-
based catalysis in the cleavage step of the Edman degradation. 
 
RESULTS 
Computational redesign of a cysteine protease to catalyze the Edman 
degradation reaction 
 We identified several selection criteria for a design scaffold.  First, we selected 
only cysteine proteases. These enzymes are more likely to have the correct chemical 
complementarily to the nucleophile on the substrate. In particular, the isothiocyanate 
group on PITC will substitute for the cysteine in the scaffold. Second, we required that 
the P1 position have an amino acid side-chain whose 
€ 
Cα −Cβ  vector is oriented away 
from the protein core and unoccluded by surrounding residues. This is desirable since we 
wanted to eliminate dependence of catalytic activity on the side-chain identity as this 
position. We also selected enzymes that had a co-crystallized inhibitor with a terminal 
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aromatic moiety. This allowed us to concentrate on engineering residues that, while in the 
binding pocket, were distant from the catalytic residues.  
 
 These criteria led us to select the cysteine protease, cruzain, from Trypanosoma 
Cruzei (PDB 1AIM (25)). A particularly attractive feature of this scaffold is its known 
affinity for phenylalanine-like inhibitors (26). We then generated an Edman degradation 
transitions state (see methods) and docked it within the scaffold by aligning the 
nucleophilic cysteine with the isothiocyanate moiety. After modeling in the Edman 
degradation transition state, we first mutated the active nucelophile (cys25) to a glycine 
in order to remove any protease activity. Previous studies have shown that mutation of 
the active-site cysteine reduces activity to background levels (27). We then modeled the 
transition state substrate for the Edman degredation reaction, and docked this substrate 
into the binding pocket. Using the Rosetta full atom energy function (28) to eliminate any 
largely unfavorable mutations, we manually selected three additional mutations, which 
after constrained relaxation, improved the computational binding energy for the TS-
substrate by 13.8 Rosetta Energy Units (REUs).  
 
 These three mutations were inspired by commonly occurring, favorable 
interactions between chemical moieties. A leucine to tyrosine mutation at position 157 
introduces a highly favorable ‘ring-to-edge’ interaction between the tyrosine and the 
aromatic group on the substrate (29-31). Additionally, it caps the binding pocket which 
helps to maintain the position of the substrate thiol near the original position of the 
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catalytic cysteine, as seen in the alignment of the design with the original catalytic triad 
(Figure 36). The introduction of an electron-rich cysteine at position 133 also introduces 
a canonical interaction with the lower edge of the aromatic ring (32, 33). The final 
mutation, glycine to serine at position 65 satisfies a solvent-exposed hydrogen bond on 
the substrate by acting as a hydrogen bond donor. The resulting design (Figure 35) packs 
tightly around the modeled substrate and places the substrate thiol in the correct 
orientation to complete the catalytic triad. We refer to this designed variant of cruzain as 
Edmanase. 
 
Edmanase exhibits specificity for the Edman reagent  
 We expressed and characterized the four-fold mutant using a fluorescence-based 
assay (described in the methods) that follows the accumulation of fluorescence as the 
engineered enzyme cleaves the PITC-amino acid from the ‘N-terminus’ of an PITC-x-
AMC substrate (where x is a specific side chain). Low levels of fluorescence 
accumulation for the negative controls (with BSA) are presumably due to the natural, 
uncatalyzed rate of cleavage of the AMC substrate under mild aqueous conditions. 
Minimal fluorescence accumulation is observed with the negative controls. Though 
cleavage of the PITC- substrate with Edmanase is comparable to that of the PITC+ with 
BSA, there is an increase in fluorescence accumulation for the PITC-derived AMC 
compared to the underivatized AMC substrate of 280-fold (Figure 40, Table 9). 
Specificity for the Edman reagent can also be seen by comparing the rate change for the 
BSA PITC- and PITC+, where we see only a 57-fold increase.  
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Edmanase exhibits enzymatic activity for all P1 residue side-chains 
 We next investigated whether or not the penultimate amino acid side chain 
identity had an effect on the rate of catalysis. Our modeled substrate orients the amino 
acid side chain away from the body of the protein, shown in Figure 37. As expected 
based on the predicted structure of our design, cleavage occurred regardless of which 
amino-acid side-chain was present in the fluorescent substrate (Figure 38). The rate of 
catalysis did vary significantly, from an efficiency of around 104 sec-1 M-1 for asparagine 
and alanine, to near 101 sec-1 M-1 for proline (Table 8). The aspAMC and alaAMC were 
best cleaved with catalytic efficiencies both on the order of 104. The Km for the bulky 
phenylalanine side-chain is similar to that of aspartate but lower than that of alanine. This 
indicates that the size of the side-chain plays a role in the catalytic efficiency, however, it 
does have a minimal effect and Edmanase acts as an enzyme for all amino acids tested. 
 
Steric blocking of the active site attenuates activity 
 We expressed several mutated variants of the Edmanase to determine if the 
substrate-assisted catalytic mechanism functioned as designed. First, we replaced gly25 
with a valine. The bulkier valine side-chain was expected to block access to the binding 
pocket, thus removing the potential to sterically enforce the catalytically active substrate 
conformation. Because of the substrate-assisted catalysis mechanism, we expected that 
this mutation would lead to a near complete attenuation of Edmanase activity. The mutant 
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was expressed and characterized using the same fluorescence based assay. Figure 40 
demonstrates that only trace levels of activity remain, comparable to background, and 
that the attenuation of catalysis resulting from this substitution is over 1000-fold.    
 
Removal of the candidate general base attenuates activity 
 Our approach to design by substrate-assisted catalysis utilizes a nucleophile on 
the substrate molecule, but should also require a basic residue to enhance proton transfer 
from the substrate (21). This has been shown to be required in other proteases that utilize 
a structurally similar catalytic triad (34-36). In Edmanase, this role is predicted to be 
fulfilled by his159. We therefore mutated this histidine to alanine, expecting a significant 
reduction in the catalytic activity. Results from the fluorescence activity assay are shown 
in Figure 40. While the reduction in activity is not as drastic as the gly25val mutant 
(approximately 11-fold reduction compared to 516-fold), the difference in activities is 
attributable to a reduction in the catalytic constant rather than the Km, which is consistent 
with our catalytic mechanism.  
 
Catalysis is inhibited with the addition of a substrate analogue 
 The two inactivating mutations provide evidence that the mechanism of catalysis 
for Edmanase is the substrate assisted mechanism that was designed computationally. To 
provide further support, we attempted to identify a substrate-analog inhibitor for 
Edmanase. Searching through commercially available compounds yielded three potential 
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molecules. We characterized the inhibition of activity in increasing concentrations of 
inhibitors. One of the three candidates, 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone 
showed notable inhibition of Edmanase. Figure 39 (left panel) shows the accumulation of 
cleaved substrate as a function of time, and (right panel) the inhibitory curve. The Ki is 
high (1.14 mM), indicating that 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone is only 
a weak inhibitor, however, the fact that it does inhibit the reaction implies that the 
structure of this molecule displaces potential substrate and provides further support for 
our substrate-assisted mechanism.  
 
DISCUSSION 
 The number of outstanding successes realized by scientists using computational 
techniques to design enzymes has grown rapidly over the past several years. We have 
previously noted the practicality of enzyme redesign versus de novo enzyme design. Here 
we utilize a distinct approach to enzyme redesign using substrate-assisted catalysis, 
which offers a number of advantages. Potentially toxic biologically active enzymes (like 
peptidases) engineered to harness such a mechanism should be easier to express and 
purify than enzymes utilizing more traditional mechanisms (eg. nucelophile-base triads)	  
(37). These enzymes should also have a far more stringent specificity due to the absolute 
requirement for the presence of the derivatized substrate for catalysis to occur (23, 38). 
Another practical advantage is that the amount and complexity of calculations and design 
choices based on chemical quantum theory are greatly reduced compared to de novo 
active-site design.  
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 While the engineering of the Edmanase enzyme is an important component of the 
biomolecular tool-kit for protein sequencing using DAPES, the strategies employed to 
engineer it are unlikely to be easily carried over to other applications. This may change as 
the number of available crystal structures grows and the chance of finding a co-crystal 
structure with a near-target substrate increases. Our approach is more likely to be utilized 
in combination with structural biology, where a co-crystal structure is determined in a 
targeted fashion once a candidate has been identified. Still, in this case the use of 
alternative protein engineering techniques, particularly directed evolution, is more apt to 
be generally applicable. 
 
 We qualitatively observed that the solubility of each PITC-derived substrate 
generally played a significant role in the catalytic efficiency. The more soluble substrates 
(alaAMC and aspAMC) have higher catalytic efficiencies while metAMC and pheAMC 
are lower. ArgAMC is an outlier, however, the fact that it is a positively charged side-
chain may indicate that this substrate is cleaved less efficiently because of secondary 
interactions with Edmanase. An HPLC analysis of the reaction products did not exhibit a 
different relative quantity of uncleaved substrate with metAMC and pheAMC, which 
would indicate that the rates derived from this assay are accurate. ProAMC also exhibited 
drastically reduced activity, however, proline is known to be troublesome even in the 
chemical Edman cleavage, so this reduction is not surprising. 
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 The utility of substrate-assisted catalysis as a mechanism for designed enzymes is 
especially important to engineering novel activities for protein therapeutics, where 
extremely high specificities will be required for practical use. This is especially true for 
protease enzymes, which may be designed to selectively target viral peptides and 
proteins. While the introduction of foreign modification agents, like the Edman reagent, 
may be impossible, substrate-assisted catalysis may provide a viable strategy for 
engineering proteases for therapeutic applications. 
 
MATERIALS AND METHODS 
Scaffold Selection 
 Selection of the cysteine protease, cruzain (PDB 1AIM), as a design scaffold was 
done by manually searching the PDB for an enzyme meeting several criteria including: 1. 
Presence of a substrate with a terminal aromatic group, 2. Presence of a nucleophilic 
cysteine attacking group, 3. An active site in which the amino-acid side chain would be 
solvent exposed and not involved in substrate recognition, and 4. An active site in which 
a peptide substrate could be accommodated. This search returned only this single scaffold 
as a potential hit. 
 
Chemical Modeling 
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 The transition-state, substrate analogue was modeled using quantum simulation in 
the GAMESS package (39), and geometry optimized at the RHF/6-31G level. The 
substrate model was then docked into the active site of the cruzain scaffold by overlaying 
the aromatic portion of the model with the substrate present in the cruzain co-crystal 
structure. The position and conformation of the modeled substrate was finalized by 
energy minimization using the Rosetta full atom energy function and constraints to 
prevent large rigid body movement of the substrate. 
 
Computational Design 
 Mutations to accommodate the modified specificity were chosen manually after 
computational saturation mutagenesis of active site residues. First, residues that made 
contact with the substrate were chosen by visual inspection. These residues were 
computationally mutated to reasonable replacements that were chosen based on well-
known, native-like interaction motifs. In particular, the ring-to-edge motif between 
tyr157 and the substrate and the thiol-edge interaction between cys133 and the substrate 
are known to be preferred packing arrangements (29, 32). The Rosetta energies for the 
individual and combined mutations were tabulated. The top mutations were visually 
inspected, and the 4-fold mutant was chosen because of the presence of two canonical 
interactions with the aromatic region of the substrate and the well-satisfied hydrogen 
bonding. 
 
 172	  
Substrates and Inhibitors 
 Single amino acid, amino-methylcoumarin (AMC) containing compounds were 
obtained from BAChem (Bubendorf, Switzerland). These included Arg-AMC, Asn-
AMC, Phe-AMC, Met-AMC, Ala-AMC, and Pro-AMC. Phenylisothiocyanate (PITC) 
was purchased from Thermo-scientific and derivatized to the N-terminus of each 
substrate by incubating for 20 minutes at 50°C in a 250 µL solution of 
acetonitrile:pyridine:water (10:5:1) with 5 µL of PITC. The derivatized substrate was 
then dried by rotary evaporation and resuspended in 250 µL of 1x PBS. Inhibitor 
compound, 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone, was obtained from Sigma-
Aldrich (St. Louis, MO). 
 
Enzyme purification 
 A synthetic gene containing the engineered enzyme was purchased from 
GenScript, cloned between the NdeI and XhoI sites in the pet42(a) (Novagen) expression 
vector, then transformed into BL-21(DE3) chemically competent cells. Protein was over-
expressed following Studier’s auto-induction protocol. Bacterial cells were harvested by 
centrifugation of the cell culture at 5000 rpm and 4 degrees for 10 minutes. Cells were 
then resuspended in 1x PBS pH 7.4 with 10% glycerol and 6M guanidine chloride. Cells 
were then lysed by sonication on ice. The cell lysate was centrifuged at 18000 rpm, 4 
degrees for 20 minutes. The supernatent was then filtered through a 0.2 um cellulose 
acetate filter. The filtered lysate was loaded onto a 5 mL HisTrap (Ni-NTA) column and 
washed with 5 column volumes of binding buffer (50 mM Tris-HCl, 150 mM NaCl, 6M 
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guanidine chloride, 25 mM imidazole). Bound protein was then eluted in 50 mM Tris-
HCl, 150 mM NaCl, 6M guanidine chloride, 500 mM imidazole. Purified fractions were 
then refolded by successive, overnight dialyses into 1x PBS containing 5M, 3M, 1M, 
0.5M, and 0M guanidine chloride. Purified protein was then prepared for SDS-PAGE 
analysis by mixing 2 parts sample with 1 part 4x loading dye. Samples were analyzed on 
16% SDS-PAGE gels, and visualized by Coomassie staining. Protein concentration was 
determined using the calculated molar extinction coefficient and measuring the A280 on 
an ND-8000 spectrophotometer (Thermo Fisher Scientific). 
 
Activity measurements 
 All kinetic measurements were performed in a 96-well corning plate on a BioTek 
Synergy2 plate reader at 30 degrees. Reactions were started by adding 5-20 µL of 
purified enzyme to 150 µL of .1-10 mM substrate solution. Side-chain identity had a 
significant effect on substrate solubility. Final enzyme concentration was between 1 nM 
and 100 nM. The difference between maximum substrate concentration and enzyme 
concentration was equal in all experiments. Fluorescence of the cleaved product was 
measured by exciting at 370 nm (30 second intervals for 1-10 hours) and monitoring 
emissions at 460 nm. Fluorescence accumulation was monitored every 30 seconds and 
relative fluorescence units were converted to rates of substrate cleavage by calibration 
with a free AMC standard curve (Sigma Aldrich, MO, USA). Reaction rates at steady 
state were calculated from the slope of the fluorescence time courses by linear regression 
of initial velocities, and kinetic parameters were calculated assuming Michaelis-Menten 
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kinetics, v = Vmax(S)/(S)+Km by non-linear regression in the R statistical software 
package. 
 
Inhibition by 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone 
 Assays were conducted as above, with 5uM substrate, 100 nM enzyme, and 500-
31.25 µM 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone. Reaction velocity was 
determined as above, plotted against the inverse of inhibitor concentration, and fit by 
non-linear least squares to determine the inhibition constant. 
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FIGURE 37: (A) The conformation of cruzain (PDB 1AIM) with the modeled PITC-
ala transition state analogue in a space-filling representation. The loose 
complementarity of the transition state analogue to the binding pocket is the primary 
reason this molecule was chosen as a design scaffold. (B) The designed Edmanase in the 
same representation as (A).  (C) Stick representation showing the location of the four 
Edmanase mutations relative to the transition state analogue. 	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FIGURE 38. Transition state model for the Edman degradation.	  The modeled 
substrate used to introduce Edmanase activity into the cruzain scaffold (A), and an 
alignment of the original catalytic triad from cruzain (B, purple) with the substrate-
assisted catalysis triad (B, black) of Edmanase. 	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FIGURE 39: Four mutations alter the activity of cruzain to catalyze the Edman 
degredation.	  (A) The introduced mutations (black) over-laid on the original cruzain 
residues (cyan). (B) The same mutations in the context of the cruzain scaffold showing 
the completed catalytic triad.	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FIGURE 40: Michaelis-menten curves for the Edmanase enzyme	  for alaAMC (A), 
aspAMC (B), metAMC (C), pheAMC (D), argAMC (E), and proAMC (F). Each 
demonstrates the ability of Edmanase to cleave a PITC-derived N-terminal amino acid 
with varying degrees of efficiency. 	  
	  	  	  	  	  	  	  	  	  	  	  	  
 182	  
FIGURE 41: Inhibition of the Edmanase enzyme by a transition state analogue.	  The 
left panel shows the directly assayed flouresence accumulation time course of the 
uninhibitied Edmanase (black) against varying concentrations of inhibitor (colored lines). 
The right panel is the inhibition curve derived from the time course and fit to obtain the 
Ki. 
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FIGURE 42: Catalytic efficiency of Edmanase and mutants.	  	  A plot showing the 
calculated catalytic efficiencies of the negative controls (BSA) and knock-out mutants 
compared to that of Edmanase.  
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TABLE 8: Kinetic parameters of Edmanase for AMC substrates. 
Substrate	   kcat	  (s-­1)	   Km	  (µM)	   kcat/Km	  Ala	   .55	   21.3	   2.6	  x	  104	  Asp	   3.6	   124.5	   2.9	  x	  104	  Phe	   .47	   122.8	   3.8	  x	  103	  Met	   .54	   271.8	   2.0	  x	  103	  Pro	   .0014	   252.0	   5.7	  x	  101	  Arg	   .087	   167.8	   5.2	  x	  102	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TABLE 9: Kinetic parameters of Edmanase compared to attenuation mutants. 
Variant	   kcat	   Km	  (µM)	   kcat/Km	   kcat(Edmanase)/	  
kcat(Mutant)	  Edmanase	  (Ala)	   .55	   21.3	   2.6	  x	  104	   1	  G25V	   .064	   1,270	   50.4	   .116	  H159A	   .24	   96.1	   2.4	  x	  103	   .436	  BSA	  (PITC-­‐)	   .0018	   1,684	   1.07	   .0033	  BSA	  (PITC+)	   .067	   1,090	   61.5	   .122	  Edmanase	  (PITC-­‐)	   .082	   889	   92.2	   .149	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CHAPTER 7: 
CONCLUSIONS AND FUTURE DIRECTIONS 
	  	   Successful	  design	  of	  novel	  proteins	  confronts	  significant	  challenges;	  the	  combinatorial	  complexity	  of	  the	  search	  process,	  the	  difficulties	  in	  modeling	  subtle	  intra-­‐molecular	  interactions,	  and	  the	  lack	  of	  a	  full	  understanding	  of	  protein	  folding	  and	  structural	  determinants.	  The	  outlining	  of	  generalized	  approaches	  for	  design	  is	  therefore	  essential	  to	  the	  continued	  success	  of	  the	  field.	  The	  approaches	  presented	  in	  this	  thesis	  fall	  into	  two	  general	  categories:	  codified	  algorithms	  and	  strategies.	  The	  former	  is	  the	  cornerstone	  of	  computational	  protein	  design	  and	  was	  outlined	  in	  depth	  in	  the	  introduction.	  The	  latter	  provides	  complementary	  guidelines	  of	  techniques	  that	  have	  led	  to	  success	  in	  specific	  cases	  and	  are	  theoretically	  applicable	  to	  a	  wide	  variety	  of	  applications.	  Both	  are	  essential	  to	  moving	  the	  field	  forward.	  	  
	  
	   Computational	  protein	  design	  is	  rapidly	  moving	  towards	  a	  more	  applied	  focus	  and	  being	  called	  upon	  to	  deliver	  user	  friendly,	  fast,	  accurate	  tools	  for	  researchers	  in	  the	  biomedical	  sciences.	  More	  than	  ever,	  these	  scientists	  are	  from	  outside	  disciplines,	  and	  seek	  to	  harness	  the	  power	  of	  biomolecular	  design	  to	  enhance	  their	  research.	  Because	  of	  this	  growing	  trend,	  it	  is	  critical	  that	  design	  algorithms	  improve	  their	  ability	  to	  generate	  productive	  protein	  variants.	  In	  the	  fourth	  and	  fifth	  chapters	  of	  this	  thesis,	  I	  described	  the	  formulation	  and	  validation	  of	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two	  techniques,	  one	  for	  stabilizing	  proteins	  and	  the	  other	  for	  engineering	  novel	  specificities	  or	  activities	  into	  an	  enzyme.	  The	  former	  approach	  allows	  us	  to	  improve	  the	  design	  process	  by	  providing	  a	  way	  forward	  when	  conventional	  approaches	  fail	  to	  design	  a	  well-­‐packed	  core.	  More	  generally,	  it	  is	  an	  example	  of	  iterative	  design	  refinement	  that	  can	  be	  extended	  to	  a	  variety	  of	  structural	  anomalies	  that	  present	  themselves	  due	  to	  the	  necessary	  simplification	  of	  physical	  force-­‐fields	  for	  computational	  design.	  The	  latter	  approach	  provides	  a	  computational	  framework	  to	  accomplish	  what	  we	  refer	  to	  as	  minimalist	  design.	  This	  relies	  on	  harnessing	  native	  interactions	  with	  the	  hypothesis	  that	  those	  interactions	  which	  occur	  in	  nature	  are	  more	  likely	  to	  be	  realizable	  in	  design.	  It	  also	  relies	  on	  the	  more	  over-­‐arching	  principle	  of	  identifying	  a	  highly	  favorable	  scaffold	  and	  changing	  as	  few	  amino	  acids	  as	  possible.	  Chapter	  2	  of	  this	  thesis	  exemplified	  this	  approach.	  For	  our	  application	  to	  the	  development	  of	  a	  protein	  sequencing	  tool-­‐kit,	  we	  sought	  absolute	  specificity	  for	  each	  amino	  acid	  side-­‐chain.	  A	  bottom-­‐up	  design	  approach	  would	  have	  required	  us	  to	  design	  a	  series	  of	  binding	  pockets	  for	  a	  set	  of	  extremely	  similar	  small	  molecules.	  In	  the	  minimalist,	  top-­‐down	  approach	  to	  protein	  engineering,	  scaffold	  identification	  and	  selection	  are	  critical	  to	  success.	  The	  minimalist	  approach	  led	  us	  to	  select	  the	  tRNA	  synthetases	  as	  design	  scaffolds	  and	  exploit	  several	  million	  years	  of	  evolution	  to	  obtain	  the	  desired	  specificity.	  We	  focused	  on	  maintaining	  that	  specificity	  while	  improving	  the	  protein	  in	  modest	  ways,	  such	  as	  removing	  a	  loop	  to	  increase	  substrate	  accessibility,	  which	  we	  were	  more	  confident	  would	  succeed.	  In	  the	  minimalist,	  top-­‐down	  approach	  to	  protein	  engineering,	  scaffold	  identification	  and	  selection	  are	  critical	  to	  success.	  We	  demonstrate	  that	  this	  is	  the	  case	  with	  both	  the	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Edmanase	  enzyme	  (Chapter	  6)	  and	  the	  biomolecular	  tool-­‐kit	  of	  NAABs	  (Chapters	  2	  and	  3).	  	  
	  
	   The	  biomolecular	  tool-­‐kit	  consisting	  of	  the	  17	  NAABs	  and	  the	  Edmanase	  enzyme	  in	  combination	  with	  our	  collaborators	  work	  on	  the	  single-­‐molecule	  TIRF	  assay	  potentially	  represent	  a	  huge	  leap	  forward	  in	  proteomics	  technology.	  The	  ability	  to	  sequence	  proteins	  on	  a	  highly	  accurate,	  high-­‐throughput	  platform	  could	  revolutionize	  protemics	  in	  the	  same	  way	  that	  next-­‐gen	  DNA	  sequencing	  has	  revolutionized	  genomics.	  As	  our	  collaborators	  in	  the	  Mitra	  Lab	  work	  diligently	  towards	  making	  DAPES	  a	  reality,	  there	  are	  a	  number	  of	  possibilities	  for	  refining	  the	  set	  of	  NAABs.	  Given	  the	  Bayesian	  framework	  introduced	  in	  Chapter	  3,	  we	  have	  a	  quantitative	  way	  to	  determine	  small	  changes	  in	  specificity	  that	  could	  reduce	  the	  number	  of	  NAABs	  required	  for	  amino	  acid	  calling	  or	  improve	  the	  probability	  of	  identifying	  amino	  acids.	  This	  could	  be	  accomplished	  by	  inverting	  the	  optimization	  procedure	  to	  find	  an	  optimal	  binding	  matrix.	  Constraints	  upon	  the	  existing	  matrix	  could	  be	  implemented	  based	  on	  our	  knowledge	  of	  the	  current	  tool-­‐kit's	  amenability	  to	  design.	  We	  may	  then	  attempt	  to	  apply	  the	  minimalist	  engineering	  strategy	  in	  a	  guided	  way	  to	  the	  existing	  set	  of	  NAABs.	  
	  
	   Additionally,	  alternative	  surface	  platforms	  can	  be	  explored.	  Our	  characterization	  of	  the	  tool-­‐kit	  relied	  on	  label-­‐free	  technology,	  BLI,	  which	  is	  similar	  to	  SPR.	  A	  number	  of	  recent	  studies	  have	  demonstrated	  that	  label-­‐free	  SPR	  can	  be	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utilized	  at	  a	  single	  molecule	  resolution,	  though	  there	  are	  still	  significant	  hurdles	  to	  overcome.	  If	  such	  a	  technology	  becomes	  feasible,	  it	  could	  help	  to	  side-­‐step	  the	  difficulties	  of	  combining	  the	  molecular	  tool-­‐kit	  with	  single	  molecule	  imaging.	  Ultimately,	  this	  thesis	  work	  in	  applied	  protein	  design	  has	  been	  successful	  and	  I	  am	  confident	  that	  it	  will	  soon	  be	  applied	  for	  its	  intended	  purpose.	  	  
	  	  
